
<html lang="en"     class="pb-page"  data-request-id="1e8d77e5-29c1-46d2-9978-d5be840bf11c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01488;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms" /></meta><meta name="dc.Creator" content="Tao  Yang" /></meta><meta name="dc.Creator" content="Mengshi  Hu" /></meta><meta name="dc.Creator" content="Yong  Chen" /></meta><meta name="dc.Creator" content="Mingli  Xiang" /></meta><meta name="dc.Creator" content="Minghai  Tang" /></meta><meta name="dc.Creator" content="Wenyan  Qi" /></meta><meta name="dc.Creator" content="Mingsong  Shi" /></meta><meta name="dc.Creator" content="Jun  He" /></meta><meta name="dc.Creator" content="Xue  Yuan" /></meta><meta name="dc.Creator" content="Chufeng  Zhang" /></meta><meta name="dc.Creator" content="Kongjun  Liu" /></meta><meta name="dc.Creator" content="Jiewen  Li" /></meta><meta name="dc.Creator" content="Zhuang  Yang" /></meta><meta name="dc.Creator" content="Lijuan  Chen" /></meta><meta name="dc.Description" content="In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–a..." /></meta><meta name="Description" content="In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–a..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 30, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01488" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01488" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01488" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01488" /></link>
        
    
    

<title>N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01488" /></meta><meta property="og:title" content="N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0019.jpeg" /></meta><meta property="og:description" content="In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0019.jpeg" /></meta><meta name="twitter:title" content="N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01488"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01488">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01488&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01488&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01488&amp;href=/doi/10.1021/acs.jmedchem.0c01488" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14921-14936</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01451" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01506" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.1c00198"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title"><i>N</i>-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tao Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Yang">Tao Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mengshi Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengshi Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengshi++Hu">Mengshi Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Chen">Yong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingli Xiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingli Xiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingli++Xiang">Mingli Xiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minghai Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minghai Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minghai++Tang">Minghai Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenyan Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenyan Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenyan++Qi">Wenyan Qi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingsong Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingsong Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingsong++Shi">Mingsong Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++He">Jun He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xue Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xue Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xue++Yuan">Xue Yuan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chufeng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chufeng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chufeng++Zhang">Chufeng Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kongjun Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kongjun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kongjun++Liu">Kongjun Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiewen Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiewen Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiewen++Li">Jiewen Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhuang Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhuang Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div><div class="loa-info-affiliations-info">Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#71081e041f1648414149314043475f121e1c"><span class="__cf_email__" data-cfemail="c1b8aeb4afa6f8f1f1f981f0f3f7efa2aeac">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhuang++Yang">Zhuang Yang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lijuan Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lijuan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div><div class="loa-info-affiliations-info">Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f3909b969d9f9a9986929dc2c1c6b3c2c5c0dd909c9e"><span class="__cf_email__" data-cfemail="76151e13181a1f1c031718474443364740455815191b">[email protected]</span></a>. Phone: +86-28-85164063.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lijuan++Chen">Lijuan Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8076-163X" title="Orcid link">http://orcid.org/0000-0002-8076-163X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01488&amp;href=/doi/10.1021%2Facs.jmedchem.0c01488" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14921–14936</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 August 2020</li><li><span class="item_label"><b>Published</b> online</span>30 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01488" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01488</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14921%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTao%2BYang%252C%2BMengshi%2BHu%252C%2BYong%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01488%26title%3DN-%2528Pyrimidin-2-yl%2529-1%252C2%252C3%252C4-tetrahydroisoquinolin-6-amine%2BDerivatives%2Bas%2BSelective%2BJanus%2BKinase%2B2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BMyeloproliferative%2BNeoplasms%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14936%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01488"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">937</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01488" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Mengshi&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Mingli&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Minghai&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Wenyan&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Mingsong&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Xue&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Chufeng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Kongjun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jiewen&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhuang&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Lijuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14921-14936&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01488&quot;},&quot;abstract&quot;:&quot;In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01488&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01488" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01488&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01488" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01488&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01488" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01488&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01488&amp;href=/doi/10.1021/acs.jmedchem.0c01488" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01488" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01488" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01488%26sid%3Dliteratum%253Aachs%26pmid%3D33256400%26genre%3Darticle%26aulast%3DYang%26date%3D2020%26atitle%3DN-%2528Pyrimidin-2-yl%2529-1%252C2%252C3%252C4-tetrahydroisoquinolin-6-amine%2BDerivatives%2Bas%2BSelective%2BJanus%2BKinase%2B2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BMyeloproliferative%2BNeoplasms%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14921%26epage%3D14936%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (5)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Volume 63, Issue 23"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Volume 63, Issue 23"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In this study, we described a series of <i>N</i>-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound <b>18e</b> led to the discovery of the superior derivative <b>13ac</b>. Compound <b>13ac</b> showed excellent potency on JAK2 kinase, SET-2, and Ba/F3<sup>V617F</sup> cells (high expression of JAK2<sup>V617F</sup> mutation) with IC<sub>50</sub> values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound <b>13ac</b> could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound <b>13ac</b> also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, <b>13ac</b> significantly ameliorated the disease symptoms in a Ba/F3-JAK2<sup>V617F</sup> allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Myeloproliferative neoplasms (MPNs) are a group of malignant bone marrow proliferative diseases originating from hematopoietic stem cells, which manifest as excessive proliferation of one or more lines of myeloid cells.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Such diseases include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and these diseases can be transformed into each other.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In myelofibrosis, stem cell transplantation and small molecule therapy are preferred methods of treatment for genetic or clinical high-risk diseases.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The study of MPNs has also facilitated the development of Janus kinase (JAK) inhibitors, such as JAK1/JAK2 inhibitor Ruxolitinib, which has shown promising activity in controlling constitutional symptoms and splenomegaly in MF and PV.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a></div><div class="NLM_p">In the JAK kinase family, JAK2 plays a key role in MPNs, especially the JAK2<sup>V617F</sup> mutation, which is up to 95% in PV and 50% in ET and PMF.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> The JAK2<sup>V617F</sup> mutation function has been fully verified, and studies of gene expression profiles have clearly shown that this mutation and the continuously activated JAK2 signal are present in many MPN patients. This continuous activation leads to malignant cell proliferation and inhibits normal cell apoptosis, thereby causing the occurrence of MPNs.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14">(10−14)</a> Because of the vital function of JAK2 in MPNs, another JAK2 inhibitor Fedratinib was approved to treat myelofibrosis (MF) in 2019.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Several other JAK2 inhibitors with varying degrees of selectivity are in mid to late-stage clinical trials for MF such as Lestaurtinib (CEP701), Momelotinib (CYT-387), Gandotinib (LY2784544), and Pacritinib.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22">(17−22)</a> Although these drugs have shown excellent disease modification, they all exhibited more or less side effects especially Fedratinib, which was given a “black box warning” on the risk of serious and fatal encephalopathy by the FDA.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The side effects may be caused by multitarget activity. Therefore, the development of novel selective JAK2 inhibitors was in need, such as the prospective candidate BMS-911543 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative drugs in clinical trials or launched JAK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our previous studies, we reported a dual JAK2/FLT3 kinase inhibitor <b>18e</b>. The 2-aminopyrimidine scaffold provided a novel hinge binding motif for the design of small-molecular ATP-competitive JAK2/FLT3 inhibitors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We analyzed the crystal structure and docking data of <b>18e</b> and found that the aminopiperidine tail formed hydrogen bonds with receptor residues such as Met665 and Asp829, which played a vital role in interaction with FLT3 protein while the tail was exposed to the solvent region in the JAK2-binding pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B). We hypothesized that the modification of the tail might provide a solution to reduce the binding activity for FLT3 but retain the activity for JAK2. Cyclization is a commonly used method in drug design to improve selectivity, such as the broad-spectrum anticancer drug Repotrectinib, Larotrectinib, and the fourth generation EGFR inhibitor BI-4020.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a> Therefore, our group considered cyclizing the tail and modifying the newly formed ring with various substituents to improve the JAK2 selectivity and activity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). In this article, we described our efforts toward identifying potent, selective JAK2 inhibitors for the treatment of MPNs.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking results of <b>18e</b> in the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (B) Docking results of <b>18e</b> in the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>); (C) Modifying plans for newly designed compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> In Vitro Structure–Activity Analysis</h3><div class="NLM_p">Our initial SAR efforts were directed toward cyclizing the tail to retain JAK2 potency and reduce FLT3 potency. SET-2 and Ba/F3 JAK2<sup>V617F</sup> cells, which overexpressed JAK2<sup>V617F</sup>, were chosen to determine the JAK2 potency. For FLT3, the activity against MOLM-13, which represents a human acute myeloid leukemia (AML) cell line harboring FLT3 internal tandem duplication (FLT3-ITD), was detected.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> At first, analogs containing four kinds of rings with active substituents hydroxyethyl and hydroxypropyl were synthesized.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> As illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, 5,6,7,8-tetrahydro-1,6-phthyridine (<b>13a</b>), isoindoline (<b>13b</b>), indoline (<b>13c</b>), and 1,2,3,4-tetrahydro-isoquinolin (<b>13d</b>–<b>13e</b>) all showed obviously weak potency on FLT3, however, the JAK2 potency also decreased apparently except for compounds <b>13d</b> and <b>13e</b>. Compared to compound <b>18e</b>, <b>13d</b>–<b>13e</b> demonstrated a similar inhibition for JAK2 and poorer activity for FLT3. We speculated that the small ring of <b>13b</b> and <b>13c</b> limited the conformation of the substituent, which resulted in poor interactions with the amino acid residue. Because 1,2,3,4-tetrahydro-isoquinolin exhibited desirable selectivity, it was selected as a skeleton. Next, we further examined the effects of substituents around the skeleton.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and In Vitro Biological Activities of Compounds <b>13a–e</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0011.gif" alt="" id="GRAPHIC-d7e481-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0012.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SI = selectivity index (IC<sub>50</sub> (MOLM-13)/IC<sub>50</sub> (SET-2)), which represents the selectivity for JAK2 on cells.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">% control = kinase activity remained.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, when R<sup>1</sup> was substituted by F, the activity of compounds <b>13f</b>, <b>13i</b>, and <b>13l–13n</b> against JAK2 slightly decreased while the FLT3 potency was increased apparently. We thought that the electron-withdrawing effect of F might enhance the interaction between the amino acid residue and pyrimidine amine, which resulted in an increase in the activity for JAK2 and FLT3. However, the effect of F went against selectivity of JAK2 versus FLT3. Furthermore, the F atom introduced into the benzene at R<sup>2</sup> position (<b>13k</b>) caused apparent loss of activity both on JAK2 and FLT3. Compounds with a rigid urea bond (<b>13g</b>, <b>13h</b>, and <b>13j</b>) reduced the activity toward JAK2 and FLT3 sharply, which indicated the R<sup>3</sup> substituent played a key role in activity and selectivity. Among these compounds, <b>13d</b> and <b>13e</b> showed the most potent cellular activity and acceptable selectivity, but the cellular activity on the JAK2 related cell lines was still unsatisfactory. Accordingly, based on 1,2,3,4-tetrahydro-isoquinolin, a series of substituents at the R<sup>3</sup> position were modified for exploring a more effective and selective compound.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and In Vitro Biological Activities of Compounds <b>13f–n</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0013.gif" alt="" id="GRAPHIC-d7e563-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0014.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">SI = selectivity index (IC<sub>50</sub> (MOLM-13)/IC<sub>50</sub> (SET-2)), which represents the selectivity for JAK2 on cells.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">% control = kinase activity remained.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">= no detected.</p></div></div><div></div></div><div class="NLM_p">In the previous research, compounds <b>13d</b> and <b>13e</b> showed selectivity for FLT3, therefore, hydrophilic saturated alkane substituents with different chain length were introduced to the R<sup>3</sup> position (<b>13o–13p</b>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the selectivity and cellular activity of these two compounds did not improve with the increase of the chain length. Comparison of the structures of <b>13q</b> and <b>13r</b> suggested that the terminal heteroatom played a certain role in maintaining the activity. Inspired by this result, the heteroatom substituent cyano was introduced to the same position and resulted in a significant improvement in cellular activity and an 8.8-fold increase in selectivity (<b>13t</b>). Subsequently, we extended the cyano chain to obtain compound <b>13u</b>, and the activity against JAK-relative cells decreased. Considering that the cyano group is an unsaturated bond, some other unsaturated groups were also introduced to the R<sup>3</sup> position. Obviously, rigid unsaturated substituents had no positive effect on activity enhancement (<b>13s</b>, <b>13v</b>, and <b>13w</b>). We further analyzed the cyano group and realized the cyano group possessed potential of hydrolyzing to carboxyl, thus, the carboxyl derivatives were synthesized. Compared to <b>13y</b>, <b>13x</b> showed more excellent activity and about 35-fold selectivity for FLT3, which indicated the importance of the double bond. This conclusion was also confirmed by the two groups of compounds <b>13aa</b> and <b>13ab</b> and <b>13ac</b> and <b>13ad</b>. As compound <b>13x</b> possessed good activity, we further investigated the conjugated structure by replacing with a larger conjugate system (<b>13z</b>, <b>13aa</b>). Obviously, the large conjugated system contributed to selectivity and activity. Both carbonyl and amino groups contributed electron-donating effects in the formation of hydrogen bonds, therefore, the benzoyl was replaced by dimethylaminoethyl (<b>13ac</b>). Not surprisingly, compound <b>13ac</b> also showed potent activity and 75.2-fold selectivity for FLT3. In view of the metabolic instability of the ester bond of compound <b>13x</b>, the ester bond was replaced with a more stable amide bond (<b>13ae</b>–<b>13ah</b>). However, the activities of these compounds were reduced to certain degrees. So far, we had obtained a number of compounds with excellent cellular activity and acceptable selectivity, occasionally, during the synthetic preparation process, we found that the 6- and 7-amino groups of tetrahydroisoquinoline were similar in space. Hence, the 7-amino tetrahydroisoquinoline analogues were also synthesized on the basis of the earlier active substituent.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures and In Vitro Biological Activities of Compounds <b>13o–13h</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0015.gif" alt="" id="GRAPHIC-d7e691-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0016.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">SI = selectivity index (IC<sub>50</sub> (MOLM-13)/IC<sub>50</sub> (SET-2)), which represents the selectivity for JAK2 on cells.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">% control = kinase activity remained.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">= no detected.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, most of the newly synthesized compounds (<b>13ai–13ak</b>) exhibited excellent cellular activity for JAK2 but demonstrated decreased selectivity for FLT3. These results also indicated the spatial position of the substituent had a certain influence on the selectivity. Consideration of the structure novelty, compounds (<b>13t</b>, <b>13x</b>, <b>13z</b>, <b>13aa</b>, <b>13ac</b>, <b>13aj</b>, <b>13al</b>, and <b>13am</b>) with excellent cellular activity and selectivity were selected for the next kinase selectivity screening.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structures and In Vitro Biological Activities of Compounds <b>13ai–am</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0017.gif" alt="" id="GRAPHIC-d7e765-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0018.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">SI = selectivity index (IC<sub>50</sub> (MOLM-13)/IC<sub>50</sub> (SET-2)), which represents the selectivity for JAK2 on cells.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">% control = kinase activity remained.</p></div></div><div></div></div><div class="NLM_p">To test the potency of these compounds for JAK2 and FLT3, kinase assays were conducted by Eurofins Discovery. Because of the high homology of the JAK family, it was thought to be selective when the selectivity was greater than 10-fold. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, compounds <b>13x</b>, <b>13aa</b>, <b>13ac</b>, and <b>13al</b> exhibited relative selectivity for JAK2. Ruxolitinib, as the first marketed drug for the treatment of myelofibrosis, has varying degrees of damage to the blood cell reduction.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Another marketed drug Fedratinib showed obvious damage on liver and spleen.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Therefore, safety is an important factor in the development of myelofibrosis drugs. The above-mentioned four compounds all had good performance on cellular and enzymatic selectivity, so we tested their toxicity on a series of normal cells. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, in comparison with other compounds, <b>13ac</b> was relatively safe on a panel of normal cells especially normal liver cell. At the same time, after continuous oral administration of 30 and 60 mg/kg of <b>13ac</b> for 14 days, the routine blood test was conducted (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">Figure S5</a>), compound <b>13ac</b> only showed a slight effect on the hematocrit (HCT %) compared to normal mice. This result was consistent with in vitro cell safety screening, and both proved that <b>13ac</b> was relatively safe. Based on the above experimental results, <b>13ac</b> was chosen for further study.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinome Activity and Selectivity of the Preferred Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center" char=".">kinase IC<sub>50 (</sub>nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">compd</th><th class="rowsep1 colsep0" align="center" char="."><b>13t</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13x</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13z</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13aa</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13ac</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13aj</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13al</b></th><th class="rowsep1 colsep0" align="center" char="."><b>13am</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase subtype</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">147</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">TYK2</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">108</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selectivity (folds)</td><td class="colsep0 rowsep0" align="left">JAK2/JAK1</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">26.6</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JAK2/JAK3</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">38.5</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">16.6</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">44.5</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JAK2/TYK2</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">33.3</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JAK2/FLT3</td><td class="colsep0 rowsep0" align="char" char=".">15.4</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">20.7</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The biochemical tests were provided by Eurofins Discovery. All data were obtained by double testing.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of Cellular Proliferation in Normal Cell Lines by Preferred Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">growth inhibition, IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">cell type</th><th class="colsep0 rowsep0" align="center" char="±"><b>13x</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>13aa</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>13ac</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>13al</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vero</td><td class="colsep0 rowsep0" align="left">African green monkey kidney cell</td><td class="colsep0 rowsep0" align="char" char="±">2.23 ± 0.45</td><td class="colsep0 rowsep0" align="char" char="±">1.05 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">6.75 ± 0.28</td><td class="colsep0 rowsep0" align="char" char="±">2.47 ± 0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H9c2 (2-1)</td><td class="colsep0 rowsep0" align="left">rat cardiomyocyte</td><td class="colsep0 rowsep0" align="char" char="±">2.89 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1.43 ± 0.32</td><td class="colsep0 rowsep0" align="char" char="±">6.93 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">1.69 ± 0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LO2</td><td class="colsep0 rowsep0" align="left">human normal liver cell</td><td class="colsep0 rowsep0" align="char" char="±">1.53 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">2.66 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">7.22 ± 0.41</td><td class="colsep0 rowsep0" align="char" char="±">2.03 ± 0.15</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%; data are expressed as the mean ± SEM from the dose–response curves of at least three independent experiments.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Selectivity Profiling of <b>13ac</b></h3><div class="NLM_p">To further investigate the kinase selectivity of <b>13ac</b>, its kinome selectivity profile was then examined with Kinase Profile technology developed by Eurofins Discovery. A panel of 361 kinases was tested at a 0.1 μM concentration of <b>13ac</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">Table S1</a>). The kinome screening revealed that <b>13ac</b> exhibited expected selectivity for JAK2 within the human kinome. In addition to high activity on JAK2, <b>13ac</b> also demonstrated activity against TrkA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). TrkA belongs to a subfamily of receptor tyrosine kinases, which is activated by phosphorylation of specific tyrosine sites through dimerization, subsequently, in turn activates downstream signaling pathways, including Ras/MAPK, PI3K/AKT, and PLCγ pathways.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> These signaling pathways are consistent with JAK2’s downstream signaling pathways, besides, patients with MPNs can secondary activate downstream pathways such as PI3K and MAPK via the JAK-STAT signaling pathway, there may be a certain synergy between JAK2 and TrkA for treating MPNs, and the follow-up process was still being conducted.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Overall, <b>13ac</b> was relatively selective for JAK2.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome-wide selectivity profiling of compound <b>13ac</b> with the Kinase Profile assay by Eurofins Discovery. Measurements were performed at a concentration of 0.1 μM of the inhibitor in duplicate. The % control means remaining active kinase percentage. The affinity was defined with respect to a dimethyl sulfoxide (DMSO) control. The TREEspot image was mapped with the KinMap software tool provided by Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetics of <b>13ac</b> in Rats</h3><div class="NLM_p">In vitro screening indicated that compound <b>13ac</b> was a potential JAK2 inhibitor, subsequently, the pharmacokinetic study was conducted. In vitro liver microsomal metabolism showed that <i>T</i><sub>1/2</sub> of <b>13ac</b> was 54.6 min, and the in vitro clearance rate was 25.4 L/h/kg, which indicated the potential druggability of <b>13ac</b>. Therefore, in vivo studies were also performed. The PK properties of <b>13ac</b> are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. In rats, <b>13ac</b> showed fast absorption (<i>T</i><sub>max</sub> = 0.9 h), with a peak concentration of 51.1 ng/mL, an AUC of 253.6 ng h/mL, and a terminal half-life of ∼1.8 h following a single oral dose of 5 mg/kg. The oral bioavailability of <b>13ac</b> in rat was 25.7%.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vivo Profiling of Compound <b>13ac</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">ADME parameter<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">administration (5 mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">Clz (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="±">AUC0-t (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> %</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ac</b></td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="char" char="±">51.1 ± 26.5</td><td class="colsep0 rowsep0" align="left">0.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">28.8 ± 9.5</td><td class="colsep0 rowsep0" align="char" char="±">253.6 ± 24.1</td><td class="colsep0 rowsep0" align="char" char=".">25.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">intravenous</td><td class="colsep0 rowsep0" align="char" char="±">479.3 ± 28.3</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">5.01 ± 0.71</td><td class="colsep0 rowsep0" align="char" char="±">987.9 ± 110.2</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Sprague-Dawley rats (<i>n</i> = 5) were treated with solution (2% ethanol and 1% tween 80, pH5) at a dose of 5 mg/kg.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Xenograft and Allograft Model Experiments</h3><div class="NLM_p">As compound <b>13ac</b> showed acceptable pharmacokinetic properties and excellent activity and kinase selectivity in vitro, the efficacy of <b>13ac</b> in vivo was tested in the SET-2 cell-inoculated xenograft NOD/SCID mouse models. The average tumor volume at the start was 163.8 mm<sup>3</sup>, mice were dosed orally daily for 16 days with three doses of <b>13ac</b>. In comparison with Ruxolitinib, <b>13ac</b> exhibited a significant tumor growth inhibition of 82.3% without obvious weight change (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">S6A</a>). After termination of the treatment, tumor growth was measured up to day 36. All mice in the control group died at the 20th day, while only one mouse died in the treatment group after 36 days (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). The survival time of mice was improved, which indicated the relative safety and effectiveness of <b>13ac</b>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) NOD/SCID mice bearing SET-2 tumors (<i>n</i> = 5) were treated for 16 consecutive days with 15, 30, and 60 mg/kg <b>13ac</b> p.o. q.d. Tumor volumes were measured every two days. ***, <i>P</i> < 0.01 ANOVA, Dunnett’s post test; (B) body weight change in SET-2 cell-inoculated xenograft NOD/SCID mouse models; (C) NOD/SCID mice bearing SET-2 tumors (<i>n</i> = 5) were treated for 36 consecutive days with 15, 30, and 60 mg/kg <b>13ac</b> p.o. q.d. the survival curve was analyzed; (D) Ba/F-JAK2<sup>V617F</sup>-bearing BALB/c-nude mice (<i>n</i> = 6) were treated for 20 consecutive days with 30 and 60 mg/kg <b>13ac</b> p.o. q.d. On day 25, mice were sacrificed and spleen and liver weights determined. ***, <i>P</i> < 0.01 ANOVA, Dunnett’s post test; (E) inhibition of the liver growth in the Ba/F-JAK2<sup>V617F</sup> allograft model. ***, <i>P</i> < 0.01; **, 0.01 < <i>P</i> < 0.05 ANOVA, Dunnett’s post test; and (F) spleen weight to body weight ratio in the Ba/F-JAK2<sup>V617F</sup> allograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Summary of Tumor Growth Inhibition of Compound <b>13ac</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">administration</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">tumor model</th><th class="colsep0 rowsep0" align="center">schedule<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">survivors</th><th class="colsep0 rowsep0" align="center" char=".">inhibition rate (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ac</b></td><td class="colsep0 rowsep0" align="left">SET-2</td><td class="colsep0 rowsep0" align="left">QD × 16</td><td class="colsep0 rowsep0" align="left">P.O</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">5/5</td><td class="colsep0 rowsep0" align="char" char=".">51.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">67.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">82.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ruxolitinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">52.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">QD, every day.</p></div></div></div><div class="NLM_p last">In order to further verify the antitumor effect of <b>13ac</b> in vivo, a Ba/F3-JAK2<sup>V617F</sup> allograft model by tail vein injection was established (detailed experiment method shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">Supporting Information</a>). The Ba/F3-JAK2<sup>V617F</sup> mouse allograft represents a model for a JAK2-driven disease exhibiting hallmark symptoms of myeloproliferative diseases such as splenomegaly and hepatomegaly. In this model, murine Ba/F3-JAK2<sup>V617F</sup> cells were engrafted by tail vein injection. Treatment with <b>13ac</b> at doses of 30 and 60 mg/kg p.o. q.d. was started 4 days after cell inoculation for 20 consecutive days. Ruxolitinib was chosen as a positive control. At the study end, model mice exhibited splenomegaly and hepatomegaly (∼5.9-fold and 1.5-fold, respectively). Compound <b>13ac</b> treatment at 30 mg/kg p.o. q.d. significantly ameliorated the disease symptoms. Compared to Ruxolitinib, at a dose of 60 mg/kg, <b>13ac</b> showed a superior treatment effect with 77.1% normalization of spleen weight (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D,E and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">S6D</a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Molecular Docking Study of <b>13ac</b></h3><div class="NLM_p">The screening results at the cell and kinase levels indicated our previous hypothesis, modification of the tail of lead compound <b>18e</b> retained the activity for JAK2 but reduced the potency for FLT3. Further in vivo study indicated the effectiveness in mice. In order to explore the protein-binding mode of <b>13ac</b>, the crystal structure of the protein kinase domain of JAK2 from the Protein Data Bank (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>) was selected as the docking model.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> The docking results are presented in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> (see docking methods in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40 ref41 ref42">(37−42)</a> As demonstrated, the newly synthesized cycle was still toward outside the binding pocket, the reasonable conformation of the <b>13ac</b>–JAK2 complex suggested that the pyrimidine amino and one nitrogen atom pyrimidine formed two strong hydrogen bonds with the Leu932 in the distance of acceptor–donor of 2.98 and 3.06 Å. The pyrazole region also connected with Val863, Lys882, Val911, Met929, Leu983, Gly993, and Asp994 with hydrophobic interaction. Meanwhile, the pyrimidine ring formed arene-<i>H</i> interaction with Leu983 and Gly935 at the same time. Simultaneously, the terminal amine of the isoquinoline exposed in the solvent formed unexpected electrostatic interaction with Asp939, which might increase the binding activity. Those interactions suggested that <b>13ac</b> possessed a good affinity for JAK2 protein.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) 3D Model of <b>13ac</b> bound to the kinase catalytic domain of JAK2; (B) 2D Model of <b>13ac</b> bound to the kinase catalytic domain of JAK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Cell Cycle Analysis and Apoptosis Assays in SET-2 Cells</h3><div class="NLM_p">JAK2 plays a vital role in cell proliferation and survival; therefore, we examined the effect of <b>13ac</b> on the cell cycle. The experimental results showed that <b>13ac</b> induced cell arrest in the G0/G1 phase in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). A flow cytometry assay was also performed to examine cell apoptosis upon treatment with compound <b>13ac</b>. Compound <b>13ac</b> induced apoptosis in SET-2 cells in a similar pattern (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). At a concentration of 0.80 μM, an apoptosis rate of 49.3% was observed.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cell cycle effects of <b>13ac</b> on SET-2 cells. Cells were treated with increasing concentrations of <b>13ac</b> for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. (B) Effects of <b>13ac</b> on the induction of apoptosis. SET-2 cells were treated with <b>13ac</b> for 2 h at 0.05, 0.2, 0.4, 0.8, and 1.6 μM, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Signaling Inhibition of <b>13ac</b> in JAK2<sup>V617F</sup>-Expressing Cell Lines and Spleen Lysates</h3><div class="NLM_p">In order to investigate whether the excellent enzymatic activity of compound <b>13ac</b> regulates the JAK2 signaling pathway, the phosphorylation status of JAK2 and downstream substrates was detected by Western blot analysis of JAK2<sup>V617F</sup>-expressing cell lines. After a 2 h treatment with increasing concentrations of compound <b>13ac</b>, SET-2 and Ba/F3-JAK2<sup>V617F</sup> cells were harvested and lysed for an IP/wt assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A, compound <b>13ac</b> inhibited JAK2 and STAT5 phosphorylation in a dose-dependent manner. To explore the selectivity of <b>13ac</b> in the signaling pathway, FLT3 and downstream signaling protein AKT were detected.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Compared to JAK2, poorer inhibition of phosphorylated FLT3 and AKT indicated the selectivity of <b>13ac</b>. Selectivity is reflected not only in the kinase level for different subtypes, but also in the downstream effector molecules in the signaling pathway. The analysis for STAT of different subtypes was conducted on the Ba/F3 JAK2<sup>V617F</sup> cell. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B, compound <b>13ac</b> reduced STAT5 phosphorylation at a concentration of 50 nM while barely showed obvious inhibition for other STAT subtypes even at a concentration of 1000 nM. Furthermore, considering the excellent efficacy of <b>13ac</b> in vivo, we also investigated the influence of <b>13ac</b> on the JAK2 signaling pathway on the spleen tissue. On day 25, mice were killed and tumor lysates were analyzed for JAK2 signaling by Western blot. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C, <b>13ac</b> demonstrated a full inhibition of STAT5 phosphorylation.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of the JAK2 signaling pathway by <b>13ac</b>. (A) SET-2, (B) Ba/F3 JAK2<sup>V617F</sup>cells, and (C) spleen lysates of the Ba/F3 JAK2<sup>V617F</sup> allograft model were treated for 3 h with <b>13ac</b>. After lysis, the proteins were detected by immunoblotting with antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Based on the progress made in JAK2/FLT3 dual target inhibitor <b>18e</b>, we designed selective 1,2,3,4-tetrahydro-isoquinolin series of JAK2 inhibitors. SAR developed around the designed cycle moieties combined with structure-based design led to the discovery of <b>13ac</b>, which possessed >14-fold selectivity over JAK1,3, FLT3 in enzyme assays. Full kinase spectrum screening indicated <b>13ac</b> possesses a relatively high selectivity. Furthermore, the western blot assay confirmed that the antitumor activities were indeed on-target. Compound <b>13ac</b> could also stimulate cell cycle arrest in the G0/G1 phase and induce tumor cell apoptosis. An efficacy study in a model of JAK2<sup>V617F</sup>-driven disease demonstrated dose-dependent tumor growth inhibition and normalization of splenomegaly and hepatomegaly at well-tolerated doses. To summarize, <b>13ac</b> is a promising inhibitor of JAK2 for the treatment of MPNs.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of the 4-(1<i>H</i>-pyrazol-4-yl)-pyrimidin-2-amine derivatives require the preparation of two pairs of building blocks, that is, 4-(1<i>H</i>-pyrazol-4-yl)-pyrimidine and anilines. The synthesis of amines is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The intermediate <b>2</b> was synthesized from commercially available phenethylamine by an amidation. Subsequently, the intermediate <b>2</b> was cyclized under concentrated sulfuric acid and paraformaldehyde to obtain intermediate <b>3</b>. Treatment of <b>3</b> with concentrated sulfuric acid and potassium nitrate at 0 °C provided <b>4a–b</b>, from which analogues without protection could be accessed. Compounds <b>5a–b</b> were further amidated under (BOC)<sub>2</sub>O. Primary amines (<b>7a–b</b>) were synthesized by hydrogen reduction.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Amino Derivatives <b>7a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) trifluoroacetic anhydride, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt; (b) paraformaldehyde, concentrated sulfuric acid, rt; (c) concentrated sulfuric acid, potassium nitrate, 0 °C; (d) hydrochloric acid, methanol, reflux; (e) (BOC)<sub>2</sub>O, 60 °C; and (f) Pd/C, H<sub>2</sub>, methanol, rt.</p></p></figure><div class="NLM_p">The primary intermediates <b>10a–b</b> were synthesized via alkylation of <b>8</b> with 2-iodopropane to provide <b>9</b>, followed by the Suzuki reaction with 2, 4-dichloropyrimidine derivatives. The anilines (<b>7a–b</b>) and pyrimidine intermediates (<b>10a–b</b>) were coupled via a Buchwald–Hartwig reaction to get <b>11a–f</b>. The Boc groups were removed from <b>11a–f</b> with hydrochloric acid to produce the corresponding piperazines. The final products <b>13a–am</b> were obtained by alkylation or amidation (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>13a–am</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (g) 2-iodopropane, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (h) 2,4-dichloropyrimidine derivatives, dioxane/EtOH/water (v/v/v, 7/3/4), 80 °C, 2 h; (i) amines, dioxane, reflux, 4 h, N<sub>2</sub> atmosphere; (j) hydrochloric acid, EA, rt; (k) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt. And (l) appropriate acid, HATU, DIEA, DCM, rt.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis</h3><div class="NLM_p last">All the chemical solvents and reagents were purchased from commercial sources and were used as received. Thin-layer chromatography was performed on 0.20 mm Silica Gel 60 F254 plates (Qingdao Haiyang Chemical, China) and visualized under UV light (254 nm). Flash column chromatography was carried out using fritted solid loaders packed with Scharlau silica gel (0.04–0.06 mm) on Biotage FlashMaster Personal + flash chromatography. Counter-current Chromatography separations was finished with a SCU-Prep instrument manufactured by our team. The volume of the counter-current chromatography column is 1500 mL and the rotation speed is 1200 rpm. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 400 spectrometer (Bruker Company, Germany) or a Varian spectrometer (Varian, Palo Alto, CA), using TMS as an internal standard. Chemical shifts were given in ppm (parts per million). Mass spectra were recorded on a Q-TOF Premier mass spectrometer (Micromass, Manchester, UK). The purity of each compound (>95%) was determined on a Waters e2695 series LC system (column, Xtimate C18, 4.6 mm × 150 mm, 5 μm; mobile phase, methanol (60%)/H<sub>2</sub>O (40%); low rate, 1.0 mL/min; UV wavelength, 254–400 nM; temperature, 25 °C; and injection volume, 10 μL).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 2,2,2-Trifluoro-<i>N</i>-phenethylacetamide (<b>2</b>)</h3><div class="NLM_p last">To a solution of 2-phenylethan-1-amine (12.1 g, 0.1 mol) in acetonitrile (200 mL), K<sub>2</sub>CO<sub>3</sub> (34.5 g, 0.25 mmol) and trifluoroacetic anhydride (17.0 mL, 0.12 mol) were added, and the mixture was stirred at room temperature (rt) for 1 h. The completion of the reaction was checked with TLC on silica (silica gel: DCM/MeOH = 20:1). The mixture was dried under reduced pressure. 50 mL of water was added to the concentrated solution, the solid was precipitated, filtered with suction, and dried to obtain the title compound. Yield: 88%. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>): δ 7.67 (t, <i>J</i> = 6.3 Hz, 1H), 7.33–7.24 (m, 2H), 7.25–7.16 (m, 3H), 3.46 (dt, <i>J</i> = 6.4, 5.6 Hz, 2H), 2.76 (tt, <i>J</i> = 5.6, 1.0 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: 217.0774 [M + H<sup>+</sup>].</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-(3,4-Dihydroisoquinolin-2(1<i>H</i>)-yl)-2,2,2-trifluoroethan-1-one (<b>3</b>)</h3><div class="NLM_p last">To a solution of 2,2,2-trifluoro-<i>N</i>-phenethylacetamide (18.5 g, 0.085 mol) in concentrated sulfuric acid (100 mL) was slowly added paraformaldehyde (3.0 g, 0.1 mol), and the mixture was stirred at room temperature (rt) for 2 h. After the reaction completed, the mixture was very slowly added to ice water and extracted with ethyl acetate (200 mL) twice. The organic phases were collected together and concentrated under reduced pressure. The solid was washed with ether (50 mL) to obtain the title compound. Yield: 60%. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>): δ 7.23 (ddt, <i>J</i> = 6.1, 3.9, 0.9 Hz, 1H), 7.20–7.11 (m, 3H), 4.55 (d, <i>J</i> = 1.0 Hz, 2H), 3.77 (dt, <i>J</i> = 8.6, 5.6 Hz, 2H), 2.90 (ddt, <i>J</i> = 8.7, 5.8, 0.7 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: 229.0768 [M + H<sup>+</sup>].</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 2,2,2-Trifluoro-1-(6-nitro-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (<b>4a</b>)</h3><div class="NLM_p last">A solution of 1-(3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-2,2,2-trifluoroethan-1-one (11.0 g, 0.048 mol) in concentrated sulfuric acid (100 mL) was cooled to 0 °C, and potassium nitrate (12.1 g, 0.12 mol) was slowly added to the mixture while keeping the temperature below 0 °C. After 2 h, the reaction solution was very slowly added to ice water and extracted with ethyl acetate (150 mL) twice. The organic phases were collected together and concentrated under reduced pressure. The residue was pretreated by counter-current chromatography (solvent system: <i>n</i>-hexane/ethyle acetate/methanol:/water 5:1:5:1; mobile phase: upper phase; rotation speed: 1200 rpm; and flow rate: 50 mL/min) and then purified by FlashMaster Personal + chromatography (silica gel: PE/EA = 90:10) to give the desired product <b>4a</b> and <b>4b</b>. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>): δ 7.99 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 7.78 (dt, <i>J</i> = 2.2, 1.0 Hz, 1H), 7.40 (dt, <i>J</i> = 8.2, 1.0 Hz, 1H), 4.59 (d, <i>J</i> = 1.0 Hz, 2H), 3.76 (ddd, <i>J</i> = 8.8, 6.0, 1.8 Hz, 2H), 2.94 (ddt, <i>J</i> = 8.4, 5.8, 1.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: 274.0628 [M + H<sup>+</sup>].</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-Nitro-1,2,3,4-tetrahydroisoquinoline (<b>5a</b>)</h3><div class="NLM_p last">To a solution of 2,2,2-trifluoro-1-(6-nitro-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (7.8 g, 0.029 mol) in MeOH (60 mL) was added hydrochloric acid (10 mL) and refluxed for 2 h. The mixture was concentrated under reduced pressure and the desired product was obtained without purification. Yield: 94%. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>): δ 7.96 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.76 (dt, <i>J</i> = 2.1, 1.0 Hz, 1H), 7.32 (dt, <i>J</i> = 8.5, 1.0 Hz, 1H), 4.06 (dd, <i>J</i> = 7.5, 1.0 Hz, 2H), 3.00 (dddd, <i>J</i> = 7.8, 6.6, 5.9, 4.0 Hz, 2H), 2.86 (dddd, <i>J</i> = 11.6, 6.6, 3.8, 0.9 Hz, 2H), 2.66 (tt, <i>J</i> = 7.5, 5.9 Hz, 1H). HRMS (ESI) <i>m</i>/<i>z</i>: 179.0756 [M + H<sup>+</sup>].</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>tert</i>-Butyl 6-Nitro-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (<b>6a</b>)</h3><div class="NLM_p last">A solution of 6-nitro-1,2,3,4-tetrahydroisoquinoline (4.8 g, 0.027 mol) in (BOC)<sub>2</sub>O (20 mL) was heated at 60 °C for 2 h, filtered, and washed with ether once to get the target compound. Yield: 90%. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>): δ 7.99 (dd, <i>J</i> = 8.1, 2.3 Hz, 1H), 7.78 (dt, <i>J</i> = 2.1, 1.0 Hz, 1H), 7.28 (dt, <i>J</i> = 8.2, 1.0 Hz, 1H), 4.61 (d, <i>J</i> = 1.1 Hz, 2H), 3.73 (ddd, <i>J</i> = 9.1, 6.4, 4.2 Hz, 2H), 2.97 (ddd, <i>J</i> = 9.1, 6.4, 1.1 Hz, 2H), 1.47 (s, 7H). HRMS (ESI) <i>m</i>/<i>z</i>: 279.1356 [M + H<sup>+</sup>].</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>tert</i>-Butyl 6-Amino-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (<b>7a</b>)</h3><div class="NLM_p">A solution of <i>tert</i>-butyl 6-nitro-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (5.2 g, 0.024 mol) and Pd/C (0.52 g) in MeOH (50 mL) was reduced under the atmosphere of H<sub>2</sub>. The mixture was filtered and concentrated to obtained the intermediate. Yield: 98%. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>): δ 7.19 (dt, <i>J</i> = 8.3, 1.0 Hz, 1H), 6.60 (dd, <i>J</i> = 8.1, 2.3 Hz, 1H), 6.54 (dt, <i>J</i> = 2.1, 1.0 Hz, 1H), 4.75 (s, 1H), 4.59 (d, <i>J</i> = 0.9 Hz, 2H), 3.73 (dd, <i>J</i> = 9.1, 6.4 Hz, 2H), 2.82 (dddd, <i>J</i> = 9.2, 7.4, 6.4, 1.0 Hz, 2H), 1.47 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i>: 271.1567 [M + Na <sup>+</sup>].</div><div class="NLM_p last">The synthesis method of intermediates <b>9–12</b> was described in the previous literature, herein, we just described the synthesis of amide.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Synthetic Procedure 1</h3><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Amidation</h4><div class="NLM_p last">To a solution of secondary amine(0.01 mmol, 1.0 equiv), HATU (0.01 mmol, 1.0 equiv), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.025 mmol, 2.5 equiv) in DCM (20 mL) was added acid (0.01 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 0.5 h and filtered, and the solid was washed with EA to give the desired product.</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-(2-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5<i>H</i>)-yl)propan-1-ol (<b>13a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.19 (s, 1H), 8.38–8.30 (m, 2H), 8.11 (t, <i>J</i> = 4.2 Hz, 2H), 7.47 (d, <i>J</i> = 8.5 Hz, 1H), 4.63 (h, <i>J</i> = 6.6 Hz, 1H), 4.44 (d, <i>J</i> = 38.4 Hz, 1H), 3.55–3.44 (m, 4H), 2.80 (t, <i>J</i> = 5.9 Hz, 2H), 2.73 (t, <i>J</i> = 6.1 Hz, 2H), 2.54 (d, <i>J</i> = 7.1 Hz, 2H), 2.33 (s, 3H), 1.72–1.64 (m, 2H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.93, 158.01, 157.82, 152.89, 151.72, 139.55, 136.47, 129.69, 123.47, 120.45, 117.59, 110.21, 59.81, 55.19, 54.71, 53.83, 50.98, 32.20, 30.45, 23.03, 17.19. HRMS (ESI) <i>m</i>/<i>z</i>: 408.5245 [M + H<sup>+</sup>].</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)ethan-1-ol (<b>13b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.90 (s, 1H), 8.24 (d, <i>J</i> = 41.8 Hz, 2H), 8.05 (s, 1H), 7.49 (s, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 6.45 (d, <i>J</i> = 8.4 Hz, 1H), 4.63 (dq, <i>J</i> = 20.3, 6.8, 6.1 Hz, 2H), 3.61 (q, <i>J</i> = 6.1 Hz, 2H), 3.31 (d, <i>J</i> = 8.9 Hz, 1H), 3.05 (t, <i>J</i> = 6.3 Hz, 2H), 2.87 (t, <i>J</i> = 8.2 Hz, 2H), 2.28 (s, 3H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.79, 159.38, 157.61, 148.07, 139.29, 132.27, 129.86, 129.27, 120.84, 118.60, 117.13, 115.43, 107.01, 59.57, 54.30, 53.78, 52.86, 29.01, 23.04, 17.11. HRMS (ESI) <i>m</i>/<i>z</i>: 379.4856 [M + H<sup>+</sup>].</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)isoindolin-2-yl)ethan-1-ol (<b>13c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.29 (s, 1H), 8.30 (d, <i>J</i> = 21.5 Hz, 2H), 8.08 (s, 1H), 7.76 (s, 1H), 7.54 (d, <i>J</i> = 8.2 Hz, 1H), 7.12 (d, <i>J</i> = 8.2 Hz, 1H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 4.51 (s, 1H), 3.85 (d, <i>J</i> = 20.6 Hz, 4H), 3.64–3.47 (m, 2H), 2.76 (t, <i>J</i> = 6.3 Hz, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.84, 159.00, 157.71, 140.81, 140.30, 139.34, 132.79, 129.43, 122.29, 120.66, 117.42, 116.47, 112.67, 60.46, 59.70, 59.04, 58.44, 53.82, 23.03, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 379.4866 [M + H<sup>+</sup>].</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-ol (<b>13d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.20 (s, 1H), 8.29 (d, <i>J</i> = 22.7 Hz, 2H), 8.08 (s, 1H), 7.65 (d, <i>J</i> = 2.3 Hz, 1H), 7.46 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.94 (d, <i>J</i> = 8.4 Hz, 1H), 4.62 (h, <i>J</i> = 6.6 Hz, 1H), 4.46 (s, 1H), 3.67–3.46 (m, 4H), 2.80 (d, <i>J</i> = 5.8 Hz, 2H), 2.71 (t, <i>J</i> = 5.8 Hz, 2H), 2.57 (t, <i>J</i> = 6.2 Hz, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.88, 159.00, 157.63, 139.42, 139.31, 134.44, 129.38, 127.92, 126.71, 120.74, 118.31, 116.72, 116.35, 60.74, 59.30, 56.07, 53.83, 51.64, 29.63, 23.03, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 393.5070 [M + H<sup>+</sup>].</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)propan-1-ol (<b>13e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.20 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 7.65 (d, <i>J</i> = 2.2 Hz, 1H), 7.47 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 4.75–4.39 (m, 2H), 3.57–3.42 (m, 4H), 2.80 (t, <i>J</i> = 5.8 Hz, 2H), 2.64 (t, <i>J</i> = 5.9 Hz, 2H), 2.50 (s, 2H), 2.31 (s, 3H), 1.68 (p, <i>J</i> = 6.5 Hz, 2H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.89, 159.00, 157.64, 139.46, 139.31, 134.46, 129.39, 127.83, 126.75, 120.74, 118.30, 116.75, 116.36, 59.96, 55.86, 55.56, 53.83, 51.25, 30.34, 29.66, 23.04, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 407.5340 [M + H<sup>+</sup>].</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-(6-((5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-2-hydroxyethan-1-one (<b>13f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.55 (d, <i>J</i> = 4.7 Hz, 1H), 8.44 (d, <i>J</i> = 45.8 Hz, 2H), 8.09 (s, 1H), 7.68 (s, 1H), 7.55 (t, <i>J</i> = 6.6 Hz, 1H), 7.11 (dd, <i>J</i> = 13.3, 8.1 Hz, 1H), 4.76–4.42 (m, 4H), 4.19 (d, <i>J</i> = 5.2 Hz, 2H), 3.64 (dt, <i>J</i> = 51.4, 5.8 Hz, 2H), 2.83 (dt, <i>J</i> = 28.2, 5.8 Hz, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 170.87, 156.92, 150.02, 147.54, 146.90, 146.25, 139.54, 138.88, 134.92, 129.87, 126.97, 126.44, 118.39, 117.31, 115.71, 60.74, 54.01, 43.89, 41.70, 29.42, 22.96. HRMS (ESI) <i>m</i>/<i>z</i>: 411.4546 [M + H<sup>+</sup>].</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(3-Chlorophenyl)-6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxamide (<b>13g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.30 (s, 1H), 8.73 (s, 1H), 8.31 (d, <i>J</i> = 21.9 Hz, 2H), 8.09 (s, 1H), 7.72 (d, <i>J</i> = 26.0 Hz, 2H), 7.57 (d, <i>J</i> = 8.3 Hz, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 1H), 7.26 (t, <i>J</i> = 8.1 Hz, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.98 (d, <i>J</i> = 7.9 Hz, 1H), 4.61 (d, <i>J</i> = 16.3 Hz, 3H), 3.71 (t, <i>J</i> = 5.8 Hz, 2H), 2.85 (t, <i>J</i> = 5.9 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.90, 158.95, 157.69, 155.14, 142.73, 139.93, 139.34, 135.07, 133.20, 130.35, 129.44, 126.68, 126.38, 121.69, 120.70, 119.38, 118.38, 118.27, 117.16, 116.57, 53.84, 45.80, 41.95, 29.27, 23.04, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 503.0190 [M + H<sup>+</sup>].</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-Ethyl-6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxamide (<b>13h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.26 (s, 1H), 8.30 (d, <i>J</i> = 22.7 Hz, 2H), 8.08 (s, 1H), 7.70 (d, <i>J</i> = 2.2 Hz, 1H), 7.53 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 6.49 (t, <i>J</i> = 5.4 Hz, 1H), 4.62 (h, <i>J</i> = 6.5 Hz, 1H), 4.41 (s, 2H), 3.54 (t, <i>J</i> = 5.8 Hz, 2H), 3.08 (dt, <i>J</i> = 12.5, 6.3 Hz, 2H), 2.75 (t, <i>J</i> = 5.9 Hz, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.03 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.90, 158.95, 157.80, 157.67, 139.71, 139.32, 135.21, 129.43, 126.95, 126.59, 120.70, 118.43, 117.08, 116.51, 53.83, 45.46, 41.38, 35.38, 29.23, 23.04, 17.15, 16.15. HRMS (ESI) <i>m</i>/<i>z</i>: 320.5330 [M + H<sup>+</sup>].</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 3-(6-((5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)propan-1-ol (<b>13i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.24 (s, 1H), 9.68 (s, 1H), 8.53 (d, <i>J</i> = 3.0 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.10 (d, <i>J</i> = 1.1 Hz, 1H), 7.76 (d, <i>J</i> = 2.2 Hz, 1H), 7.60 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.14 (d, <i>J</i> = 8.5 Hz, 1H), 4.67 (p, <i>J</i> = 6.6 Hz, 1H), 4.25 (d, <i>J</i> = 36.4 Hz, 2H), 3.37 (s, 4H), 3.24 (t, <i>J</i> = 8.1 Hz, 2H), 3.12 (s, 2H), 1.94 (dq, <i>J</i> = 11.9, 6.0 Hz, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 156.98, 149.96, 147.48, 146.97, 146.18, 139.09, 138.86, 134.51, 128.24, 126.82, 118.38, 116.85, 115.73, 59.94, 55.80, 55.52, 54.00, 51.18, 30.28, 29.56, 22.94. HRMS (ESI) <i>m</i>/<i>z</i>: 411.4974 [M + H<sup>+</sup>].</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-<i>N</i>-propyl-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxamide (<b>13j</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.26 (s, 1H), 8.30 (d, <i>J</i> = 22.9 Hz, 2H), 8.09 (s, 1H), 7.71 (d, <i>J</i> = 2.2 Hz, 1H), 7.54 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 6.50 (t, <i>J</i> = 5.5 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 4.43 (s, 2H), 3.55 (t, <i>J</i> = 5.8 Hz, 2H), 3.02 (q, <i>J</i> = 7.8, 7.0 Hz, 2H), 2.76 (t, <i>J</i> = 5.8 Hz, 2H), 2.32 (s, 3H), 1.46 (dd, <i>J</i> = 18.8, 6.9 Hz, 8H), 0.84 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.90, 158.95, 157.88, 157.67, 139.70, 139.32, 135.21, 129.43, 126.99, 126.60, 120.70, 118.43, 117.08, 116.51, 53.83, 45.50, 42.47, 41.44, 29.22, 23.56, 23.04, 17.15, 11.87. HRMS (ESI) <i>m</i>/<i>z</i>: 434.5600 [M + H<sup>+</sup>].</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 2-(7-Fluoro-6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-ol (<b>13k</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.56 (s, 1H), 8.26 (d, <i>J</i> = 25.6 Hz, 2H), 8.01 (s, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 6.92 (d, <i>J</i> = 11.5 Hz, 1H), 4.61 (p, <i>J</i> = 6.7 Hz, 1H), 4.54 (s, 1H), 3.82–3.42 (m, 4H), 2.96–2.63 (m, 4H), 2.55 (t, <i>J</i> = 6.5 Hz, 2H), 2.30 (s, 3H), 1.46 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.91, 159.09, 157.81, 154.07, 151.66, 139.34, 130.75, 129.94, 129.42, 123.69, 120.56, 116.87, 113.15, 60.46, 59.27, 55.69, 53.82, 51.37, 28.78, 23.02, 17.08. HRMS (ESI) <i>m</i>/<i>z</i>: 411.4974 [M + H<sup>+</sup>].</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-(6-((5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-ol (<b>13l</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.49 (s, 1H), 8.49 (d, <i>J</i> = 2.9 Hz, 1H), 8.38 (s, 1H), 8.08 (s, 1H), 7.62 (s, 1H), 7.48 (d, <i>J</i> = 8.3 Hz, 1H), 6.99 (d, <i>J</i> = 8.4 Hz, 1H), 4.66 (td, <i>J</i> = 14.4, 13.9, 7.2 Hz, 2H), 3.83–3.50 (m, 4H), 2.78 (d, <i>J</i> = 66.0 Hz, 6H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 53.94, 147.50, 143.35, 142.60, 139.98, 138.80, 132.96, 128.37, 127.01, 126.49, 120.09, 118.70, 117.83, 59.30, 56.76, 56.40, 54.17, 51.12, 28.89, 23.16. HRMS (ESI) <i>m</i>/<i>z</i>: 397.4704 [M + H<sup>+</sup>].</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-(6-((5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)butan-1-ol (<b>13m</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.48 (s, 1H), 8.49 (d, <i>J</i> = 3.0 Hz, 1H), 8.38 (d, <i>J</i> = 1.9 Hz, 1H), 8.08 (d, <i>J</i> = 1.3 Hz, 1H), 7.60 (d, <i>J</i> = 2.2 Hz, 1H), 7.46 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 4.68 (h, <i>J</i> = 6.6 Hz, 1H), 4.56 (s, 1H), 3.42 (t, <i>J</i> = 6.3 Hz, 2H), 2.81 (t, <i>J</i> = 5.9 Hz, 2H), 2.64 (t, <i>J</i> = 5.8 Hz, 2H), 2.44 (t, <i>J</i> = 7.1 Hz, 2H), 1.60–1.40 (m, 10H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 157.01, 149.95, 147.47, 146.97, 145.96, 139.05, 138.85, 134.58, 129.78, 128.38, 126.82, 118.39, 116.83, 115.73, 61.22, 58.22, 55.74, 54.00, 51.11, 31.13, 29.61, 23.80, 22.95. HRMS (ESI) <i>m</i>/<i>z</i>: 424.5244 [M + H<sup>+</sup>].</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 5-(6-((5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)pentan-1-ol (<b>13n</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.46 (s, 1H), 8.49 (d, <i>J</i> = 3.0 Hz, 1H), 8.38 (d, <i>J</i> = 1.6 Hz, 1H), 8.08 (s, 1H), 7.59 (s, 1H), 7.46 (dd, <i>J</i> = 8.4, 1.9 Hz, 2H), 6.98 (d, <i>J</i> = 8.3 Hz, 1H), 4.67 (dt, <i>J</i> = 13.3, 6.6 Hz, 2H), 4.35 (t, <i>J</i> = 4.9 Hz, 2H), 3.50 (s, 1H), 3.44–3.37 (m, 5H), 2.86–2.75 (m, 4H), 2.66 (s, 0H), 2.44 (d, <i>J</i> = 5.0 Hz, 1H), 1.58–1.40 (m, 8H), 1.33 (dt, <i>J</i> = 15.3, 7.1 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i>: 439.5514 [M + H<sup>+</sup>].</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)butan-1-ol (<b>13o</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.19 (s, 1H), 8.29 (d, <i>J</i> = 23.0 Hz, 2H), 8.08 (s, 1H), 7.64 (d, <i>J</i> = 2.3 Hz, 1H), 7.46 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 4.63 (q, <i>J</i> = 6.6 Hz, 1H), 4.56 (d, <i>J</i> = 26.0 Hz, 1H), 3.56–3.35 (m, 4H), 2.80 (t, <i>J</i> = 5.9 Hz, 2H), 2.63 (t, <i>J</i> = 5.8 Hz, 2H), 2.43 (t, <i>J</i> = 7.0 Hz, 2H), 2.31 (s, 3H), 1.55 (q, <i>J</i> = 7.2 Hz, 2H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.03, 158.27, 158.19, 140.86, 139.50, 131.80, 129.78, 127.32, 121.05, 120.48, 118.02, 117.76, 116.99, 60.49, 60.22, 55.58, 53.89, 52.27, 49.47, 29.86, 29.68, 25.74, 23.02, 22.91, 21.01, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 421.5610 [M + H<sup>+</sup>].</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 5-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)pentan-1-ol (<b>13p</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1H), 8.32 (s, 1H), 8.27 (s, 1H), 8.08 (s, 1H), 7.65 (d, <i>J</i> = 2.2 Hz, 1H), 7.47 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 4.34 (s, 1H), 3.40 (t, <i>J</i> = 5.7 Hz, 2H), 2.80 (t, <i>J</i> = 5.9 Hz, 2H), 2.63 (t, <i>J</i> = 5.9 Hz, 2H), 2.43 (t, <i>J</i> = 7.3 Hz, 2H), 2.31 (s, 3H), 1.58–1.41 (m, 10H), 1.35 (qd, <i>J</i> = 9.8, 8.4, 4.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 158.46, 157.32, 157.25, 152.31, 138.89, 133.23, 128.99, 125.84, 125.17, 122.18, 119.75, 119.28, 117.87, 62.50, 55.23, 54.16, 51.07, 31.69, 28.71, 27.04, 24.94, 23.19, 15.49. HRMS (ESI) <i>m</i>/<i>z</i>: 435.5880 [M + H<sup>+</sup>].</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 2-(2-Ethoxyethyl)-<i>N</i>-(4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine (<b>13q</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.20 (s, 1H), 8.30 (d, <i>J</i> = 22.7 Hz, 2H), 8.08 (s, 1H), 7.65 (d, <i>J</i> = 2.2 Hz, 1H), 7.47 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.94 (d, <i>J</i> = 8.3 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.61–3.51 (m, 4H), 3.46 (q, <i>J</i> = 7.0 Hz, 2H), 2.79 (d, <i>J</i> = 5.8 Hz, 2H), 2.70 (t, <i>J</i> = 5.8 Hz, 2H), 2.64 (t, <i>J</i> = 6.0 Hz, 2H), 2.31 (s, 3H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H), 1.12 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.87, 159.01, 157.63, 139.46, 139.32, 134.35, 129.35, 127.83, 126.68, 120.76, 118.31, 116.74, 116.34, 68.48, 65.94, 57.73, 56.03, 53.83, 51.59, 29.65, 23.02, 17.15, 15.62. HRMS (ESI) <i>m</i>/<i>z</i>: 421.5610 [M + H<sup>+</sup>].</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 2-Butyl-<i>N</i>-(4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine (<b>13r</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ9.19 (s, 1H), 8.29 (d, <i>J</i> = 23.5 Hz, 2H), 8.09 (s, 1H), 7.65 (s, 1H), 7.47 (d, <i>J</i> = 7.7 Hz, 1H), 6.94 (d, <i>J</i> = 8.2 Hz, 1H), 4.70–4.56 (m, <i>J</i> = 6.8 Hz, 1H), 3.46 (s, 2H), 2.79 (s, 2H), 2.61 (s, 2H), 2.41 (s, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.8 Hz, 8H), 1.31 (p, <i>J</i> = 7.3 Hz, 2H), 0.90 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.88, 158.98, 157.65, 139.71, 139.32, 134.06, 129.40, 126.80, 120.72, 118.22, 116.86, 116.43, 57.61, 55.28, 53.83, 50.97, 29.10, 28.73, 23.03, 20.51, 17.16, 14.34. HRMS (ESI) <i>m</i>/<i>z</i>: 405.5620 [M + H<sup>+</sup>].</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 2-Allyl-<i>N</i>-(4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine (<b>13s</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.33 (s, 1H), 8.27 (d, <i>J</i> = 0.8 Hz, 1H), 8.08 (s, 1H), 7.66 (d, <i>J</i> = 2.2 Hz, 1H), 7.47 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 5.91 (ddt, <i>J</i> = 16.6, 10.2, 6.3 Hz, 1H), 5.26 (dq, <i>J</i> = 17.2, 1.7 Hz, 1H), 5.18 (ddt, <i>J</i> = 10.1, 2.2, 1.2 Hz, 1H), 4.62 (h, <i>J</i> = 6.7 Hz, 1H), 3.48 (s, 2H), 3.12 (dt, <i>J</i> = 6.4, 1.4 Hz, 2H), 2.81 (t, <i>J</i> = 5.9 Hz, 2H), 2.65 (t, <i>J</i> = 5.8 Hz, 2H), 2.31 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.87, 159.01, 157.64, 139.49, 139.32, 136.22, 134.40, 129.36, 127.75, 126.70, 120.75, 118.35, 117.80, 116.77, 116.35, 61.23, 55.59, 53.83, 50.75, 29.62, 23.03, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 389.5190 [M + H<sup>+</sup>].</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 2-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)acetonitrile (<b>13t</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.24 (s, 1H), 8.30 (d, <i>J</i> = 21.8 Hz, 2H), 8.09 (s, 1H), 7.69 (d, <i>J</i> = 2.3 Hz, 1H), 7.51 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.00 (d, <i>J</i> = 8.4 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.91 (s, 2H), 3.62 (s, 2H), 2.86 (d, <i>J</i> = 6.0 Hz, 2H), 2.77 (d, <i>J</i> = 5.7 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.87, 158.97, 157.66, 139.77, 139.34, 133.54, 129.35, 126.77, 126.45, 120.74, 118.35, 116.96, 116.47, 116.34, 53.85, 53.79, 49.74, 45.59, 29.43, 23.01, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 388.4910 [M + H<sup>+</sup>].</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)propanenitrile (<b>13u</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.29 (d, <i>J</i> = 22.7 Hz, 2H), 8.08 (s, 1H), 7.67 (d, <i>J</i> = 2.2 Hz, 1H), 7.48 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 2.76 (ddt, <i>J</i> = 20.6, 9.8, 5.7 Hz, 8H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.89, 158.98, 157.64, 139.57, 139.31, 134.24, 129.40, 127.33, 126.74, 120.73, 120.50, 118.32, 116.81, 116.41, 54.95, 53.83, 53.09, 50.51, 29.46, 23.03, 17.15, 15.80. HRMS (ESI) <i>m</i>/<i>z</i>: 402.5180 [M + H<sup>+</sup>].</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-2-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine (<b>13v</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.22 (s, 1H), 8.30 (d, <i>J</i> = 22.4 Hz, 2H), 8.09 (s, 1H), 7.75–7.61 (m, 1H), 7.56–7.42 (m, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 3.59 (s, 2H), 3.51–3.40 (m, 2H), 3.23–3.13 (m, 1H), 2.84 (s, 2H), 2.72 (s, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.89, 158.99, 157.65, 139.51, 139.32, 133.99, 129.39, 127.46, 126.76, 120.73, 118.34, 116.82, 116.40, 79.84, 76.20, 53.90, 53.83, 49.71, 46.51, 29.64, 23.04, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 387.5030 [M + H<sup>+</sup>].</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 2-(But-2-yn-1-yl)-<i>N</i>-(4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine (<b>13w</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.08 (s, 1H), 7.66 (d, <i>J</i> = 2.3 Hz, 1H), 7.48 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.97 (d, <i>J</i> = 8.4 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.38 (q, <i>J</i> = 2.4 Hz, 2H), 2.82 (t, <i>J</i> = 5.8 Hz, 2H), 2.70 (t, <i>J</i> = 5.9 Hz, 2H), 2.32 (s, 3H), 1.83 (t, <i>J</i> = 2.3 Hz, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.88, 159.00, 157.65, 139.47, 139.32, 134.07, 129.38, 127.60, 126.75, 120.74, 118.31, 116.78, 116.38, 81.12, 75.17, 54.12, 53.83, 49.85, 47.01, 29.68, 23.03, 17.15, 3.55. HRMS (ESI) <i>m</i>/<i>z</i>: 401.5300 [M + H<sup>+</sup>].</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Methyl-(<i>E</i>)-4-(6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-enoate (<b>13x</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.22 (s, 1H), 8.33 (s, 1H), 8.29 (s, 1H), 8.08 (s, 1H), 7.67 (d, <i>J</i> = 2.2 Hz, 1H), 7.52–7.44 (m, 1H), 6.96 (d, <i>J</i> = 8.8 Hz, 2H), 6.10 (d, <i>J</i> = 15.7 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.68 (s, 3H), 3.52 (s, 2H), 2.83 (t, <i>J</i> = 5.8 Hz, 2H), 2.68 (t, <i>J</i> = 5.8 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 166.38, 159.88, 158.99, 157.64, 146.64, 139.58, 139.31, 134.22, 129.37, 127.43, 126.73, 122.53, 120.74, 118.34, 116.78, 116.39, 58.56, 55.68, 53.83, 51.80, 50.99, 29.53, 23.02, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 447.5550 [M + H<sup>+</sup>].</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Methyl-4-(6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)butanoate (<b>13y</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.18 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 7.64 (s, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 1H), 6.95 (d, <i>J</i> = 8.3 Hz, 1H), 4.62 (dt, <i>J</i> = 13.2, 6.6 Hz, 1H), 3.57 (d, <i>J</i> = 9.1 Hz, 3H), 3.46 (s, 2H), 2.78 (d, <i>J</i> = 5.3 Hz, 2H), 2.62 (t, <i>J</i> = 5.6 Hz, 2H), 2.44 (t, <i>J</i> = 6.9 Hz, 2H), 2.36 (t, <i>J</i> = 7.2 Hz, 2H), 2.31 (s, 3H), 1.83–1.74 (m, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 173.86, 159.90, 158.99, 157.63, 139.44, 139.31, 134.48, 129.40, 127.83, 126.74, 120.73, 118.28, 116.72, 116.36, 57.30, 55.71, 53.83, 51.61, 51.04, 31.80, 29.63, 23.04, 22.51, 17.14. HRMS (ESI) <i>m</i>/<i>z</i>: 449.5710 [M + H<sup>+</sup>].</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>E</i>)-1-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-4-phenylbut-2-ene-1,4-dione (<b>13z</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.31 (d, <i>J</i> = 2.2 Hz, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.13–8.02 (m, 3H), 7.85–7.79 (m, 1H), 7.76 (d, <i>J</i> = 2.2 Hz, 1H), 7.74–7.68 (m, 1H), 7.64–7.50 (m, 4H), 7.15 (dd, <i>J</i> = 8.5, 4.3 Hz, 1H), 4.73 (d, <i>J</i> = 36.9 Hz, 2H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 3.83 (dt, <i>J</i> = 11.2, 5.9 Hz, 2H), 2.88 (dt, <i>J</i> = 23.7, 6.0 Hz, 2H), 2.32 (s, 3H), 1.49 (dd, <i>J</i> = 6.7, 1.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 188.40, 167.72, 157.94, 151.75, 138.93, 138.16, 132.71, 129.12, 125.20, 121.82, 120.43, 119.95, 117.79, 54.16, 47.73, 44.20, 29.77, 23.16, 15.47. HRMS (ESI) <i>m</i>/<i>z</i>: 507.6100 [M + H<sup>+</sup>].</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>E</i>)-1-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-4-(<i>p</i>-tolyl)but-2-ene-1,4-dione (<b>13aa</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.31 (d, <i>J</i> = 2.1 Hz, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.09 (s, 1H), 7.96 (dd, <i>J</i> = 8.3, 2.8 Hz, 2H), 7.84–7.72 (m, 2H), 7.59–7.48 (m, 2H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 7.14 (dd, <i>J</i> = 8.5, 3.8 Hz, 1H), 4.79–4.58 (m, 3H), 3.82 (dt, <i>J</i> = 10.1, 5.9 Hz, 2H), 2.88 (dt, <i>J</i> = 23.6, 6.0 Hz, 2H), 2.40 (s, 3H), 2.32 (s, 3H), 1.48 (dd, J = 6.7, 1.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 189.47, 164.43, 164.20, 159.91, 158.92, 157.70, 144.87, 140.16, 140.04, 139.33, 135.04, 134.85, 134.59, 134.11, 133.90, 133.72, 130.06, 129.46, 129.31, 126.99, 126.82, 125.73, 125.62, 120.66, 118.21, 117.29, 117.17, 116.62, 53.84, 47.03, 44.33, 43.85, 29.88, 28.79, 23.04, 21.70, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 521.6370 [M + H<sup>+</sup>].</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-4-(<i>p</i>-tolyl)butane-1,4-dione (<b>13ab</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.30 (d, <i>J</i> = 5.9 Hz, 1H), 8.31 (d, <i>J</i> = 20.9 Hz, 2H), 8.09 (d, <i>J</i> = 1.7 Hz, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 2H), 7.75 (dd, <i>J</i> = 11.7, 1.8 Hz, 1H), 7.61–7.51 (m, 1H), 7.33 (d, <i>J</i> = 7.8 Hz, 2H), 7.11 (dd, <i>J</i> = 25.0, 8.4 Hz, 1H), 4.71–4.49 (m, 3H), 3.71 (dt, <i>J</i> = 35.7, 5.9 Hz, 2H), 3.24 (t, <i>J</i> = 6.2 Hz, 2H), 2.95–2.71 (m, 4H), 2.35 (d, <i>J</i> = 24.3 Hz, 6H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 198.87, 170.54, 170.46, 159.90, 158.95, 157.69, 143.72, 140.03, 139.92, 139.34, 135.26, 135.03, 134.80, 129.62, 129.44, 128.41, 126.84, 126.47, 125.93, 120.70, 118.31, 118.24, 117.19, 116.59, 116.56, 53.84, 46.43, 43.82, 43.09, 33.38, 29.66, 29.02, 27.73, 27.30, 23.03, 21.59, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 523.6530 [M + H<sup>+</sup>].</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>E</i>)-4-(Dimethylamino)-1-(6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-en-1-one (<b>13ac</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.30 (d, <i>J</i> = 5.2 Hz, 1H), 8.30 (d, <i>J</i> = 20.8 Hz, 2H), 8.09 (s, 1H), 7.75 (d, <i>J</i> = 6.4 Hz, 1H), 7.56 (t, <i>J</i> = 9.0 Hz, 1H), 7.10 (t, <i>J</i> = 8.8 Hz, 1H), 6.85 (d, <i>J</i> = 15.1 Hz, 1H), 6.70–6.56 (m, 1H), 4.71 (s, 1H), 4.65–4.57 (m, 2H), 3.77 (dt, <i>J</i> = 18.4, 5.8 Hz, 2H), 3.51 (d, <i>J</i> = 6.6 Hz, 2H), 2.84 (dt, <i>J</i> = 28.8, 6.0 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 164.68, 164.48, 159.88, 158.92, 157.67, 148.07, 140.10, 139.97, 139.46, 139.34, 139.22, 135.13, 134.82, 129.41, 127.95, 126.92, 126.65, 126.19, 125.84, 125.23, 120.69, 119.55, 118.33, 118.23, 117.26, 117.15, 116.59, 65.38, 59.54, 53.85, 44.57, 44.17, 43.46, 29.96, 23.01, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 460.5980 [M + H<sup>+</sup>].</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 4-(Dimethylamino)-1-(6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)butan-1-one (<b>13ad</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.30 (d, <i>J</i> = 6.4 Hz, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.09 (s, 1H), 7.75 (dd, <i>J</i> = 10.1, 2.2 Hz, 1H), 7.56 (ddd, <i>J</i> = 14.8, 8.4, 2.2 Hz, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 4.68–4.54 (m, 3H), 3.68 (dt, <i>J</i> = 12.1, 5.9 Hz, 2H), 3.09–2.99 (m, 2H), 2.88 (s, 8H), 2.56–2.51 (m, 2H), 2.32 (s, 3H), 1.87 (p, <i>J</i> = 7.0 Hz, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 170.49, 170.41, 159.92, 158.92, 157.68, 140.07, 139.95, 139.34, 135.21, 134.95, 129.44, 126.88, 126.71, 126.30, 125.78, 120.66, 118.34, 118.21, 117.22, 116.66, 116.62, 57.26, 53.86, 46.45, 43.82, 43.07, 42.89, 30.17, 29.84, 29.58, 28.94, 23.02, 22.89, 20.15, 17.13. HRMS (ESI) <i>m</i>/<i>z</i>: 462.6140 [M + H<sup>+</sup>].</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>E</i>)-4-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-enoic Acid (<b>13ae</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.30 (d, <i>J</i> = 22.4 Hz, 2H), 8.08 (s, 1H), 7.67 (d, <i>J</i> = 2.3 Hz, 1H), 7.48 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 6.79 (dt, <i>J</i> = 15.6, 5.9 Hz, 1H), 6.02–5.94 (m, 1H), 4.62 (h, <i>J</i> = 6.6 Hz, 1H), 3.51 (s, 2H), 3.27 (d, <i>J</i> = 5.5 Hz, 2H), 3.18 (s, 1H), 2.83 (t, <i>J</i> = 5.8 Hz, 2H), 2.67 (t, <i>J</i> = 5.8 Hz, 2H), 2.31 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.53, 158.50, 157.32, 152.38, 144.77, 138.89, 133.26, 129.05, 125.84, 125.17, 122.18, 120.54, 119.69, 119.22, 117.89, 56.52, 55.36, 54.11, 50.45, 28.84, 23.16, 15.48. HRMS (ESI) <i>m</i>/<i>z</i>: 433.5680 [M + H<sup>+</sup>].</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>E</i>)-4-(6-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-<i>N</i>-(2-(piperidin-1-yl)ethyl)but-2-enamide (<b>13af</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.22 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.09 (s, 2H), 7.68 (d, <i>J</i> = 2.2 Hz, 1H), 7.48 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.96 (d, <i>J</i> = 8.3 Hz, 1H), 6.67 (dt, <i>J</i> = 15.4, 5.9 Hz, 1H), 6.14 (d, <i>J</i> = 15.5 Hz, 1H), 4.62 (h, <i>J</i> = 6.6 Hz, 1H), 3.53 (s, 2H), 3.29–3.21 (m, 3H), 2.87–2.81 (m, 2H), 2.69 (d, <i>J</i> = 8.0 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 12H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.03, 157.94, 157.26, 151.81, 141.33, 138.80, 138.62, 134.04, 128.44, 125.75, 125.22, 122.48, 120.43, 120.19, 120.13, 117.84, 56.00, 55.63, 54.14, 53.65, 50.44, 38.81, 28.20, 26.43, 23.84, 23.16, 15.43. HRMS (ESI) <i>m</i>/<i>z</i>: 543.7320 [M + H<sup>+</sup>].</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (<i>E</i>)-<i>N</i>-(<i>tert</i>-Butyl)-4-(6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-enamide (<b>13ag</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.30 (d, <i>J</i> = 22.0 Hz, 2H), 8.09 (s, 1H), 7.71–7.56 (m, 2H), 7.48 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 6.58 (dt, <i>J</i> = 15.4, 5.9 Hz, 1H), 6.15 (dd, <i>J</i> = 15.4, 1.6 Hz, 1H), 4.63 (p, <i>J</i> = 6.6 Hz, 1H), 3.50 (s, 2H), 3.26–3.15 (m, 2H), 2.84 (t, <i>J</i> = 5.8 Hz, 2H), 2.66 (t, <i>J</i> = 5.8 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H), 1.29 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 164.52, 159.90, 158.99, 157.65, 139.53, 139.31, 138.56, 134.34, 129.41, 127.68, 127.63, 126.77, 120.71, 118.32, 116.76, 116.39, 58.83, 55.77, 53.83, 51.06, 50.47, 29.59, 29.03, 23.05, 17.15. HRMS (ESI) <i>m</i>/<i>z</i>: 488.6520 [M + H<sup>+</sup>].</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>E</i>)-<i>N</i>,<i>N</i>-Diethyl-4-(6-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-enamide (<b>13ah</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.30 (d, J = 22.5 Hz, 2H), 8.08 (s, 1H), 7.67 (d, <i>J</i> = 2.2 Hz, 1H), 7.48 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 6.71 (dt, <i>J</i> = 15.1, 6.0 Hz, 1H), 6.61–6.52 (m, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.52 (s, 2H), 3.38 (s, 3H), 3.30–3.25 (m, 2H), 2.83 (t, <i>J</i> = 5.9 Hz, 2H), 2.68 (t, <i>J</i> = 5.8 Hz, 2H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H), 1.17–0.99 (m, 7H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.85, 158.70, 157.79, 154.11, 139.32, 137.19, 137.08, 129.48, 120.53, 120.22, 116.78, 114.55, 106.91, 63.14, 53.84, 48.24, 35.15, 33.95, 23.05, 18.71, 17.15, 11.35. HRMS (ESI) <i>m</i>/<i>z</i>: 488.6542 [M + H<sup>+</sup>].</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-(7-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)acetonitrile (<b>13ai</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.25 (s, 1H), 8.30 (d, <i>J</i> = 21.5 Hz, 2H), 8.09 (s, 1H), 7.65 (d, <i>J</i> = 2.3 Hz, 1H), 7.50 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.04 (d, <i>J</i> = 8.4 Hz, 1H), 4.63 (hept, <i>J</i> = 6.7 Hz, 1H), 3.93 (s, 2H), 3.68 (s, 2H), 2.84–2.71 (m, 4H), 2.32 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 159.90, 158.96, 157.66, 139.32, 139.29, 133.95, 133.95, 129.38, 128.93, 125.94, 120.72, 117.55, 116.47, 116.34, 116.20, 54.40, 53.85, 49.90, 45.51, 40.00, 28.39, 23.04, 17.16. HRMS (ESI) <i>m</i>/<i>z</i>: 388.4910 [M + H<sup>+</sup>].</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>E</i>)-1-(7-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-4-phenylbut-2-ene-1,4-dione (<b>13aj</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.31 (d, <i>J</i> = 3.6 Hz, 1H), 8.34 (s, 1H), 8.28 (d, <i>J</i> = 7.3 Hz, 1H), 8.12–8.01 (m, 3H), 7.85–7.75 (m, 2H), 7.73–7.67 (m, 1H), 7.62–7.50 (m, 4H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 4.79 (d, <i>J</i> = 40.6 Hz, 2H), 4.61 (dq, <i>J</i> = 13.3, 6.7 Hz, 1H), 3.82 (dt, <i>J</i> = 10.9, 5.9 Hz, 2H), 2.82 (dt, <i>J</i> = 24.6, 5.9 Hz, 2H), 2.32 (d, <i>J</i> = 4.6 Hz, 3H), 1.48 (dd, <i>J</i> = 16.7, 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 188.48, 167.69, 157.94, 151.81, 138.93, 138.61, 138.16, 132.55, 132.01, 131.74, 130.78, 128.97, 127.02, 125.22, 121.82, 119.95, 118.78, 54.13, 46.66, 44.21, 29.07, 23.19, 15.44. HRMS (ESI) <i>m</i>/<i>z</i>: 507.6100 [M + H<sup>+</sup>].</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Methyl-(<i>E</i>)-4-(7-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-enoate (<b>13ak</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.21 (s, 1H), 8.32 (s, 1H), 8.26 (d, <i>J</i> = 5.5 Hz, 1H), 8.07 (d, <i>J</i> = 6.0 Hz, 1H), 7.61 (s, 1H), 7.50–7.45 (m, 1H), 7.00 (t, <i>J</i> = 9.9 Hz, 1H), 6.93 (dt, <i>J</i> = 15.7, 5.8 Hz, 1H), 6.10 (d, <i>J</i> = 15.7 Hz, 1H), 4.62 (dt, <i>J</i> = 13.3, 6.6 Hz, 1H), 3.68 (s, 3H), 3.58 (s, 2H), 3.32–3.29 (m, 2H), 2.75 (d, <i>J</i> = 5.1 Hz, 2H), 2.67 (t, <i>J</i> = 5.4 Hz, 2H), 2.30 (d, <i>J</i> = 9.3 Hz, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 166.38, 159.89, 158.97, 157.64, 146.65, 139.26, 139.16, 134.82, 129.36, 128.84, 126.72, 122.54, 120.75, 117.36, 116.39, 116.26, 65.38, 58.42, 56.33, 53.83, 51.81, 51.08, 28.45, 23.02, 17.14, 15.62. HRMS (ESI) <i>m</i>/<i>z</i>: 447.5550 [M + H<sup>+</sup>].</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>E</i>)-1-(7-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-4-(<i>p</i>-tolyl)but-2-ene-1,4-dione (<b>13al</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.31 (d, <i>J</i> = 3.4 Hz, 1H), 8.39–8.21 (m, 2H), 8.08 (d, <i>J</i> = 10.4 Hz, 1H), 7.96 (dd, <i>J</i> = 8.0, 4.3 Hz, 2H), 7.88–7.68 (m, 2H), 7.61–7.47 (m, 2H), 7.38 (dd, <i>J</i> = 8.1, 4.2 Hz, 2H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 4.94–4.49 (m, 3H), 3.82 (dt, <i>J</i> = 9.7, 5.9 Hz, 2H), 2.81 (dt, <i>J</i> = 24.2, 5.9 Hz, 2H), 2.40 (d, <i>J</i> = 3.7 Hz, 3H), 2.32 (d, <i>J</i> = 4.5 Hz, 3H), 1.48 (dd, J = 16.3, 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 188.51, 167.69, 157.92, 151.75, 142.36, 138.67, 136.61, 131.44, 130.18, 129.22, 128.97, 126.98, 125.22, 121.82, 119.95, 118.51, 54.14, 46.66, 44.23, 29.07, 23.16, 21.34, 15.44. HRMS (ESI) <i>m</i>/<i>z</i>: 521.6370 [M + H<sup>+</sup>].</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>E</i>)-4-(Dimethylamino)-1-(7-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)but-2-en-1-one (<b>13am</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.32 (d, <i>J</i> = 10.3 Hz, 1H), 8.34 (d, <i>J</i> = 5.4 Hz, 1H), 8.28 (s, 1H), 8.10 (s, 1H), 7.76 (d, <i>J</i> = 13.3 Hz, 1H), 7.54 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 6.95 (dd, <i>J</i> = 23.4, 15.0 Hz, 1H), 6.65 (dt, <i>J</i> = 14.7, 6.8 Hz, 1H), 4.79 (s, 1H), 4.69 (s, 1H), 4.63 (q, <i>J</i> = 6.7 Hz, 1H), 3.79 (dt, <i>J</i> = 15.3, 5.9 Hz, 2H), 3.68 (d, <i>J</i> = 6.9 Hz, 2H), 2.79 (dt, <i>J</i> = 30.7, 5.8 Hz, 2H), 2.63 (s, 6H), 2.32 (s, 3H), 1.50 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 166.48, 157.98, 157.32, 151.95, 139.51, 138.89, 138.61, 131.22, 130.08, 126.99, 125.17, 122.18, 119.89, 119.75, 118.46, 58.03, 54.16, 46.57, 45.19, 44.61, 29.28, 23.19, 15.48. HRMS (ESI) <i>m</i>/<i>z</i>: 460.5988 [M + H<sup>+</sup>].</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01488" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01488?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01488</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding affinities of <b>13ac</b> with 365 protein kinases;1H NMR, 13C NMR, MS/MS, and HPLC spectra of compound <b>13ac</b>; routine blood test in normal mice; and effect of <b>13ac</b> on mouse models (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> used for modeling docking in JAK2 of <b>13ac</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> used for modeling docking in FLT3 of <b>18e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">(<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings of the prepared compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf">jm0c01488_si_001.pdf (527.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb">jm0c01488_si_002.pdb (184.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb">jm0c01488_si_003.pdb (742.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb">jm0c01488_si_004.pdb (504.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv">jm0c01488_si_005.csv (5.11 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01488" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhuang Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span>; 
    <span class="hlFld-Affiliation affiliation">Chengdu
Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4e37213b2029777e7e760e7f7c78602d2123"><span class="__cf_email__" data-cfemail="0b72647e656c323b3b334b3a393d25686466">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijuan Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span>; 
    <span class="hlFld-Affiliation affiliation">Chengdu
Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8076-163X" title="Orcid link">http://orcid.org/0000-0002-8076-163X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d0b3b8b5bebcb9baa5b1bee1e2e590e1e6e3feb3bfbd"><span class="__cf_email__" data-cfemail="cba8a3aea5a7a2a1beaaa5faf9fe8bfafdf8e5a8a4a6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengshi Hu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingli Xiang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minghai Tang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyan Qi</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingsong Shi</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun He</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue Yuan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chufeng Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kongjun Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiewen Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, National Clinical
Research Center for Geriatrics, West China
Hospital of Sichuan University, Chengdu 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.Y, M.H., and Y.C. contributed equally and should be considered as co-first authors</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors greatly appreciate the financial support from the National Science Foundation of China (81527806, 82073693, and 81673289) and Post-Doctor Research Project, West China Hospital, Sichuan Univeristy (2018HXBH054). The authors also greatly appreciate the financial support from 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University. Thanks to West China College of Pharmacy Sichuan University for providing Schrodinger software and technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31810" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31810" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spivak, J. L.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative neoplasms</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">2168</span>– <span class="NLM_lpage">2181</span>, <span class="refDoi"> DOI: 10.1056/nejmra1406186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1056%2FNEJMra1406186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28564565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=2168-2181&author=J.+L.+Spivak&title=Myeloproliferative+neoplasms&doi=10.1056%2Fnejmra1406186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative neoplasms</span></div><div class="casAuthors">Spivak, Jerry L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2168-2181</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this study the myeloproliferative neoplasms- polycythemia vera, essential thrombocytosis, and primary myelofibrosis are unique hematopoietic stem-cell disorders that share mutations that constitutively activate the physiol. signal-transduction pathways responsible for hematopoiesis.  In contrast to the myeloid neoplasms, the myeloproliferative neoplasms have a natural history, with supportive care alone, that is usually measured in decades rather than years.  The pathogenesis of myeloproliferative neoplasms has been enigmatic, and therapy largely supportive.  Recently, however, driver mutations have been identified in more than 90% of patients with myeloproliferative neoplasms, providing substantial insight into their pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsmtVJJhElCLVg90H21EOLACvtfcHk0ljNzG0FCz5Llg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrrF&md5=a9b824de674e48af2fd534dc4e1a3cfc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1406186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1406186%26sid%3Dliteratum%253Aachs%26aulast%3DSpivak%26aufirst%3DJ.%2BL.%26atitle%3DMyeloproliferative%2520neoplasms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D2168%26epage%3D2181%26doi%3D10.1056%2Fnejmra1406186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nangalia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative neoplasms: from origins to outcomes</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2475</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-06-782037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2017-06-782037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29212804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eru7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2475-2483&author=J.+Nangaliaauthor=A.+R.+Green&title=Myeloproliferative+neoplasms%3A+from+origins+to+outcomes&doi=10.1182%2Fblood-2017-06-782037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative neoplasms: from origins to outcomes</span></div><div class="casAuthors">Nangalia, Jyoti; Green, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2475-2483</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms.  The discovery of mutations in JAK2 over a decade ago heralded a new age for patient care as a consequence of improved diagnosis and the development of therapeutic JAK inhibitors.  The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients with myeloproliferative neoplasm now having a biol. basis for their excessive myeloproliferation.  We are also beginning to understand the processes that lead to acquisition of somatic mutations and the factors that influence subsequent clonal expansion and emergence of disease.  Extended genomic profiling has established a multitude of addnl. acquired mutations, particularly prevalent in myelofibrosis, where their presence carries prognostic implications.  A major goal is to integrate genetic, clin., and lab. features to identify patients who share disease biol. and clin. outcome, such that therapies, both existing and novel, can be better targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1aAK9C5xtZbVg90H21EOLACvtfcHk0ljRNl7gT34WYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eru7zO&md5=8e10cb2da4186470af3b6d6eaa514427</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-06-782037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-06-782037%26sid%3Dliteratum%253Aachs%26aulast%3DNangalia%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DMyeloproliferative%2520neoplasms%253A%2520from%2520origins%2520to%2520outcomes%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D2475%26epage%3D2483%26doi%3D10.1182%2Fblood-2017-06-782037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasserjian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowitz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardiman, J. W.</span></span> <span> </span><span class="NLM_article-title">The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-643544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2016-03-643544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=27069254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1agu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2391-2405&author=D.+A.+Arberauthor=A.+Oraziauthor=R.+Hasserjianauthor=J.+Thieleauthor=M.+J.+Borowitzauthor=M.+M.+Le+Beauauthor=C.+D.+Bloomfieldauthor=M.+Cazzolaauthor=J.+W.+Vardiman&title=The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+leukemia&doi=10.1182%2Fblood-2016-03-643544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</span></div><div class="casAuthors">Arber, Daniel A.; Orazi, Attilio; Hasserjian, Robert; Thiele, Juergen; Borowitz, Michael J.; Le Beau, Michelle M.; Bloomfield, Clara D.; Cazzola, Mario; Vardiman, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2391-2405</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008.  Since then, there have been numerous advances in the identification of unique biomarkers assocd. with some myeloid neoplasms and acute leukemias, largely derived from gene expression anal. and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added.  Therefore, there is a clear need for a revision to the current classification.  The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists.  The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clin., prognostic, morphol., immunophenotypic, and genetic data that have emerged since the last edition.  The major changes in the classification and their rationale are presented here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVRZ1wWthKVrVg90H21EOLACvtfcHk0ljRNl7gT34WYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1agu7g%253D&md5=fa799ac2063bb46f5bcef22fcaea9a30</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-643544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-643544%26sid%3Dliteratum%253Aachs%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DOrazi%26aufirst%3DA.%26aulast%3DHasserjian%26aufirst%3DR.%26aulast%3DThiele%26aufirst%3DJ.%26aulast%3DBorowitz%26aufirst%3DM.%2BJ.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26atitle%3DThe%25202016%2520revision%2520to%2520the%2520World%2520Health%2520Organization%2520classification%2520of%2520myeloid%2520neoplasms%2520and%2520acute%2520leukemia%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2391%26epage%3D2405%26doi%3D10.1182%2Fblood-2016-03-643544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative neoplasms: a contemporary review</span>. <i>JAMA. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1001%2Fjamaoncol.2015.89" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=26182311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fkt1Cmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=97-105&author=A.+Tefferiauthor=A.+Pardanani&title=Myeloproliferative+neoplasms%3A+a+contemporary+review&doi=10.1001%2Fjamaoncol.2015.89"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative Neoplasms: A Contemporary Review</span></div><div class="casAuthors">Tefferi Ayalew; Pardanani Animesh</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-105</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF.  These mutations might be accompanied by other mutations that are less specific to myeloproliferative neoplasms but are prognostically relevant, such as additional sex combs-like 1 (ASXL1).  Characteristic bone marrow morphology is required for World Health Organization-compliant diagnosis, especially in distinguishing ET from prefibrotic PMF and masked PV.  Survival is the longest in ET, although still inferior to that of the age- and sex-matched control population; median survivals for patients younger than 60 years are approximately 33 years for ET, 24 for PV, and 15 for PMF.  Major disease complications include thrombosis and leukemic or fibrotic transformation.  In PV and ET, risk factors for survival include older age, leukocytosis, and thrombosis, whereas JAK2 mutation in ET is associated with increased risk of thrombosis.  In PMF, type 1 or type 1-like CALR mutations are associated with superior and ASXL1 with inferior survival.  Prevention of thrombosis in PV is secured by phlebotomy (hematocrit target <45%) and in both PV and ET by low-dose aspirin therapy; high-risk patients derive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice.  Although the JAK inhibitor ruxolitinib was recently approved for use in hydroxyurea-resistant PV, its role in routine clinical practice remains debatable.  In myelofibrosis, stem cell transplant is the current treatment of choice for genetically or clinically high-risk disease; for all other patients requiring treatment, participation in clinical trials may be preferred because currently available drugs, including JAK inhibitors, are palliative and not shown to be disease modifying.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSOpnvZaOu_QyMywPm6HgQfW6udTcc2ebEwo1381rkw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fkt1Cmtw%253D%253D&md5=d9d42b40433720dda35e87fa19288b50</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.89%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DPardanani%26aufirst%3DA.%26atitle%3DMyeloproliferative%2520neoplasms%253A%2520a%2520contemporary%2520review%26jtitle%3DJAMA.%2520Oncol.%26date%3D2015%26volume%3D1%26spage%3D97%26epage%3D105%26doi%3D10.1001%2Fjamaoncol.2015.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltzman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fleu.2017.330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29263442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1035-1038&author=A.+Pardananiauthor=J.+Gotlibauthor=A.+W.+Robertsauthor=M.+Wadleighauthor=S.+Sirhanauthor=J.+Kawashimaauthor=J.+A.+Maltzmanauthor=L.+Shaoauthor=V.+Guptaauthor=A.+Tefferi&title=Long-term+efficacy+and+safety+of+momelotinib%2C+a+JAK1+and+JAK2+inhibitor%2C+for+the+treatment+of+myelofibrosis&doi=10.1038%2Fleu.2017.330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis</span></div><div class="casAuthors">Pardanani, A.; Gotlib, J.; Roberts, A. W.; Wadleigh, M.; Sirhan, S.; Kawashima, J.; Maltzman, J. A.; Shao, L.; Gupta, V.; Tefferi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1035-1038</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) 2 mutation (JAK2V617F) is frequently present in patients with the BCR-ABL1-neg. myeloproliferative neoplasms,1 including primary myelofibrosis or secondary myelofibrosis (MF) following progression of polycythemia vera (PV) or essential thrombocythemia (ET).2, 3, 4, 5 Momelotinib, a JAK1 and JAK2 inhibitor, has demonstrated activity in preclin. studies.6, 7, 8 The efficacy and safety of momelotinib was evaluated in a two-part, phase 1/2 core study (NCT00935987) in patients with intermediate or high risk primary myelofibrosis or post-PV/ET MF.  In part 1 (dose-escalation study) five successive cohorts of three patients received increasing oral once-daily doses of momelotinib capsule (100, 150, 200, 300 and 400 mg).  In an initial preplanned anal. of 60 patients, momelotinib (max. tolerated dose 300 mg once daily) was well tolerated and led to significant anemia and spleen responses.9 In part 2 (dose-confirmation study), patients continued momelotinib treatment for up to nine 28-day cycles (in the absence of toxicity) with expansion of the 150 mg once-daily, 300 mg once-daily and 150 mg twice-daily cohorts.  Patients who completed nine cycles of momelotinib in the core study could enroll in the open-label extension study (NCT01236638).  More details on methods can be found in Supplementary Materials.  Of 166 patients enrolled in the core study between Nov. 2009 and August 2011, 165 received at least one dose of study drug and had at least one postbaseline efficacy evaluation.  In total, 124 (75%) patients completed the core study and 120 enrolled in the extension study (August 2010-Apr. 2012).  The study ended in June 2014 and the data cutoff for this anal. is Feb. 2015.  Thirty (25.0%) patients completed the extension study.  In both studies, the most common reasons for discontinuation were adverse events (AEs) and disease progression (Supplementary Table 1).  Most patients were male (58.4%) and white (91.0%); median age (range) was 67 (34-89) years.  Overall, 105 (63.3%) patients were diagnosed with primary myelofibrosis.  The JAK2V617F mutation was present in 116 (69.9%) patients and 145 (87.3%) had a spleen size ≥10 cm (median (range) 18 (6-34) cm; Supplementary Table 2).  At baseline, 73 (44.0%) patients were transfusion-dependent and 104 (62.7%) had Hb values <10 g/dL.  The median Hb level was 9.4 g/dL (range 5.9-15.1), and median platelets and abs. neutrophils counts were 182.0 × 109/l and 8.1 × 109/l, resp.  Overall, 23 (13.9%) and 15 (9.0%) patients received prior treatment with a JAK inhibitor or immunomodulatory drugs, resp.  Over the course of the core and extension studies (median (range) 15.3 (0.1-48.8) months), 95/165 (57.6%) patients achieved a response (partial response (n=1, in 150 mg twice-daily group), or clin. improvement (n=94)).  Sixty-nine patients had stable disease and one patient (300 mg once-daily group) experienced progressive disease.  Of 111 anemia-evaluable patients, defined as those who completed ≥8 wk on study and were, at baseline, either transfusion-dependent (n=72) or were not transfusion-dependent but had a Hb level <10 g/dL (n=39), 65 (58.6%) patients were 8-wk anemia responders; 54/72 (75.0%) transfusion-dependent patients achieved transfusion-independence response and 11/39 (28.2%) patients with a Hb level <10 g/dL achieved a Hb response (Table 1).  Median increase in Hb was 2.4 g/dL.  Median (95% confidence interval (CI)) duration of 8-wk anemia response was 7.7 (4.1, 16.1) months (Table 1, Supplementary Figure 1A).  Even when using the more stringent definition for anemia response (≥12 wk),10 the response among anemic patients was evident in over 50% of patients (Table 1).  Forty-nine patients achieved a 12-wk transfusion-independence response (8 in the extension study) and 11 patients experienced a 12-wk Hb response (7 in the extension study).  For the 11 Hb responders, the median (range) increase in Hb was 2.3 (2.1-3.6) g/dL.  Median (95% CI) duration of 12-wk anemia response was 12.8 (7.4, 26.7) months (Table 1, Supplementary Figure 1B).  Overall, the nos. of anemia responders were consistently higher, and the duration of responses was longer, in the dose cohort of momelotinib 300 mg once daily compared with momelotinib 150 mg once daily (Table 1).  Among 147 patients with palpable splenomegaly (>5 cm) at baseline, 59 (40.1%) patients achieved spleen response for clin. improvement (per 2006 IWG-MRT criteria)11 (Table 1)-48 during the core study and 11 during the extension study.  Median time (range) to onset of response was 0.8 (0.2, 33.4) months.  Median duration of spleen response was not reached (NR; Supplementary Figure 1C), and the median follow-up time during response was 14.2 (1.8, 49.3) months.  The estd. 2-yr probability of remaining in response was 68% (95 CI, 52, 80%).  Over the course of both studies, a redn. in palpable splenomegaly was obsd., with a mean decrease from baseline of 59.7% (Supplementary Figure 2).  MRI-assessment of spleen size was performed in 12 patients receiving momelotinib 150 mg twice daily, and confirmed a redn. in spleen vol. over time.  In eight patients evaluable at 197 days, the median decrease of spleen vol. was 35%, compared to baseline.  Although symptom response was not uniformly assessed in the core study, an overall improvement of constitutional symptoms was noted (Supplementary Table 3).  The JAK2V617F allele burden was not reduced by momelotinib treatment (Supplementary Figure 3).  Disease progression (per 2006 IWG-MRT criteria) or death occurred in 53/165 (32.1%) patients; 6 (3.6%) patients reported acute leukemia.  The estd. median (95% CI) time to disease progression or death was 43.7 (34.5, NR) months.  After a median follow-up of 19.5 (1.5, 49.8) months, the median OS was NR.  The min. follow-up time for patients who did not have an event at this data cutoff was 2.3 mo.  The progression free survival and overall survival Kaplan-Meier curves are depicted in Supplementary Figures 4a and b.  The median (range) duration of exposure to momelotinib was 15.3 (0.1, 48.8) months and median daily dose was 281 mg.  Dose redns. at any time during the study, based on total daily dose compared with initial dosing assignment, occurred in 96 (57.8%) patients (Supplementary Table 4).  All 166 patients experienced at least one treatment-emergent AE (TEAE) (Table 2).  Adverse events considered by the investigator to be related to momelotinib treatment were reported in 160 (96.4%) patients.  The most common grade 1/2 treatment-related AEs included diarrhea, peripheral neuropathy, peripheral sensory neuropathy, dizziness, nausea and thrombocytopenia (Supplementary Table 5).  A treatment-related first-dose effect was assocd. with AEs of dizziness, nausea, hypotension, headache and flushing.  Among AEs of neurol. origin considered related to study drug, the most frequent AEs were peripheral neuropathy (44 (26.5%)), peripheral sensory neuropathy (41 (24.7%)), dizziness (41 (24.7%)), and headache (26 (15.7); Supplementary Tables 5 and 6).  All peripheral neuropathy AEs were either grade 1 or 2.  Twenty (12.0%) patients who reported a TEAE of peripheral neuropathy had a past medical history of peripheral neuropathy.  Twenty-two of 166 (13.3%) patients and 23 of 120 (19.2%) patients discontinued the core and extension studies, resp., due to AEs, excluding disease progression.  The most common AEs leading to study discontinuation were thrombocytopenia, peripheral sensory neuropathy and peripheral neuropathy (Supplementary Table 7).  Overall, 32 patients (19.3%) died due to AEs during the core and extension studies (Supplementary Table 8); no deaths were considered related to momelotinib treatment.  Causes of death were consistent with known causes of death in patients with MF.  This study demonstrates that long-term treatment with momelotinib is effective and well tolerated in patients with MF at a daily oral dose of 300 mg capsule.  No new safety concerns emerged compared with the core study.9 Recently, a study by Gupta et al. reported evidence of efficacy and tolerability of momelotinib 200 mg twice daily in a similar patient population.12 The higher rates of anemia response with momelotinib, compared to those previously reported for ruxolitinib,13, 14 are consistent with data from the SIMPLIFY-1 study, where a significantly higher proportion of patients on the momelotinib arm achieved improvement in transfusion rate, transfusion independence and transfusion dependence, compared to the ruxolitinib arm.15.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDGpiOe7LpgbVg90H21EOLACvtfcHk0ljupTkRZxj7Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejsbfO&md5=e70542f4b6ff1837e0f710f04fdc5dd7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.330%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DSirhan%26aufirst%3DS.%26aulast%3DKawashima%26aufirst%3DJ.%26aulast%3DMaltzman%26aufirst%3DJ.%2BA.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DLong-term%2520efficacy%2520and%2520safety%2520of%2520momelotinib%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1035%26epage%3D1038%26doi%3D10.1038%2Fleu.2017.330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pungolino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramazza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span> <span> </span><span class="NLM_article-title">Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-02-414631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2012-02-414631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=22718840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WjsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=1202-1209&author=S.+Verstovsekauthor=H.+M.+Kantarjianauthor=Z.+Estrovauthor=J.+E.+Cortesauthor=D.+A.+Thomasauthor=T.+Kadiaauthor=S.+Pierceauthor=E.+Jabbourauthor=G.+Borthakurauthor=E.+Rumiauthor=E.+Pungolinoauthor=E.+Morraauthor=D.+Caramazzaauthor=M.+Cazzolaauthor=F.+Passamonti&title=Long-term+outcomes+of+107+patients+with+myelofibrosis+receiving+JAK1%2FJAK2+inhibitor+ruxolitinib%3A+survival+advantage+in+comparison+to+matched+historical+controls&doi=10.1182%2Fblood-2012-02-414631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop M.; Estrov, Zeev; Cortes, Jorge E.; Thomas, Deborah A.; Kadia, Tapan; Pierce, Sherry; Jabbour, Elias; Borthakur, Gautham; Rumi, Elisa; Pungolino, Ester; Morra, Enrica; Caramazza, Domenica; Cazzola, Mario; Passamonti, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1202-1209</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ruxolitinib is JAK1/JAK2 inhibitor with established clin. benefit in myelofibrosis (MF).  We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial.  After a median of 32 mo of follow-up, 58 patients (54%) were still receiving ruxolitinib, with overall survival (OS) of 69%.  The splenomegaly and symptom redns. achieved with ruxolitinib were sustained with long-term therapy.  Therapy was well tolerated; discontinuation rates at 1, 2, and 3 years were 24%, 36%, and 46%, resp.  OS of 107 MDACC patients was significantly better (P = .005) than that of 310 matched (based on trial enrollment criteria) historical control patients, primarily because of highly significant difference in OS in the high-risk subgroup (P = .006).  Furthermore, among MDACC patients, those with high-risk MF experienced the same OS as those with intermediate-2 risk.  Patients with ≥ 50% redn. in splenomegaly had significantly prolonged survival vs. those with < 25% redn. (P < .0001).  Comparison of discontinuation rates and reasons for stopping the therapy to those reported for other 51 patients in the phase 1/2 trial, and 155 ruxolitinib-treated patients in phase 3 COMFORT-I study, suggest that continued therapy with ruxolitinib at optimal doses contributes to the benefits seen, including OS benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNPbH3KU9dQrVg90H21EOLACvtfcHk0ljupTkRZxj7Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WjsrrJ&md5=d1d30c8d1ac158ff181e743dd56e3107</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-02-414631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-02-414631%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DRumi%26aufirst%3DE.%26aulast%3DPungolino%26aufirst%3DE.%26aulast%3DMorra%26aufirst%3DE.%26aulast%3DCaramazza%26aufirst%3DD.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DPassamonti%26aufirst%3DF.%26atitle%3DLong-term%2520outcomes%2520of%2520107%2520patients%2520with%2520myelofibrosis%2520receiving%2520JAK1%252FJAK2%2520inhibitor%2520ruxolitinib%253A%2520survival%2520advantage%2520in%2520comparison%2520to%2520matched%2520historical%2520controls%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D1202%26epage%3D1209%26doi%3D10.1182%2Fblood-2012-02-414631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1038/nrc2210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fnrc2210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=17721432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=673-683&author=R.+L.+Levineauthor=A.+Pardananiauthor=A.+Tefferiauthor=D.+G.+Gilliland&title=Role+of+JAK2+in+the+pathogenesis+and+therapy+of+myeloproliferative+disorders&doi=10.1038%2Fnrc2210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders</span></div><div class="casAuthors">Levine, Ross L.; Pardanani, Animesh; Tefferi, Ayalew; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The myeloproliferative disorders polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent hematopoietic progenitors.  The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F).  These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new mol. targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5nfhX3BsOrVg90H21EOLACvtfcHk0ljupTkRZxj7Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsbg%253D&md5=89429b6786f421d06163a48540c03dcb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2210%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DRole%2520of%2520JAK2%2520in%2520the%2520pathogenesis%2520and%2520therapy%2520of%2520myeloproliferative%2520disorders%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D673%26epage%3D683%26doi%3D10.1038%2Fnrc2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffioli, M.</span></span> <span> </span><span class="NLM_article-title">The role of JAK2 inhibitors in MPNs 7 years after approval</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2426</span>– <span class="NLM_lpage">2435</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-01-791491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2018-01-791491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29650801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaqsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2426-2435&author=F.+Passamontiauthor=M.+Maffioli&title=The+role+of+JAK2+inhibitors+in+MPNs+7+years+after+approval&doi=10.1182%2Fblood-2018-01-791491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of JAK2 inhibitors in MPNs 7 years after approval</span></div><div class="casAuthors">Passamonti, Francesco; Maffioli, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2426-2435</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF).  Phenotype-driver mutations of JAK2, CALR, and MPL genes are present in MPNs and can be variably combined with addnl. mutations.  Driver mutations entail a constitutive activation of the JAK2/STAT pathway, the key signaling cascade inMPNs.  Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea.  Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF.  The primary end points in MF trials were spleen vol. response (SVR) and symptom response, whereas in PV trials they were hematocrit control with or without spleen response.  In advanced MF, RUX achieved a long lasting SVR of >35% in ∼60% of patients, establishing a new benchmark for MF treatment.  RUX efficacy in early MF is also remark-able and toxicity is mild.  In PV, RUX achieved hematocrit control in ∼60% of cases and SVR in 40%.  Symptom relief was evident in both conditions.  In the long-term, however, many MF patients lose their SVR.  Indeed, the definition of RUX failure and the design of new trials in this setting are unmet needs.  Decrease of Hb/ platelet levels and increased infection rates are the most common side effects of RUX, and nonmelanoma skin tumors need to be monitored while on treatment.  In conclusion, the introduction of JAKis raises the bar of treatment goals in MF and PV. (Blood. 2018; 131(22):2426-2435).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXyflp1d4F27Vg90H21EOLACvtfcHk0lh-GjsRvteXMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaqsb7P&md5=067d39b49a22ac9b13f121c366afbd72</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-01-791491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-01-791491%26sid%3Dliteratum%253Aachs%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DMaffioli%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520JAK2%2520inhibitors%2520in%2520MPNs%25207%2520years%2520after%2520approval%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D2426%26epage%3D2435%26doi%3D10.1182%2Fblood-2018-01-791491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntly, B. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelsperger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2Fj.ccr.2005.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=15837627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=387-397&author=R.+L.+Levineauthor=M.+Wadleighauthor=J.+Coolsauthor=B.+L.+Ebertauthor=G.+Wernigauthor=B.+J.+P.+Huntlyauthor=T.+J.+Boggonauthor=I.+Wlodarskaauthor=J.+J.+Clarkauthor=S.+Mooreauthor=J.+Adelspergerauthor=S.+Kooauthor=J.+C.+Leeauthor=S.+Gabrielauthor=T.+Mercherauthor=A.+D%E2%80%99Andreaauthor=S.+Fr%C3%B6hlingauthor=K.+D%C3%B6hnerauthor=P.+Marynenauthor=P.+Vandenbergheauthor=R.+A.+Mesaauthor=A.+Tefferiauthor=J.+D.+Griffinauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=T.+R.+Golubauthor=S.+J.+Leeauthor=D.+G.+Gilliland&title=Activating+mutation+in+the+tyrosine+kinase+JAK2+in+polycythemia+vera%2C+essential+thrombocythemia%2C+and+myeloid+metaplasia+with+myelofibrosis&doi=10.1016%2Fj.ccr.2005.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span></div><div class="casAuthors">Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J. P.; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Froehling, Stefan; Doehner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-397</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.  An internet-based protocol was used to collect clin. information and biol. specimens from patients with these diseases.  High-throughput DNA re-sequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.  Mol. and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele.  JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not obsd. in 269 normal individuals.  In vitro anal. demonstrated that JAK2V617F is a constitutively active tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJNzUFm3Q3bVg90H21EOLACvtfcHk0lh-GjsRvteXMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D&md5=2a3e893867b114e8749cd6f5e55990b7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%2BP.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DAdelsperger%26aufirst%3DJ.%26aulast%3DKoo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DMercher%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DActivating%2520mutation%2520in%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520polycythemia%2520vera%252C%2520essential%2520thrombocythemia%252C%2520and%2520myeloid%2520metaplasia%2520with%2520myelofibrosis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D387%26epage%3D397%26doi%3D10.1016%2Fj.ccr.2005.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span> <span> </span><span class="NLM_article-title">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">854</span>, <span class="refDoi"> DOI: 10.3390/cells8080854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.3390%2Fcells8080854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=854&author=F.+Pernerauthor=C.+Pernerauthor=T.+Ernstauthor=F.+H.+Heidel&title=Roles+of+JAK2+in+aging%2C+inflammation%2C+hematopoiesis+and+malignant+transformation&doi=10.3390%2Fcells8080854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span></div><div class="casAuthors">Perner, Florian; Perner, Caroline; Ernst, Thomas; Heidel, Florian H.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clonal alterations in hematopoietic cells occur during aging and are often assocd. with the establishment of a subclin. inflammatory environment.  Several age-related conditions and diseases may be initiated or promoted by these alterations.  JAK2 mutations are among the most frequently mutated genes in blood cells during aging.  The most common mutation within the JAK2 gene is JAK2-V617F that leads to constitutive activation of the kinase and thereby aberrant engagement of downstream signaling pathways.  JAK2 mutations can act as central drivers of myeloproliferative neoplasia, a pre-leukemic and age-related malignancy.  Likewise, hyperactive JAK-signaling is a hallmark of immune diseases and critically influences inflammation, coagulation and thrombosis.  In this review we aim to summarize the current knowledge on JAK2 in clonal hematopoiesis during aging, the role of JAK-signaling in inflammation and lymphocyte biol. and JAK2 function in age-related diseases and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbCzDy7BOo7Vg90H21EOLACvtfcHk0lh-GjsRvteXMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D&md5=8433e74cbd00a65cd218101e5ca62d79</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fcells8080854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8080854%26sid%3Dliteratum%253Aachs%26aulast%3DPerner%26aufirst%3DF.%26aulast%3DPerner%26aufirst%3DC.%26aulast%3DErnst%26aufirst%3DT.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26atitle%3DRoles%2520of%2520JAK2%2520in%2520aging%252C%2520inflammation%252C%2520hematopoiesis%2520and%2520malignant%2520transformation%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D854%26doi%3D10.3390%2Fcells8080854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boissinot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleyrat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilaine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermouet, S.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1038/onc.2010.479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fonc.2010.479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=21042281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKit73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=990-1001&author=M.+Boissinotauthor=C.+Cleyratauthor=M.+Vilaineauthor=Y.+Jacquesauthor=I.+Correauthor=S.+Hermouet&title=Anti-inflammatory+cytokines+hepatocyte+growth+factor+and+interleukin-11+are+over-expressed+in+polycythemia+vera+and+contribute+to+the+growth+of+clonal+erythroblasts+independently+of+JAK2V617F&doi=10.1038%2Fonc.2010.479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F</span></div><div class="casAuthors">Boissinot, M.; Cleyrat, C.; Vilaine, M.; Jacques, Y.; Corre, I.; Hermouet, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">990-1001</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The V617F activating mutation of janus kinase 2 (JAK2), a kinase essential for cytokine signalling, characterizes Polycythemia vera (PV), one of the myeloproliferative neoplasms (MPN).  However, not all MPNs carry mutations of JAK2, and in JAK2-mutated patients, expression of JAK2V617F does not always result in clone expansion.  In the present study, we provide evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors.  In a first series of expts., we searched for cytokines over-expressed in PV using cytokine antibody (Ab) arrays, and enzyme-linked immunosorbent assays for analyses of serum and bone marrow (BM) plasma, and quant. reverse transcription-PCRs for analyses of cells purified from PV patients and controls.  We found that PV patients over-expressed anti-inflammatory hepatocyte growth factor (HGF) and interleukin-11 (IL-11), BM mesenchymal stromal cells (BMMSCs) and erythroblasts being the main producers.  In a second series of expts., autocrine/paracrine cytokine stimulation of erythroblasts was blocked using neutralizing Abs specific for IL-11 or c-MET, the HGF receptor.  The growth of JAK2V617F-mutated HEL cells and PV erythroblasts was inhibited, indicating that JAK2-mutated cells depend on HGF and IL-11 for their growth.  Addnl. expts. showed that transient expression of JAK2V617F in BaF-3/erythropoietin receptor cells, and invalidation of JAK2V617F in HEL cells using anti-JAK2 small interfering RNA, did not affect HGF and IL-11 expression.  Thus, anti-inflammatory HGF and IL-11 are upregulated in PV and their overprodn. is not a consequence of JAK2V617F.  As both cytokines contribute to the proliferation of PV erythroblasts, blocking the c-MET/HGF/IL-11 pathways could be of interest as an addnl. therapeutic option in PV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR59CpYTfgLbVg90H21EOLACvtfcHk0lhi7Y8RW5_IEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKit73J&md5=0b3519e7a3fd7571a41fb9e694c43b1e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.479%26sid%3Dliteratum%253Aachs%26aulast%3DBoissinot%26aufirst%3DM.%26aulast%3DCleyrat%26aufirst%3DC.%26aulast%3DVilaine%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DY.%26aulast%3DCorre%26aufirst%3DI.%26aulast%3DHermouet%26aufirst%3DS.%26atitle%3DAnti-inflammatory%2520cytokines%2520hepatocyte%2520growth%2520factor%2520and%2520interleukin-11%2520are%2520over-expressed%2520in%2520polycythemia%2520vera%2520and%2520contribute%2520to%2520the%2520growth%2520of%2520clonal%2520erythroblasts%2520independently%2520of%2520JAK2V617F%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D990%26epage%3D1001%26doi%3D10.1038%2Fonc.2010.479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massé, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teyssandier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lécluse, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larbret, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koscielny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Couédic, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span> <span> </span><span class="NLM_article-title">The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-10-054940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2006-10-054940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=17389763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos1Cqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1013-1021&author=S.+Dupontauthor=A.+Mass%C3%A9author=C.+Jamesauthor=I.+Teyssandierauthor=Y.+L%C3%A9cluseauthor=F.+Larbretauthor=V.+Ugoauthor=P.+Saulnierauthor=S.+Koscielnyauthor=J.+P.+Le+Cou%C3%A9dicauthor=N.+Casadevallauthor=W.+Vainchenkerauthor=F.+Delhommeau&title=The+JAK2+617V%3EF+mutation+triggers+erythropoietin+hypersensitivity+and+terminal+erythroid+amplification+in+primary+cells+from+patients+with+polycythemia+vera&doi=10.1182%2Fblood-2006-10-054940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera</span></div><div class="casAuthors">Dupont, Sabrina; Masse, Aline; James, Chloe; Teyssandier, Irene; Lecluse, Yann; Larbret, Frederic; Ugo, Valerie; Saulnier, Patrick; Koscielny, Serge; Le Couedic, Jean Pierre; Casadevall, Nicole; Vainchenker, William; Delhommeau, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1013-1021</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The JAK2 617V>F mutation is frequent in polycythemia vera (PV) and essential thrombocythemia (ET).  Using quant. polymerase chain reaction (PCR), the authors found that high levels of JAK2 617V>F in PV correlate with increased granulocytes and high levels of Hb and endogenous erythroid colony formation.  The authors detected normal progenitors and those that were heterozygous or homozygous for the mutation by genotyping ET and PV clonal immature and committed progenitors.  In PV patients, the authors distinguished homozygous profiles with normal, heterozygous, and homozygous progenitors from heterozygous profiles with only heterozygous and normal progenitors.  PV patients with a heterozygous profile had more mutated, committed progenitors than did other PV and ET patients, suggesting a selective amplification of mutated cells in the early phases of hematopoiesis.  The authors demonstrated that mutated erythroid progenitors were more sensitive to erythropoietin than normal progenitors, and that most homozygous erythroid progenitors were erythropoietin independent.  Moreover, the authors obsd. a greater in vitro erythroid amplification and a selective advantage in vivo for mutated cells in late stages of hematopoiesis.  These results suggest that, for PV, erythrocytosis can occur through 2 mechanisms: terminal erythroid amplification triggered by JAK2 617V>F homozygosity, and a 2-step process including the upstream amplification of heterozygous cells that may involve addnl. mol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz7bdbCw13ArVg90H21EOLACvtfcHk0lhi7Y8RW5_IEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos1Cqtrw%253D&md5=5f50d8dd790b2e266d7d1d616a8c3c18</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-10-054940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-10-054940%26sid%3Dliteratum%253Aachs%26aulast%3DDupont%26aufirst%3DS.%26aulast%3DMass%25C3%25A9%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DC.%26aulast%3DTeyssandier%26aufirst%3DI.%26aulast%3DL%25C3%25A9cluse%26aufirst%3DY.%26aulast%3DLarbret%26aufirst%3DF.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DSaulnier%26aufirst%3DP.%26aulast%3DKoscielny%26aufirst%3DS.%26aulast%3DLe%2BCou%25C3%25A9dic%26aufirst%3DJ.%2BP.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DDelhommeau%26aufirst%3DF.%26atitle%3DThe%2520JAK2%2520617V%253EF%2520mutation%2520triggers%2520erythropoietin%2520hypersensitivity%2520and%2520terminal%2520erythroid%2520amplification%2520in%2520primary%2520cells%2520from%2520patients%2520with%2520polycythemia%2520vera%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D1013%26epage%3D1021%26doi%3D10.1182%2Fblood-2006-10-054940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, E. J.</span></span> <span> </span><span class="NLM_article-title">JAK-STAT pathway and myogenic differentiation</span>. <i>JAK-STAT</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e23282</span>, <span class="refDoi"> DOI: 10.4161/jkst.23282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.4161%2Fjkst.23282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=24058805" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e23282&author=Y.-N.+Jangauthor=E.+J.+Baik&title=JAK-STAT+pathway+and+myogenic+differentiation&doi=10.4161%2Fjkst.23282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4161%2Fjkst.23282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.23282%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DY.-N.%26aulast%3DBaik%26aufirst%3DE.%2BJ.%26atitle%3DJAK-STAT%2520pathway%2520and%2520myogenic%2520differentiation%26jtitle%3DJAK-STAT%26date%3D2013%26volume%3D2%26spage%3De23282%26doi%3D10.4161%2Fjkst.23282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Couédic, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staerk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garçon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raslova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennaceur-Griscelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeval, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span> <span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span>,  <span class="NLM_fpage">1144</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.1038/nature03546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.-P.+Le+Cou%C3%A9dicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Gar%C3%A7onauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signalling+causes+polycythaemia+vera&doi=10.1038%2Fnature03546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0lhi7Y8RW5_IEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCou%25C3%25A9dic%26aufirst%3DJ.-P.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGar%25C3%25A7on%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signalling%2520causes%2520polycythaemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148%26doi%3D10.1038%2Fnature03546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griesshammer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pane, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirron, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib versus standard therapy for the treatment of polycythemia vera</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1409002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1056%2FNEJMoa1409002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=25629741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=426-435&author=A.+M.+Vannucchiauthor=J.+J.+Kiladjianauthor=M.+Griesshammerauthor=T.+Massziauthor=S.+Durrantauthor=F.+Passamontiauthor=C.+N.+Harrisonauthor=F.+Paneauthor=P.+Zacheeauthor=R.+Mesaauthor=S.+Heauthor=M.+M.+Jonesauthor=W.+Garrettauthor=J.+Liauthor=U.+Pirronauthor=D.+Habrauthor=S.+Verstovsek&title=Ruxolitinib+versus+standard+therapy+for+the+treatment+of+polycythemia+vera&doi=10.1056%2Fnejmoa1409002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib versus standard therapy for the treatment of polycythemia vera</span></div><div class="casAuthors">Vannucchi, Alessandro M.; Kiladjian, Jean Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Mesa, Ruben; He, Shui; Jones, Mark M.; Garrett, William; Li, Jingjin; Pirron, Ulrich; Habr, Dany; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-435/1-426-435/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clin. benefit in patients with polycythemia vera in a phase 2 study.  We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib vs. std. therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea.  METHODS: We randomly assigned phlebotomy-dependent patients with splenomegaly, in a 1:1 ratio, to receive ruxolitinib (110 patients) or std. therapy (112 patients).  The primary end point was both hematocrit control through week 32 and at least a 35% redn. in spleen vol. at week 32, as assessed by means of imaging.  RESULTS: The primary end point was achieved in 21% of the patients in the ruxolitinib group vs. 1% of those in the std.-therapy group (P<0.001).  Hematocrit control was achieved in 60% of patients receiving ruxolitinib and 20% of those receiving std. therapy; 38% and 1% of patients in the two groups, resp., had at least a 35% redn. in spleen vol.  A complete hematol. remission was achieved in 24% of patients in the ruxolitinib group and 9% of those in the std.-therapy group (P = 0.003); 49% vs. 5% had at least a 50% redn. in the total symptom score at week 32.  In the ruxolitinib group, grade 3 or 4 anemia occurred in 2% of patients, and grade 3 or 4 thrombocytopenia occurred in 5%; the corresponding percentages in the std.-therapy group were 0% and 4%.  Herpes zoster infection was reported in 6% of patients in the ruxolitinib group and 0% of those in the std.- therapy group (grade 1 or 2 in all cases).  Thromboembolic events occurred in one patient receiving ruxolitinib and in six patients receiving std. therapy.  CONCLUSIONS: In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to std. therapy in controlling the hematocrit, reducing the spleen vol., and improving symptoms assocd. with polycythemia vera.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCL1K9GkL--rVg90H21EOLACvtfcHk0lhLbhliD8nU6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGqsrw%253D&md5=de3cbe6f9bf1fc04b573c1dc4e74f085</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1409002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1409002%26sid%3Dliteratum%253Aachs%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DGriesshammer%26aufirst%3DM.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DDurrant%26aufirst%3DS.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DPane%26aufirst%3DF.%26aulast%3DZachee%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DM.%2BM.%26aulast%3DGarrett%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPirron%26aufirst%3DU.%26aulast%3DHabr%26aufirst%3DD.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DRuxolitinib%2520versus%2520standard%2520therapy%2520for%2520the%2520treatment%2520of%2520polycythemia%2520vera%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D426%26epage%3D435%26doi%3D10.1056%2Fnejmoa1409002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Fedratinib: first approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01205-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1007%2Fs40265-019-01205-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=31571162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1719-1725&author=H.+A.+Blair&title=Fedratinib%3A+first+approval&doi=10.1007%2Fs40265-019-01205-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib: First approval for treating myelofibrosis</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1719-1725</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis.  In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.  Phase III clin. development for myelofibrosis is ongoing worldwide.  This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0phtMTwbye7Vg90H21EOLACvtfcHk0lhLbhliD8nU6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP&md5=36fa843febf45050d5dd2d1044b715c8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01205-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01205-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DFedratinib%253A%2520first%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1719%26epage%3D1725%26doi%3D10.1007%2Fs40265-019-01205-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hexner, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serdikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swider, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span> <span> </span><span class="NLM_article-title">Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">5663</span>– <span class="NLM_lpage">5671</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-04-083402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2007-04-083402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=17984313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=5663-5671&author=E.+O.+Hexnerauthor=C.+Serdikoffauthor=M.+Janauthor=C.+R.+Swiderauthor=C.+Robinsonauthor=S.+Yangauthor=T.+Angelesauthor=S.+G.+Emersonauthor=M.+Carrollauthor=B.+Ruggeriauthor=P.+Dobrzanski&title=Lestaurtinib+%28CEP701%29+is+a+JAK2+inhibitor+that+suppresses+JAK2%2FSTAT5+signaling+and+the+proliferation+of+primary+erythroid+cells+from+patients+with+myeloproliferative+disorders&doi=10.1182%2Fblood-2007-04-083402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</span></div><div class="casAuthors">Hexner, Elizabeth O.; Serdikoff, Cynthia; Jan, Mahfuza; Swider, Cezary R.; Robinson, Candy; Yang, Shi; Angeles, Thelma; Emerson, Stephen G.; Carroll, Martin; Ruggeri, Bruce; Dobrzanski, Pawel</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5663-5671</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase.  A multikinase screen detd. that lestaurtinib (formerly known as CEP-701) inhibits wild type JAK2 kinase activity with a concn. that inhibits response by 50% (IC50) of 1 nM in vitro.  We hypothesized that lestaurtinib would inhibit mutant JAK2 kinase activity and suppress the growth of cells from patients with MPDs.  We found that lestaurtinib inhibits the growth of HEL92.1.7 cells, which are dependent on mutant JAK2 activity for growth in vitro and in xenograft models.  Erythroid cells expanded from primary CD34+ cells from patients with MPDs were inhibited by lestaurtinib at concns. of 100 nM or more in 15 of 18 subjects, with concomitant inhibition of phosphorylation of STAT5 and other downstream effectors of JAK2.  By contrast, growth of erythroid cells derived from 3 healthy controls was not significantly inhibited.  These results demonstrate that lestaurtinib, in clin. achievable concns., inhibits proliferation and JAK2/STAT5 signaling in cells from patients with MPDs, and therefore holds promise as a therapeutic agent for patients with these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWg4QF0tD5VbVg90H21EOLACvtfcHk0lhLbhliD8nU6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVOktbw%253D&md5=0fd7e1be98ccd01dde2220364a747877</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-04-083402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-04-083402%26sid%3Dliteratum%253Aachs%26aulast%3DHexner%26aufirst%3DE.%2BO.%26aulast%3DSerdikoff%26aufirst%3DC.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DSwider%26aufirst%3DC.%2BR.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DEmerson%26aufirst%3DS.%2BG.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDobrzanski%26aufirst%3DP.%26atitle%3DLestaurtinib%2520%2528CEP701%2529%2520is%2520a%2520JAK2%2520inhibitor%2520that%2520suppresses%2520JAK2%252FSTAT5%2520signaling%2520and%2520the%2520proliferation%2520of%2520primary%2520erythroid%2520cells%2520from%2520patients%2520with%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D5663%26epage%3D5671%26doi%3D10.1182%2Fblood-2007-04-083402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumm, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichberger, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">5232</span>– <span class="NLM_lpage">5240</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-223727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2009-05-223727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=20385788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=5232-5240&author=J.+W.+Tynerauthor=T.+G.+Bummauthor=J.+Deiningerauthor=L.+Woodauthor=K.+J.+Aichbergerauthor=M.+M.+Loriauxauthor=B.+J.+Drukerauthor=C.+J.+Burnsauthor=E.+Fantinoauthor=M.+W.+Deininger&title=CYT387%2C+a+novel+JAK2+inhibitor%2C+induces+hematologic+responses+and+normalizes+inflammatory+cytokines+in+murine+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-05-223727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</span></div><div class="casAuthors">Tyner, Jeffrey W.; Bumm, Thomas G.; Deininger, Jutta; Wood, Lisa; Aichberger, Karl J.; Loriaux, Marc M.; Druker, Brian J.; Burns, Christopher J.; Fantino, Emmanuelle; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">5232-5240</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating alleles of Janus kinase 2 (JAK2) such as JAK2V617F are central to the pathogenesis of myeloproliferative neoplasms (MPN), suggesting that small mol. inhibitors targeting JAK2 may be therapeutically useful.  We have identified an aminopyrimidine deriv. (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concns., with few addnl. targets.  Between 0.5 and 1.5μM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected.  In a murine MPN model, CYT387 normalized white cell counts, hematocrit, spleen size, and restored physiol. levels of inflammatory cytokines.  Despite the hematol. responses and redn. of the JAK2V617F allele burden, JAK2V617F cells persisted and MPN recurred upon cessation of treatment, suggesting that JAK2 inhibitors may be unable to eliminate JAK2V617F cells, consistent with preliminary results from clin. trials of JAK2 inhibitors in myelofibrosis.  While the clin. benefit of JAK2 inhibitors may be substantial, not the least due to redn. of inflammatory cytokines and symptomatic improvement, our data add to increasing evidence that kinase inhibitor monotherapy of malignant disease is not curative, suggesting a need for drug combinations to optimally target the malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOU9Loc4HZuLVg90H21EOLACvtfcHk0ljTfnLRcnvOag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVWltLg%253D&md5=dc77faf0dbce8bf1cbbda4e1b5799e72</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-223727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-223727%26sid%3Dliteratum%253Aachs%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DBumm%26aufirst%3DT.%2BG.%26aulast%3DDeininger%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DAichberger%26aufirst%3DK.%2BJ.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DCYT387%252C%2520a%2520novel%2520JAK2%2520inhibitor%252C%2520induces%2520hematologic%2520responses%2520and%2520normalizes%2520inflammatory%2520cytokines%2520in%2520murine%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D5232%26epage%3D5240%26doi%3D10.1182%2Fblood-2009-05-223727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platzbecker, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winton, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltzman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e73</span>– <span class="NLM_lpage">e81</span>, <span class="refDoi"> DOI: 10.1016/s2352-3026(17)30237-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2FS2352-3026%2817%2930237-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29275119" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=e73-e81&author=C.+N.+Harrisonauthor=A.+M.+Vannucchiauthor=U.+Platzbeckerauthor=F.+Cervantesauthor=V.+Guptaauthor=D.+Lavieauthor=F.+Passamontiauthor=E.+F.+Wintonauthor=H.+Dongauthor=J.+Kawashimaauthor=J.+D.+Maltzmanauthor=J.-J.+Kiladjianauthor=S.+Verstovsek&title=Momelotinib+versus+best+available+therapy+in+patients+with+myelofibrosis+previously+treated+with+ruxolitinib+%28SIMPLIFY+2%29%3A+a+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2Fs2352-3026%2817%2930237-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2817%2930237-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252817%252930237-5%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DPlatzbecker%26aufirst%3DU.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLavie%26aufirst%3DD.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DWinton%26aufirst%3DE.%2BF.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DKawashima%26aufirst%3DJ.%26aulast%3DMaltzman%26aufirst%3DJ.%2BD.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DMomelotinib%2520versus%2520best%2520available%2520therapy%2520in%2520patients%2520with%2520myelofibrosis%2520previously%2520treated%2520with%2520ruxolitinib%2520%2528SIMPLIFY%25202%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Haematol.%26date%3D2018%26volume%3D5%26spage%3De73%26epage%3De81%26doi%3D10.1016%2Fs2352-3026%2817%2930237-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palandri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerds, A. T.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2018.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2Fj.leukres.2018.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=30025280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=82-88&author=J.+Berdejaauthor=F.+Palandriauthor=M.+R.+Baerauthor=D.+Quickauthor=J.+J.+Kiladjianauthor=G.+Martinelliauthor=A.+Vermaauthor=O.+Hamidauthor=R.+Walgrenauthor=C.+Pitouauthor=P.+L.+Liauthor=A.+T.+Gerds&title=Phase+2+study+of+gandotinib+%28LY2784544%29+in+patients+with+myeloproliferative+neoplasms&doi=10.1016%2Fj.leukres.2018.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms</span></div><div class="casAuthors">Berdeja, J.; Palandri, F.; Baer, M. R.; Quick, D.; Kiladjian, J. J.; Martinelli, G.; Verma, A.; Hamid, O.; Walgren, R.; Pitou, C.; Li, P. L.; Gerds, A. T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-88</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Philadelphia chromosome-neg. myeloproliferative neoplasms (MPNs) are assocd. with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation.  LY2784544 (gandotinib) is a potent, selective, small-mol. inhibitor of JAK2 that has potential dose-dependent selectivity for the JAK2 V617F mutation and may inhibit addnl. JAK2 mutant isoforms in nonclin. testing.  A multicenter, single-arm, outpatient phase 2 study evaluated the efficacy, safety, and pharmacokinetics (PK) of gandotinib administered to patients (120 mg once daily) with MPNs, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).  Between May 2012 and March 2015, 138 patients received at least one dose of study drug.  Most frequent Grade 3 or 4 treatment-emergent adverse events that were considered study-drug related were anemia (11.6%), hyperuricemia (3.2%), fatigue (2.9%), diarrhea (2.2%), and thrombocytopenia (2.2%).  Overall response rates (ORRs) in patients with JAK2 V617F-mutated PV, ET, and MF were 95%, 90.5%, and 9.1%, resp., while patients with ET and MF without the JAK2 V617F mutations had ORRs of 43.7% and 0%, resp.  LY2784544 demonstrated efficacy in JAK2 V617F-mutated MPNs, including in patients previously on ruxolitinib therapy, who had an ORR of 3.3%.  At the 1-yr visit, 44% of patients experienced a ≥50% improvement in the MPN-Symptom Assessment Form Total Symptom Score, and 26% of patients had a 50% redn. in Brief Fatigue Inventory score.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSGC6yNVigZ7Vg90H21EOLACvtfcHk0ljTfnLRcnvOag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrsrfJ&md5=897c90f8b02ad7dc1fbbe71bdf1667a9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2018.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2018.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DBerdeja%26aufirst%3DJ.%26aulast%3DPalandri%26aufirst%3DF.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DQuick%26aufirst%3DD.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DWalgren%26aufirst%3DR.%26aulast%3DPitou%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DP.%2BL.%26aulast%3DGerds%26aufirst%3DA.%2BT.%26atitle%3DPhase%25202%2520study%2520of%2520gandotinib%2520%2528LY2784544%2529%2520in%2520patients%2520with%2520myeloproliferative%2520neoplasms%26jtitle%3DLeuk.%2520Res.%26date%3D2018%26volume%3D71%26spage%3D82%26epage%3D88%26doi%3D10.1016%2Fj.leukres.2018.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerds, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pristupa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granston, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Fayoumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial</span>. <i>JAMA. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2017.5818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1001%2Fjamaoncol.2017.5818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29522138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsVaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=652-659&author=J.+Mascarenhasauthor=R.+Hoffmanauthor=M.+Talpazauthor=A.+T.+Gerdsauthor=B.+Steinauthor=V.+Guptaauthor=A.+Szokeauthor=M.+Drummondauthor=A.+Pristupaauthor=T.+Granstonauthor=R.+Dalyauthor=S.+Al-Fayoumiauthor=J.+A.+Callahanauthor=J.+W.+Singerauthor=J.+Gotlibauthor=C.+Jamiesonauthor=C.+Harrisonauthor=R.+Mesaauthor=S.+Verstovsek&title=Pacritinib+vs+best+available+therapy%2C+including+ruxolitinib%2C+in+patients+with+myelofibrosis%3A+a+randomized+clinical+trial&doi=10.1001%2Fjamaoncol.2017.5818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial</span></div><div class="casAuthors">Mascarenhas John; Hoffman Ronald; Talpaz Moshe; Gerds Aaron T; Stein Brady; Gupta Vikas; Szoke Anita; Drummond Mark; Pristupa Alexander; Granston Tanya; Daly Robert; Al-Fayoumi Suliman; Callahan Jennifer A; Singer Jack W; Gotlib Jason; Jamieson Catriona; Harrison Claire; Mesa Ruben; Verstovsek Srdan</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-659</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms.  Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib.  Objective:  To compare the efficacy and safety of JAK2 inhibitor pacritinib with that of best available therapy (BAT), including ruxolitinib, in patients with myelofibrosis and thrombocytopenia.  Design, Setting, and Participants:  For this phase 3 randomized international multicenter study-the PERSIST-2 study-of pacritinib vs BAT, 311 patients with myelofibrosis and platelet count 100 × 109/L or less were recruited for analysis.  Crossover from BAT was allowed after week 24 or for progression of splenomegaly.  Interventions:  Patients were randomized 1:1:1 to pacritinib 400 mg once daily, pacritinib 200 mg twice daily, or BAT.  Main Outcomes and Measures:  Coprimary end points were rates of patients achieving 35% or more spleen volume reduction (SVR) and 50% or more reduction in total symptom score (TSS) at week 24.  Efficacy analyses were performed on the intention-to-treat efficacy population, comprising all patients with a randomization date allowing for week 24 data.  Results:  Overall, 311 patients (mean [SD] age, 63.70 [9.08] years; 171 men [55%] and 140 women [45%]) were included in the study; 149 patients (48%) had prior ruxolitinib.  The most common BAT was ruxolitinib (44 patients [45%]); 19 patients (19%) received watchful-waiting only.  The intention-to-treat efficacy population included 75 patients randomized to pacritinib once daily; 74, pacritinib twice daily, and 72, BAT.  Pacritinib (arms combined) was more effective than BAT for 35% or more SVR (27 patients [18%] vs 2 patients [3%]; P = .001) and had a nonsignificantly greater rate of 50% or more reduction in TSS (37 patients [25%] vs 10 patients [14%]; P = .08).  Pacritinib twice daily led to significant improvements in both end points over BAT (≥35% SVR: 16 patients [22%] vs 2 patients [3%]; P = .001; ≥50% reduction in TSS: 24 patients [32%] vs 10 patients [14%]; P = .01).  Clinical improvement in hemoglobin and reduction in transfusion burden were greatest with pacritinib twice daily.  For pacritinib once daily, pacritinib twice daily, and BAT, the most common (>10%) grade 3 or 4 adverse events were thrombocytopenia (32 patients [31%], 34 patients [32%], 18 patients [18%]), and anemia (28 patients [27%], 23 patients [22%], 14 patients [14%]).  In the pacritinib once daily, twice daily, and BAT arms, discontinuation owing to adverse events occurred in 15 patients (14%), 10 patients (9%), and 4 patients (4%).  Conclusions and Relevance:  In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.  Trial Registration:  clinicaltrials.gov Identifier: NCT02055781.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7kXsuFf2C9pVVjGoY74BafW6udTcc2eayprT-_kfLRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsVaktA%253D%253D&md5=03e8bfd4e9b7566b07d1452a42346705</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2017.5818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2017.5818%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DGerds%26aufirst%3DA.%2BT.%26aulast%3DStein%26aufirst%3DB.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DSzoke%26aufirst%3DA.%26aulast%3DDrummond%26aufirst%3DM.%26aulast%3DPristupa%26aufirst%3DA.%26aulast%3DGranston%26aufirst%3DT.%26aulast%3DDaly%26aufirst%3DR.%26aulast%3DAl-Fayoumi%26aufirst%3DS.%26aulast%3DCallahan%26aufirst%3DJ.%2BA.%26aulast%3DSinger%26aufirst%3DJ.%2BW.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPacritinib%2520vs%2520best%2520available%2520therapy%252C%2520including%2520ruxolitinib%252C%2520in%2520patients%2520with%2520myelofibrosis%253A%2520a%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA.%2520Oncol.%26date%3D2018%26volume%3D4%26spage%3D652%26epage%3D659%26doi%3D10.1001%2Fjamaoncol.2017.5818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurgutis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuliczkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial</span>. <i>JAMA. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1001%2Fjamaoncol.2015.1590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=26181658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=643-651&author=A.+Pardananiauthor=C.+Harrisonauthor=J.+E.+Cortesauthor=F.+Cervantesauthor=R.+A.+Mesaauthor=D.+Milliganauthor=T.+Massziauthor=E.+Mishchenkoauthor=E.+Jourdanauthor=A.+M.+Vannucchiauthor=M.+W.+Drummondauthor=M.+Jurgutisauthor=K.+Kuliczkowskiauthor=E.+Gheorghitaauthor=F.+Passamontiauthor=F.+Neumannauthor=A.+Patkiauthor=G.+Gaoauthor=A.+Tefferi&title=Safety+and+efficacy+of+fedratinib+in+patients+with+primary+or+secondary+myelofibrosis%3A+a+randomized+clinical+trial&doi=10.1001%2Fjamaoncol.2015.1590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial</span></div><div class="casAuthors">Pardanani Animesh; Tefferi Ayalew; Harrison Claire; Cortes Jorge E; Cervantes Francisco; Mesa Ruben A; Milligan Donald; Masszi Tamas; Mishchenko Elena; Jourdan Eric; Vannucchi Alessandro M; Drummond Mark W; Jurgutis Mindaugas; Kuliczkowski Kazimierz; Gheorghita Emanuil; Passamonti Francesco; Neumann Frank; Patki Abhay; Gao Guozhi</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">643-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.  Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials.  OBJECTIVE:  To evaluate the efficacy and safety of fedratinib therapy in patients with primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF.  DESIGN, SETTING, AND PARTICIPANTS:  Double-blind, randomized, placebo-controlled phase 3 study in 94 sites in 24 countries in which 289 adult patients (≥18 years of age) with intermediate-2 or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF were randomly assigned between December 2011 and September 2012 to once-daily oral fedratinib, at a dose of 400 mg or 500 mg, or placebo, for at least 6 consecutive 4-week cycles.  MAIN OUTCOMES AND MEASURES:  The primary end point was spleen response (≥35% reduction in spleen volume from baseline as determined by magnetic resonance imaging or computed tomography) at week 24 and confirmed 4 weeks later.  The main secondary end point was symptom response (≥50% reduction in total symptom score, assessed using the modified Myelofibrosis Symptom Assessment Form).  RESULTS:  The primary end point was achieved by 35 of 96 (36% [95% CI, 27%-46%]) and 39 of 97 (40% [95% CI, 30%-50%]) patients in the fedratinib 400-mg and 500-mg groups, vs 1 of 96 (1% [95% CI, 0%-3%]) in the placebo group (P < .001).  Symptom response rates at week 24 were 33 of 91 (36% [95% CI, 26%-46%]), 31 of 91 (34% [95% CI, 24%-44%]), and 6 of 85 (7% [95% CI, 2%-13%]) in the fedratinib 400-mg, 500-mg, and placebo groups, respectively (P < .001).  Common adverse events with fedratinib treatment were anemia, gastrointestinal symptoms, and increased levels of liver transaminases, serum creatinine, and pancreatic enzymes.  Encephalopathy was reported in 4 women who received fedratinib 500 mg/d.  A diagnosis of Wernicke encephalopathy was supported by magnetic resonance imaging in 3 cases and suspected clinically in 1 case.  CONCLUSIONS AND RELEVANCE:  Fedratinib therapy significantly reduced splenomegaly and symptom burden in patients with MF.  These benefits were accompanied by toxic effects in some patients, the most important being encephalopathy of unknown mechanism.  Clinical development of fedratinib was subsequently discontinued.  TRIAL REGISTRATION:  clinicaltrials.gov identifier: NCT01437787.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMj69zv1FsJFMfW6udTcc2eayprT-_kfLRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVOmtw%253D%253D&md5=e7fe11f4b8edbd1a6ebc4edeca59b551</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1590%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DMilligan%26aufirst%3DD.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DMishchenko%26aufirst%3DE.%26aulast%3DJourdan%26aufirst%3DE.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DDrummond%26aufirst%3DM.%2BW.%26aulast%3DJurgutis%26aufirst%3DM.%26aulast%3DKuliczkowski%26aufirst%3DK.%26aulast%3DGheorghita%26aufirst%3DE.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DNeumann%26aufirst%3DF.%26aulast%3DPatki%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520fedratinib%2520in%2520patients%2520with%2520primary%2520or%2520secondary%2520myelofibrosis%253A%2520a%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA.%2520Oncol.%26date%3D2015%26volume%3D1%26spage%3D643%26epage%3D651%26doi%3D10.1001%2Fjamaoncol.2015.1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span> <span> </span><span class="NLM_article-title">Fedratinib in myelofibrosis</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1792</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fbloodadvances.2019000954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=32343799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BB38vgsFehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=1792-1800&author=A.+Mullallyauthor=J.+Hoodauthor=C.+Harrisonauthor=R.+Mesa&title=Fedratinib+in+myelofibrosis&doi=10.1182%2Fbloodadvances.2019000954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib in myelofibrosis</span></div><div class="casAuthors">Mullally Ann; Mullally Ann; Mullally Ann; Hood John; Harrison Claire; Mesa Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Blood advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1792-1800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2.  It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM) and was identified to be selective for JAK2 relative to other JAK family members (eg, JAK1, JAK3, and TYK2).  It quickly moved into clinical development with a phase 1 clinical trial opening in 2008, where a favorable impact on spleen and myelofibrosis (MF) symptom responses was reported.  A phase 3 trial in JAK2 inhibitor treatment-naive MF patients followed in 2011 (JAKARTA); a phase 2 trial in MF patients resistant or intolerant to ruxolitinib followed in 2012 (JAKARTA-2).  Clinical development suffered a major setback between 2013 and 2017 when the US Food and Drug Administration (FDA) placed fedratinib on clinical hold due to the development of symptoms concerning for Wernicke encephalopathy (WE) in 8 of 608 subjects (1.3%) who had received the drug.  It was ultimately concluded that there was no evidence that fedratinib directly induces WE, but clear risk factors (eg, poor nutrition, uncontrolled gastrointestinal toxicity) were identified.  In August 2019, the FDA approved fedratinib for the treatment of adults with intermediate-2 or high-risk MF.  Notably, approval includes a "black box warning" on the risk of serious and fatal encephalopathy, including WE.  FDA approval was granted on the basis of the JAKARTA studies in which the primary end points (ie, spleen and MF symptom responses) were met in ∼35% to 40% of patients (JAKARTA) and 25% to 30% of patients (JAKARTA-2), respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr9kz2EmYIWxOk4JA3soTqfW6udTcc2eayprT-_kfLRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vgsFehuw%253D%253D&md5=1345b1b8335ab1c62a01cb546738a812</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000954%26sid%3Dliteratum%253Aachs%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DMesa%26aufirst%3DR.%26atitle%3DFedratinib%2520in%2520myelofibrosis%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26spage%3D1792%26epage%3D1800%26doi%3D10.1182%2Fbloodadvances.2019000954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghrim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penhallow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppugalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjundaswamy, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms</span>. <i>ACS. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=850-855&author=H.+Wanauthor=G.+M.+Schroederauthor=A.+C.+Hartauthor=J.+Inghrimauthor=J.+Grebinskiauthor=J.+S.+Tokarskiauthor=M.+V.+Lorenziauthor=D.+Youauthor=T.+McDevittauthor=B.+Penhallowauthor=R.+Vuppugallaauthor=Y.+Zhangauthor=X.+Guauthor=R.+Iyerauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=S.+Rueppauthor=J.+Lippyauthor=Y.+Blatauthor=J.+S.+Sackauthor=J.+A.+Khanauthor=K.+Stefanskiauthor=B.+Sleczkaauthor=A.+Mathurauthor=J.-H.+Sunauthor=M.+K.+Wongauthor=D.-R.+Wuauthor=P.+Liauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=B.+Pragalathanauthor=S.+Narayananauthor=K.+C.+Nanjundaswamyauthor=P.+Kuppusamyauthor=A.+V.+Purandare&title=Discovery+of+a+highly+selective+JAK2+inhibitor%2C+BMS-911543%2C+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1021%2Facsmedchemlett.5b00226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms</span></div><div class="casAuthors">Wan, Honghe; Schroeder, Gretchen M.; Hart, Amy C.; Inghrim, Jennifer; Grebinski, James; Tokarski, John S.; Lorenzi, Matthew V.; You, Dan; McDevitt, Theresa; Penhallow, Becky; Vuppugalla, Ragini; Zhang, Yueping; Gu, Xiaomei; Iyer, Ramaswamy; Lombardo, Louis J.; Trainor, George L.; Ruepp, Stefan; Lippy, Jonathan; Blat, Yuval; Sack, John S.; Khan, Javed A.; Stefanski, Kevin; Sleczka, Bogdan; Mathur, Arvind; Sun, Jung-Hui; Wong, Michael K.; Wu, Dauh-Rurng; Li, Peng; Gupta, Anuradha; Arunachalam, P. N.; Pragalathan, Bala; Narayanan, Sankara; Nanjundaswamy, K. C.; Kuppusamy, Prakasam; Purandare, Ashok V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-855</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway.  X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole (I) led to the discovery of a clin. candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LTsDfjeehLVg90H21EOLACvtfcHk0lgdS2mDMC_rOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF&md5=d6bdb9b070a8f7492352600ea1222a8f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00226%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DHart%26aufirst%3DA.%2BC.%26aulast%3DInghrim%26aufirst%3DJ.%26aulast%3DGrebinski%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DMcDevitt%26aufirst%3DT.%26aulast%3DPenhallow%26aufirst%3DB.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DNanjundaswamy%26aufirst%3DK.%2BC.%26aulast%3DKuppusamy%26aufirst%3DP.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520selective%2520JAK2%2520inhibitor%252C%2520BMS-911543%252C%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DACS.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D850%26epage%3D855%26doi%3D10.1021%2Facsmedchemlett.5b00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally effective dual janus kinase 2/FLT3 Inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10305</span>– <span class="NLM_lpage">10320</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10305-10320&author=T.+Yangauthor=M.+Huauthor=W.+Qiauthor=Z.+Yangauthor=M.+Tangauthor=J.+Heauthor=Y.+Chenauthor=P.+Baiauthor=X.+Yuanauthor=C.+Zhangauthor=K.+Liuauthor=Y.+Luauthor=M.+Xiangauthor=L.+Chen&title=Discovery+of+potent+and+orally+effective+dual+janus+kinase+2%2FFLT3+Inhibitors+for+the+treatment+of+acute+myelogenous+leukemia+and+myeloproliferative+neoplasms&doi=10.1021%2Facs.jmedchem.9b01348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></div><div class="casAuthors">Yang, Tao; Hu, Mengshi; Qi, Wenyan; Yang, Zhuang; Tang, Minghai; He, Jun; Chen, Yong; Bai, Peng; Yuan, Xue; Zhang, Chufeng; Liu, Kongjun; Lu, Yulin; Xiang, Mingli; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10305-10320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivs. that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases is described.  These screening cascades revealed that I was a preferred compd. with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, resp.  Moreover, I was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, resp., and possessed an excellent selectivity profile over the other 100 representative kinases.  In a series of cytokine-stimulated cell-based assays, I exhibited a higher JAK2 selectivity over other JAK isoforms.  The oral administration of 60 mg/kg of I could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, resp.  Addnl., I showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that I might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHnNcuajGNcLVg90H21EOLACvtfcHk0lgdS2mDMC_rOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE&md5=86c811cf77a95a7250996456cd29e6dc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520effective%2520dual%2520janus%2520kinase%25202%252FFLT3%2520Inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10305%26epage%3D10320%26doi%3D10.1021%2Facs.jmedchem.9b01348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+selective+and+rigidify%3A+the+discovery+path+toward+a+next+generation+of+EGFR+tyrosine+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lgHn4R3gYjiCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520selective%2520and%2520rigidify%253A%2520the%2520discovery%2520path%2520toward%2520a%2520next%2520generation%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.-I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+next-generation+TRK+kinase+inhibitor+overcomes+acquired+resistance+to+prior+TRK+kinase+inhibition+in+patients+with+TRK+fusion-positive+solid+tumors&doi=10.1158%2F2159-8290.cd-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. ©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0lgHn4R3gYjiCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520next-generation%2520TRK%2520kinase%2520inhibitor%2520overcomes%2520acquired%2520resistance%2520to%2520prior%2520TRK%2520kinase%2520inhibition%2520in%2520patients%2520with%2520TRK%2520fusion-positive%2520solid%2520tumors%26jtitle%3DCanc.%2520Discov.%26date%3D2017%26volume%3D7%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.cd-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&author=A.+Drilonauthor=S.-H.+I.+Ouauthor=B.+C.+Choauthor=D.-W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.-J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+is+a+next-generation+ROS1%2FTRK%2FALK+inhibitor+that+potently+inhibits+ROS1%2FTRK%2FALK+solvent-+front+mutations&doi=10.1158%2F2159-8290.cd-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0lgHxAmhpZwvtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520is%2520a%2520next-generation%2520ROS1%252FTRK%252FALK%2520inhibitor%2520that%2520potently%2520inhibits%2520ROS1%252FTRK%252FALK%2520solvent-%2520front%2520mutations%26jtitle%3DCanc.%2520Discov.%26date%3D2018%26volume%3D8%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.cd-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+novel+irreversible+FLT3+inhibitor%2C+FF-10101%2C+shows+excellent+efficacy+against+AML+cells+with+FLT3+mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lgHxAmhpZwvtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520novel%2520irreversible%2520FLT3%2520inhibitor%252C%2520FF-10101%252C%2520shows%2520excellent%2520efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barraco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willenbacher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymakers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liersch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wroclawska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumanchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisslinger, H.</span></span> <span> </span><span class="NLM_article-title">Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1111/bjh.16729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1111%2Fbjh.16729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=32583458" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Barracoauthor=R.+Greilauthor=R.+Herbrechtauthor=B.+Schmidtauthor=A.+Reiterauthor=W.+Willenbacherauthor=R.+Raymakersauthor=R.+Lierschauthor=M.+Wroclawskaauthor=R.+Packauthor=K.+Burockauthor=D.+Karumanchiauthor=H.+Gisslinger&title=Real-world+non-interventional+long-term+post-authorisation+safety+study+of+ruxolitinib+in+myelofibrosis&doi=10.1111%2Fbjh.16729"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fbjh.16729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.16729%26sid%3Dliteratum%253Aachs%26aulast%3DBarraco%26aufirst%3DF.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DHerbrecht%26aufirst%3DR.%26aulast%3DSchmidt%26aufirst%3DB.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DWillenbacher%26aufirst%3DW.%26aulast%3DRaymakers%26aufirst%3DR.%26aulast%3DLiersch%26aufirst%3DR.%26aulast%3DWroclawska%26aufirst%3DM.%26aulast%3DPack%26aufirst%3DR.%26aulast%3DBurock%26aufirst%3DK.%26aulast%3DKarumanchi%26aufirst%3DD.%26aulast%3DGisslinger%26aufirst%3DH.%26atitle%3DReal-world%2520non-interventional%2520long-term%2520post-authorisation%2520safety%2520study%2520of%2520ruxolitinib%2520in%2520myelofibrosis%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2020%26doi%3D10.1111%2Fbjh.16729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaap, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lager, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span> <span> </span><span class="NLM_article-title">Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e317</span>– <span class="NLM_lpage">e324</span>, <span class="refDoi"> DOI: 10.1016/s2352-3026(17)30088-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2FS2352-3026%2817%2930088-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28602585" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=e317-e324&author=C.+N.+Harrisonauthor=N.+Schaapauthor=A.+M.+Vannucchiauthor=J.-J.+Kiladjianauthor=R.+V.+Tiuauthor=P.+Zacheeauthor=E.+Jourdanauthor=E.+Wintonauthor=R.+T.+Silverauthor=H.+C.+Schoutenauthor=F.+Passamontiauthor=S.+Zweegmanauthor=M.+Talpazauthor=J.+Lagerauthor=Z.+Shunauthor=R.+A.+Mesa&title=Janus+kinase-2+inhibitor+fedratinib+in+patients+with+myelofibrosis+previously+treated+with+ruxolitinib+%28JAKARTA-2%29%3A+a+single-arm%2C+open-label%2C+non-randomised%2C+phase+2%2C+multicentre+study&doi=10.1016%2Fs2352-3026%2817%2930088-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2817%2930088-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252817%252930088-1%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DSchaap%26aufirst%3DN.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DTiu%26aufirst%3DR.%2BV.%26aulast%3DZachee%26aufirst%3DP.%26aulast%3DJourdan%26aufirst%3DE.%26aulast%3DWinton%26aufirst%3DE.%26aulast%3DSilver%26aufirst%3DR.%2BT.%26aulast%3DSchouten%26aufirst%3DH.%2BC.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DLager%26aufirst%3DJ.%26aulast%3DShun%26aufirst%3DZ.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DJanus%2520kinase-2%2520inhibitor%2520fedratinib%2520in%2520patients%2520with%2520myelofibrosis%2520previously%2520treated%2520with%2520ruxolitinib%2520%2528JAKARTA-2%2529%253A%2520a%2520single-arm%252C%2520open-label%252C%2520non-randomised%252C%2520phase%25202%252C%2520multicentre%2520study%26jtitle%3DLancet%2520Haematol.%26date%3D2017%26volume%3D4%26spage%3De317%26epage%3De324%26doi%3D10.1016%2Fs2352-3026%2817%2930088-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minturn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A. E.</span></span> <span> </span><span class="NLM_article-title">Trk receptor expression and inhibition in neuroblastomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-1815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1158%2F1078-0432.CCR-08-1815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=19417027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3244-3250&author=G.+M.+Brodeurauthor=J.+E.+Minturnauthor=R.+Hoauthor=A.+M.+Simpsonauthor=R.+Iyerauthor=C.+R.+Varelaauthor=J.+E.+Lightauthor=V.+Kollaauthor=A.+E.+Evans&title=Trk+receptor+expression+and+inhibition+in+neuroblastomas&doi=10.1158%2F1078-0432.ccr-08-1815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Trk Receptor Expression and Inhibition in Neuroblastomas</span></div><div class="casAuthors">Brodeur, Garrett M.; Minturn, Jane E.; Ho, Ruth; Simpson, Anisha M.; Iyer, Radhika; Varela, Carly R.; Light, Jennifer E.; Kolla, Venkatadri; Evans, Audrey E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3244-3250</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Neuroblastoma, the most common and deadly solid tumor in children, exhibits heterogeneous clin. behavior, from spontaneous regression to relentless progression.  Current evidence suggests that the TRK family of neurotrophin receptors plays a crit. role in these diverse behaviors.  Neuroblastomas expressing TrkA are biol. favorable and prone to spontaneous regression or differentiation, depending on the absence or presence of its ligand (NGF) in the microenvironment.  In contrast, TrkB-expressing tumors frequently have MYCN amplification and are very aggressive and often fatal tumors.  These tumors also express the TrkB ligand (BDNF), resulting in an autocrine or paracrine survival pathway.  Exposure to BDNF promotes survival, drug resistance, and angiogenesis of TrkB-expressing tumors.  Here we review the role of Trks in normal development, the different functions of Trk isoforms, and the major Trk signaling pathways.  We also review the roles these receptors play in the heterogeneous biol. and clin. behavior of neuroblastomas, and the activation of Trk receptors in other cancers.  Finally we address the progress that has been made in developing targeted therapy with Trk-selective inhibitors to treat neuroblastomas and other tumors with activated Trk expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XUqj0KJ-GLVg90H21EOLACvtfcHk0lg6XvuIEnB9dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D&md5=cb21a6625f5d8464325522fb5b87c710</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1815%26sid%3Dliteratum%253Aachs%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DMinturn%26aufirst%3DJ.%2BE.%26aulast%3DHo%26aufirst%3DR.%26aulast%3DSimpson%26aufirst%3DA.%2BM.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DVarela%26aufirst%3DC.%2BR.%26aulast%3DLight%26aufirst%3DJ.%2BE.%26aulast%3DKolla%26aufirst%3DV.%26aulast%3DEvans%26aufirst%3DA.%2BE.%26atitle%3DTrk%2520receptor%2520expression%2520and%2520inhibition%2520in%2520neuroblastomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3244%26epage%3D3250%26doi%3D10.1158%2F1078-0432.ccr-08-1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khotskaya, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills Shaw, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span> <span> </span><span class="NLM_article-title">Targeting TRK family proteins in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2Fj.pharmthera.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28174090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=58-66&author=Y.+B.+Khotskayaauthor=V.+R.+Hollaauthor=A.+F.+Faragoauthor=K.+R.+Mills+Shawauthor=F.+Meric-Bernstamauthor=D.+S.+Hong&title=Targeting+TRK+family+proteins+in+cancer&doi=10.1016%2Fj.pharmthera.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting TRK family proteins in cancer</span></div><div class="casAuthors">Khotskaya, Yekaterina B.; Holla, Vijaykumar R.; Farago, Anna F.; Mills Shaw, Kenna R.; Meric-Bernstam, Funda; Hong, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3 genes, resp.  Binding of neurotrophins to TRK proteins induces receptor dimerization, phosphorylation, and activation of the downstream signaling cascades via PI3K, RAS/MAPK/ERK, and PLC-gamma.  TRK pathway aberrations, including gene fusions, protein overexpression, and single nucleotide alterations, have been implicated in the pathogenesis of many cancer types, with NTRK gene fusions being the most well validated oncogenic events to date.  Although the NTRK gene fusions are infrequent in most cancer types, certain rare tumor types are predominately driven by these events.  Conversely, in more common histologies, such as lung and colorectal cancers, prevalence of the NTRK fusions is well below 5%.  Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations.  Currently, several TRK-targeting compds. are in clin. development.  The ongoing Phase 2 trials with entrectinib and LOXO-101, two of the leading TRK inhibitors, are designed as 'basket trials', inclusive of patients whose tumors harbor NTRK gene fusions, independent of histol.  Addnl. Phase 1 studies of other TRK inhibitors, including MGCD516, PLX7486, DS-6051b, and TSR-011, are underway.  Interim data examg. NTRK-rearranged tumors treated with entrectinib or LOXO-101 demonstrate encouraging activity, with patients achieving rapid and durable responses.  Consequently, both drugs have achieved orphan designation from regulatory agencies, and efforts are underway to further expedite their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozoy77YmUc_LVg90H21EOLACvtfcHk0lg6XvuIEnB9dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D&md5=f18f232e6d3c4c9a5d2e398fe60ae7e4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKhotskaya%26aufirst%3DY.%2BB.%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DMills%2BShaw%26aufirst%3DK.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DD.%2BS.%26atitle%3DTargeting%2520TRK%2520family%2520proteins%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.pharmthera.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najfeld, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span> <span> </span><span class="NLM_article-title">A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1111/bjh.12220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1111%2Fbjh.12220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=23330839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2013&pages=68-75&author=J.+Mascarenhasauthor=M.+Luauthor=T.+Liauthor=B.+Petersenauthor=T.+Hochmanauthor=V.+Najfeldauthor=J.+D.+Goldbergauthor=R.+Hoffman&title=A+phase+I+study+of+panobinostat+%28LBH589%29+in+patients+with+primary+myelofibrosis+%28PMF%29+and+post-polycythaemia+vera%2Fessential+thrombocythaemia+myelofibrosis+%28post-PV%2FET+MF%29&doi=10.1111%2Fbjh.12220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)</span></div><div class="casAuthors">Mascarenhas, John; Lu, Min; Li, Timmy; Petersen, Bruce; Hochman, Tsivia; Najfeld, Vesna; Goldberg, Judith D.; Hoffman, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-75</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Panobinostat (LBH589), a novel histone deacetylase inhibitor (HDACi), was evaluated in a phase I study of patients with primary myelofibrosis (PMF) and post-essential thrombocythemia/polycythemia vera-related myelofibrosis (Post-ET/PV MF).  Eighteen patients (PMF 56%; Post-PV MF 28%; Post-ET MF 17%) were treated in three cohorts at oral doses of (i) 20, (ii) 30, and (iii) 25 mg three times weekly consecutively.  Reversible thrombocytopenia was the dose-limiting toxicity.  Five patients (two in Dose Cohort 1, one in Dose Cohort 2 and two in Dose Cohort 3) received six or more cycles and were evaluable for response assessment.  After the sixth cycle, three of these five patients achieved clin. improvement (CI) with 100% redn. in palpable splenomegaly from baseline, and two patients experienced stable disease.  Panobinostat therapy was also assocd. with improvement in the degree of anemia in two of the five patients.  Of the three patients who achieved CI after six cycles, one patient achieved a near complete remission after 15 cycles of treatment and another patient had resoln. of marrow fibrosis after 16 cycles.  We conclude that panobinostat is a well-tolerated, clin. active treatment for MF patients, regardless of JAK2V617F status, and most effective when given at low doses over long periods of time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEaXVB9hUs0LVg90H21EOLACvtfcHk0liK0gjHNTEc_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKnt7c%253D&md5=94aed025cf2409d836acb96994a8c849</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12220%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DB.%26aulast%3DHochman%26aufirst%3DT.%26aulast%3DNajfeld%26aufirst%3DV.%26aulast%3DGoldberg%26aufirst%3DJ.%2BD.%26aulast%3DHoffman%26aufirst%3DR.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520panobinostat%2520%2528LBH589%2529%2520in%2520patients%2520with%2520primary%2520myelofibrosis%2520%2528PMF%2529%2520and%2520post-polycythaemia%2520vera%252Fessential%2520thrombocythaemia%2520myelofibrosis%2520%2528post-PV%252FET%2520MF%2529%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D161%26spage%3D68%26epage%3D75%26doi%3D10.1111%2Fbjh.12220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistuz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluhm, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iype, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marvin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravichandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardecki, C.</span></span> <span> </span><span class="NLM_article-title">The protein data bank</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">907</span>, <span class="refDoi"> DOI: 10.1107/s0907444902003451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1107%2Fs0907444902003451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=12037327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2002&pages=899-907&author=H.+M.+Bermanauthor=T.+Battistuzauthor=T.+N.+Bhatauthor=W.+F.+Bluhmauthor=P.+E.+Bourneauthor=K.+Burkhardtauthor=Z.+Fengauthor=G.+L.+Gillilandauthor=L.+Iypeauthor=S.+Jainauthor=P.+Faganauthor=J.+Marvinauthor=D.+Padillaauthor=V.+Ravichandranauthor=B.+Schneiderauthor=N.+Thankiauthor=H.+Weissigauthor=J.+D.+Westbrookauthor=C.+Zardecki&title=The+protein+data+bank&doi=10.1107%2Fs0907444902003451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Battistuz, Tammy; Bhat, T. N.; Bluhm, Wolfgang F.; Bourne, Philip E.; Burkhardt, Kyle; Feng, Zukang; Gilliland, Gary L.; Iype, Lisa; Jain, Shri; Fagan, Phoebe; Marvin, Jessica; Padilla, David; Ravichandran, Veerasamy; Schneider, Bohdan; Thanki, Narmada; Weissig, Helge; Westbrook, John D.; Zardecki, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">D58</span>
        (<span class="NLM_cas:issue">6, No. 1</span>),
    <span class="NLM_cas:pages">899-907</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Munksgaard</span>)
        </div><div class="casAbstract">The Protein Data Bank [PDB; Berman, Westbrook et al. (2000), Nucleic Acids Res. 28, 235-242; http://www.pdb.org/] is the single worldwide archive of primary structural data of biol. macromols.  Many secondary sources of information are derived from PDB data.  It is the starting point for studies in structural bioinformatics.  This article describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information and plans for the future development of the resource.  The reader should come away with an understanding of the scope of the PDB and what is provided by the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsUFcMyys-PrVg90H21EOLACvtfcHk0liK0gjHNTEc_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKhtLg%253D&md5=d7594ad00ec8e5bacc413d38bceaa360</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2Fs0907444902003451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444902003451%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DBattistuz%26aufirst%3DT.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DBluhm%26aufirst%3DW.%2BF.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26aulast%3DBurkhardt%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%2BL.%26aulast%3DIype%26aufirst%3DL.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DFagan%26aufirst%3DP.%26aulast%3DMarvin%26aufirst%3DJ.%26aulast%3DPadilla%26aufirst%3DD.%26aulast%3DRavichandran%26aufirst%3DV.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DThanki%26aufirst%3DN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DWestbrook%26aufirst%3DJ.%2BD.%26aulast%3DZardecki%26aufirst%3DC.%26atitle%3DThe%2520protein%2520data%2520bank%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2002%26volume%3D58%26spage%3D899%26epage%3D907%26doi%3D10.1107%2Fs0907444902003451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/jm1011319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.-J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol-3-yl%29p+yrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+Jak%2FStat+pathway&doi=10.1021%2Fjm1011319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Wang, Tao; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Peng, Bo; Su, Mei; Zhang, Hai-Jun; Hoffmann, Ethan; Rivard, Caroline; Green, Isabelle; Howard, Tina; Pollard, Hannah; Read, Jon; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Min-Wei; Huszar, Dennis; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematol. malignancies characterized by clonal expansion of one or more myeloid lineages.  The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs.  Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.  9E inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent phys. properties and preclin. pharmacokinetics, and is currently being evaluated in Phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG6RQUv4HqbVg90H21EOLACvtfcHk0liK0gjHNTEc_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN&md5=c8141c5b0e25a007e68b6e2567a576fe</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol-3-yl%2529p%2520yrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276%26doi%3D10.1021%2Fjm1011319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span> <span> </span><span class="NLM_article-title">Python: a programming language for software integration and development</span>. <i>J. Mol. Graphics Modell.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10660911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=57-61&author=M.+F.+Sanner&title=Python%3A+a+programming+language+for+software+integration+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Python: a programming language for software integration and development</span></div><div class="casAuthors">Sanner, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-61</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The use of interpreted languages in biocomputing has been investigated to create a programmable, dynamic environment in which components can be tied together at a high level.  This work has demonstrated the benefits of such an approach and the features of the interpreted language that are key to successful component integration.  This involved Python, an interpreted, interactive, object-oriented programming language.  It provides high-level data structures such as list and associative arrays, dynamic typing and dynamic binding, modules, classes, exceptions, automatic memory management and others.  Python has been found to be instrumental in the mol. modeling research environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaCFXA1JC8X7Vg90H21EOLACvtfcHk0liJI_7xBWDuqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D&md5=3bf94934548080055dda54f68468c656</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanner%26aufirst%3DM.%2BF.%26atitle%3DPython%253A%2520a%2520programming%2520language%2520for%2520software%2520integration%2520and%2520development%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D1999%26volume%3D17%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open Babel: An open chemical toolbox</span>. <i>J. Cheminf</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=21982300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=33&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+Babel%3A+An+open+chemical+toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Open Babel: an open chemical toolbox</span></div><div class="casAuthors">O'Boyle, Noel M.; Banck, Michael; James, Craig A.; Morley, Chris; Vandermeersch, Tim; Hutchison, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Background: A frequent problem in computational modeling is the interconversion of chem. structures between different formats.  While std. interchange formats exist (for example, Chem. Markup Language) and de facto stds. have arisen (for example, SMILES format), the need to interconvert formats is a continuing problem due to the multitude of different application areas for chem. data, differences in the data stored by different formats (0D vs. 3D, for example), and competition between software along with a lack of vendor-neutral formats.  Results: We discuss, for the first time, Open Babel, an open-source chem. toolbox that speaks the many languages of chem. data.  Open Babel version 2.3 interconverts over 110 formats.  The need to represent such a wide variety of chem. and mol. data requires a library that implements a wide range of cheminformatics algorithms, from partial charge assignment and aromaticity detection, to bond order perception and canonicalization.  We detail the implementation of Open Babel, describe key advances in the 2.3 release, and outline a variety of uses both in terms of software products and scientific research, including applications far beyond simple format interconversion.  Conclusions: Open Babel presents a soln. to the proliferation of multiple chem. file formats.  In addn., it provides a variety of useful utilities from conformer searching and 2D depiction, to filtering, batch conversion, and substructure and similarity searching.  For developers, it can be used as a programming library to handle chem. data in areas such as org. chem., drug design, materials science, and computational chem.  It is freely available under an open-source license.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQ1lvaS5767Vg90H21EOLACvtfcHk0liJI_7xBWDuqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF&md5=74e4f19b7f87417f916d57f7abcfb761</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520Babel%253A%2520An%2520open%2520chemical%2520toolbox%26jtitle%3DJ.%2520Cheminf%26date%3D2011%26volume%3D3%26spage%3D33%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+Automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0liJI_7xBWDuqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520Automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rurainski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhof, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, D.</span></span> <span> </span><span class="NLM_article-title">A new lamarckian genetic algorithm for flexible ligand-receptor docking</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1002/jcc.21478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1002%2Fjcc.21478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=20082382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=1911-1918&author=J.+Fuhrmannauthor=A.+Rurainskiauthor=H.+P.+Lenhofauthor=D.+Neumann&title=A+new+lamarckian+genetic+algorithm+for+flexible+ligand-receptor+docking&doi=10.1002%2Fjcc.21478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A new Lamarckian genetic algorithm for flexible ligand-receptor docking</span></div><div class="casAuthors">Fuhrmann, Jan; Rurainski, Alexander; Lenhof, Hans-Peter; Neumann, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1911-1918</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors present a Lamarckian genetic algorithm (LGA) variant for flexible ligand-receptor docking which allows to handle a large no. of degrees of freedom.  The authors' hybrid method combines a multi-deme LGA with a recently published gradient-based method for local optimization of mol. complexes.  The authors compared the performance of their new hybrid method to two non-gradient-based search heuristics on the Astex diverse set for flexible ligand-receptor docking.  The authors' results show that the novel approach is clearly superior to other LGAs employing a stochastic optimization method.  The new algorithm features a shorter run time and gives substantially better results, esp. with increasing complexity of the ligands.  Thus, it may be used to dock ligands with many rotatable bonds with high efficiency. © 2010 Wiley Periodicals, Inc.  J Comput Chem, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoFNlhZnxim7Vg90H21EOLACvtfcHk0liJI_7xBWDuqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D&md5=34a78af702d8ee9bace9b5db8221e2db</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21478%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann%26aufirst%3DJ.%26aulast%3DRurainski%26aufirst%3DA.%26aulast%3DLenhof%26aufirst%3DH.%2BP.%26aulast%3DNeumann%26aufirst%3DD.%26atitle%3DA%2520new%2520lamarckian%2520genetic%2520algorithm%2520for%2520flexible%2520ligand-receptor%2520docking%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D1911%26epage%3D1918%26doi%3D10.1002%2Fjcc.21478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasteiger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsili, M.</span></span> <span> </span><span class="NLM_article-title">Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3219</span>– <span class="NLM_lpage">3228</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(80)80168-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2F0040-4020%2880%2980168-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1980&pages=3219-3228&author=J.+Gasteigerauthor=M.+Marsili&title=Iterative+partial+equalization+of+orbital+electronegativity-a+rapid+access+to+atomic+charges&doi=10.1016%2F0040-4020%2880%2980168-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges</span></div><div class="casAuthors">Gasteiger, Johann; Marsili, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3219-22</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">A method is presented for the rapid calcn. of at. charges in σ-bonded and nonconjugated π-systems (alkyl halides and oxoalkanes, resp.), considering only the connectivities of the atoms.  Atoms are characterized by their orbital electronegativities.  Partial equalization of orbital electronegativity is obtained by an iterative procedure.  Excellent correlations of the at. charges with core-electron binding energies and with acidity consts. are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKA3wil1SiWrVg90H21EOLACvtfcHk0lg3tScJOiF6aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D&md5=90c580857e6001482bee92450278fe9f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2880%2980168-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252880%252980168-2%26sid%3Dliteratum%253Aachs%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DMarsili%26aufirst%3DM.%26atitle%3DIterative%2520partial%2520equalization%2520of%2520orbital%2520electronegativity-a%2520rapid%2520access%2520to%2520atomic%2520charges%26jtitle%3DTetrahedron%26date%3D1980%26volume%3D36%26spage%3D3219%26epage%3D3228%26doi%3D10.1016%2F0040-4020%2880%2980168-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods I. method</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1002%2Fjcc.540100208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=209-220&author=J.+J.+P.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+I.+method&doi=10.1002%2Fjcc.540100208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  I.  Method</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-20</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">A new method for obtaining optimized parameters for semiempirical methods is developed and applied to the MNDO method.  The method uses derivs. of calcd. values for properties with respect to adjustable parameters to obtain the optimized values of parameters.  The large increase in speed is a result of using a simple series expression for calcd. values of properties rather than employing full semiempirical calcns.  With this optimization procedure, the rate-detg. step for parameterizing elements changes from the mechanics of parameterization to the assembling of exptl. ref. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwG85ot7_Rq7Vg90H21EOLACvtfcHk0lg3tScJOiF6aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D&md5=cbf1b7604277340a97e061539b65af71</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100208%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520I.%2520method%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D209%26epage%3D220%26doi%3D10.1002%2Fjcc.540100208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingsong  Shi</span>, <span class="hlFld-ContribAuthor ">Min  Zhao</span>, <span class="hlFld-ContribAuthor ">Lun  Wang</span>, <span class="hlFld-ContribAuthor ">Kongjun  Liu</span>, <span class="hlFld-ContribAuthor ">Penghui  Li</span>, <span class="hlFld-ContribAuthor ">Jiang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Cai</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>, <span class="hlFld-ContribAuthor ">Dingguo  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2021,</strong> <em>453 </em><a href="https://doi.org/10.1039/D1CP00717C" title="DOI URL">https://doi.org/10.1039/D1CP00717C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CP00717C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CP00717C%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DExploring%252Bthe%252Bstability%252Bof%252Binhibitor%252Bbinding%252Bto%252BSIK2%252Busing%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bbinding%252Bfree%252Benergy%252Bcalculation%26aulast%3DShi%26aufirst%3DMingsong%26date%3D2021%26date%3D2021%26volume%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative drugs in clinical trials or launched JAK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking results of <b>18e</b> in the JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>); (B) Docking results of <b>18e</b> in the FLT3 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>); (C) Modifying plans for newly designed compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome-wide selectivity profiling of compound <b>13ac</b> with the Kinase Profile assay by Eurofins Discovery. Measurements were performed at a concentration of 0.1 μM of the inhibitor in duplicate. The % control means remaining active kinase percentage. The affinity was defined with respect to a dimethyl sulfoxide (DMSO) control. The TREEspot image was mapped with the KinMap software tool provided by Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) NOD/SCID mice bearing SET-2 tumors (<i>n</i> = 5) were treated for 16 consecutive days with 15, 30, and 60 mg/kg <b>13ac</b> p.o. q.d. Tumor volumes were measured every two days. ***, <i>P</i> < 0.01 ANOVA, Dunnett’s post test; (B) body weight change in SET-2 cell-inoculated xenograft NOD/SCID mouse models; (C) NOD/SCID mice bearing SET-2 tumors (<i>n</i> = 5) were treated for 36 consecutive days with 15, 30, and 60 mg/kg <b>13ac</b> p.o. q.d. the survival curve was analyzed; (D) Ba/F-JAK2<sup>V617F</sup>-bearing BALB/c-nude mice (<i>n</i> = 6) were treated for 20 consecutive days with 30 and 60 mg/kg <b>13ac</b> p.o. q.d. On day 25, mice were sacrificed and spleen and liver weights determined. ***, <i>P</i> < 0.01 ANOVA, Dunnett’s post test; (E) inhibition of the liver growth in the Ba/F-JAK2<sup>V617F</sup> allograft model. ***, <i>P</i> < 0.01; **, 0.01 < <i>P</i> < 0.05 ANOVA, Dunnett’s post test; and (F) spleen weight to body weight ratio in the Ba/F-JAK2<sup>V617F</sup> allograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) 3D Model of <b>13ac</b> bound to the kinase catalytic domain of JAK2; (B) 2D Model of <b>13ac</b> bound to the kinase catalytic domain of JAK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cell cycle effects of <b>13ac</b> on SET-2 cells. Cells were treated with increasing concentrations of <b>13ac</b> for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. (B) Effects of <b>13ac</b> on the induction of apoptosis. SET-2 cells were treated with <b>13ac</b> for 2 h at 0.05, 0.2, 0.4, 0.8, and 1.6 μM, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of the JAK2 signaling pathway by <b>13ac</b>. (A) SET-2, (B) Ba/F3 JAK2<sup>V617F</sup>cells, and (C) spleen lysates of the Ba/F3 JAK2<sup>V617F</sup> allograft model were treated for 3 h with <b>13ac</b>. After lysis, the proteins were detected by immunoblotting with antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Amino Derivatives <b>7a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) trifluoroacetic anhydride, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt; (b) paraformaldehyde, concentrated sulfuric acid, rt; (c) concentrated sulfuric acid, potassium nitrate, 0 °C; (d) hydrochloric acid, methanol, reflux; (e) (BOC)<sub>2</sub>O, 60 °C; and (f) Pd/C, H<sub>2</sub>, methanol, rt.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/medium/jm0c01488_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>13a–am</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01488/20201203/images/large/jm0c01488_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01488&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (g) 2-iodopropane, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux; (h) 2,4-dichloropyrimidine derivatives, dioxane/EtOH/water (v/v/v, 7/3/4), 80 °C, 2 h; (i) amines, dioxane, reflux, 4 h, N<sub>2</sub> atmosphere; (j) hydrochloric acid, EA, rt; (k) appropriate halide, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, rt. And (l) appropriate acid, HATU, DIEA, DCM, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i76">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spivak, J. L.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative neoplasms</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">2168</span>– <span class="NLM_lpage">2181</span>, <span class="refDoi"> DOI: 10.1056/nejmra1406186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1056%2FNEJMra1406186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28564565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=2168-2181&author=J.+L.+Spivak&title=Myeloproliferative+neoplasms&doi=10.1056%2Fnejmra1406186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative neoplasms</span></div><div class="casAuthors">Spivak, Jerry L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2168-2181</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this study the myeloproliferative neoplasms- polycythemia vera, essential thrombocytosis, and primary myelofibrosis are unique hematopoietic stem-cell disorders that share mutations that constitutively activate the physiol. signal-transduction pathways responsible for hematopoiesis.  In contrast to the myeloid neoplasms, the myeloproliferative neoplasms have a natural history, with supportive care alone, that is usually measured in decades rather than years.  The pathogenesis of myeloproliferative neoplasms has been enigmatic, and therapy largely supportive.  Recently, however, driver mutations have been identified in more than 90% of patients with myeloproliferative neoplasms, providing substantial insight into their pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsmtVJJhElCLVg90H21EOLACvtfcHk0lj53uTgfgETjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrrF&md5=a9b824de674e48af2fd534dc4e1a3cfc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1406186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1406186%26sid%3Dliteratum%253Aachs%26aulast%3DSpivak%26aufirst%3DJ.%2BL.%26atitle%3DMyeloproliferative%2520neoplasms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D2168%26epage%3D2181%26doi%3D10.1056%2Fnejmra1406186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nangalia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative neoplasms: from origins to outcomes</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2475</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-06-782037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2017-06-782037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29212804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eru7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2475-2483&author=J.+Nangaliaauthor=A.+R.+Green&title=Myeloproliferative+neoplasms%3A+from+origins+to+outcomes&doi=10.1182%2Fblood-2017-06-782037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative neoplasms: from origins to outcomes</span></div><div class="casAuthors">Nangalia, Jyoti; Green, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2475-2483</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms.  The discovery of mutations in JAK2 over a decade ago heralded a new age for patient care as a consequence of improved diagnosis and the development of therapeutic JAK inhibitors.  The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients with myeloproliferative neoplasm now having a biol. basis for their excessive myeloproliferation.  We are also beginning to understand the processes that lead to acquisition of somatic mutations and the factors that influence subsequent clonal expansion and emergence of disease.  Extended genomic profiling has established a multitude of addnl. acquired mutations, particularly prevalent in myelofibrosis, where their presence carries prognostic implications.  A major goal is to integrate genetic, clin., and lab. features to identify patients who share disease biol. and clin. outcome, such that therapies, both existing and novel, can be better targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1aAK9C5xtZbVg90H21EOLACvtfcHk0lj53uTgfgETjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eru7zO&md5=8e10cb2da4186470af3b6d6eaa514427</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-06-782037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-06-782037%26sid%3Dliteratum%253Aachs%26aulast%3DNangalia%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DMyeloproliferative%2520neoplasms%253A%2520from%2520origins%2520to%2520outcomes%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D2475%26epage%3D2483%26doi%3D10.1182%2Fblood-2017-06-782037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasserjian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowitz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardiman, J. W.</span></span> <span> </span><span class="NLM_article-title">The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-643544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2016-03-643544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=27069254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1agu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2391-2405&author=D.+A.+Arberauthor=A.+Oraziauthor=R.+Hasserjianauthor=J.+Thieleauthor=M.+J.+Borowitzauthor=M.+M.+Le+Beauauthor=C.+D.+Bloomfieldauthor=M.+Cazzolaauthor=J.+W.+Vardiman&title=The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+leukemia&doi=10.1182%2Fblood-2016-03-643544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</span></div><div class="casAuthors">Arber, Daniel A.; Orazi, Attilio; Hasserjian, Robert; Thiele, Juergen; Borowitz, Michael J.; Le Beau, Michelle M.; Bloomfield, Clara D.; Cazzola, Mario; Vardiman, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2391-2405</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008.  Since then, there have been numerous advances in the identification of unique biomarkers assocd. with some myeloid neoplasms and acute leukemias, largely derived from gene expression anal. and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added.  Therefore, there is a clear need for a revision to the current classification.  The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists.  The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clin., prognostic, morphol., immunophenotypic, and genetic data that have emerged since the last edition.  The major changes in the classification and their rationale are presented here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVRZ1wWthKVrVg90H21EOLACvtfcHk0lj53uTgfgETjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1agu7g%253D&md5=fa799ac2063bb46f5bcef22fcaea9a30</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-643544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-643544%26sid%3Dliteratum%253Aachs%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DOrazi%26aufirst%3DA.%26aulast%3DHasserjian%26aufirst%3DR.%26aulast%3DThiele%26aufirst%3DJ.%26aulast%3DBorowitz%26aufirst%3DM.%2BJ.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26atitle%3DThe%25202016%2520revision%2520to%2520the%2520World%2520Health%2520Organization%2520classification%2520of%2520myeloid%2520neoplasms%2520and%2520acute%2520leukemia%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2391%26epage%3D2405%26doi%3D10.1182%2Fblood-2016-03-643544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative neoplasms: a contemporary review</span>. <i>JAMA. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1001%2Fjamaoncol.2015.89" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=26182311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fkt1Cmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=97-105&author=A.+Tefferiauthor=A.+Pardanani&title=Myeloproliferative+neoplasms%3A+a+contemporary+review&doi=10.1001%2Fjamaoncol.2015.89"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative Neoplasms: A Contemporary Review</span></div><div class="casAuthors">Tefferi Ayalew; Pardanani Animesh</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-105</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF.  These mutations might be accompanied by other mutations that are less specific to myeloproliferative neoplasms but are prognostically relevant, such as additional sex combs-like 1 (ASXL1).  Characteristic bone marrow morphology is required for World Health Organization-compliant diagnosis, especially in distinguishing ET from prefibrotic PMF and masked PV.  Survival is the longest in ET, although still inferior to that of the age- and sex-matched control population; median survivals for patients younger than 60 years are approximately 33 years for ET, 24 for PV, and 15 for PMF.  Major disease complications include thrombosis and leukemic or fibrotic transformation.  In PV and ET, risk factors for survival include older age, leukocytosis, and thrombosis, whereas JAK2 mutation in ET is associated with increased risk of thrombosis.  In PMF, type 1 or type 1-like CALR mutations are associated with superior and ASXL1 with inferior survival.  Prevention of thrombosis in PV is secured by phlebotomy (hematocrit target <45%) and in both PV and ET by low-dose aspirin therapy; high-risk patients derive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice.  Although the JAK inhibitor ruxolitinib was recently approved for use in hydroxyurea-resistant PV, its role in routine clinical practice remains debatable.  In myelofibrosis, stem cell transplant is the current treatment of choice for genetically or clinically high-risk disease; for all other patients requiring treatment, participation in clinical trials may be preferred because currently available drugs, including JAK inhibitors, are palliative and not shown to be disease modifying.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSOpnvZaOu_QyMywPm6HgQfW6udTcc2ebrom5JkKB8A7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fkt1Cmtw%253D%253D&md5=d9d42b40433720dda35e87fa19288b50</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.89%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DPardanani%26aufirst%3DA.%26atitle%3DMyeloproliferative%2520neoplasms%253A%2520a%2520contemporary%2520review%26jtitle%3DJAMA.%2520Oncol.%26date%3D2015%26volume%3D1%26spage%3D97%26epage%3D105%26doi%3D10.1001%2Fjamaoncol.2015.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltzman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fleu.2017.330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29263442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1035-1038&author=A.+Pardananiauthor=J.+Gotlibauthor=A.+W.+Robertsauthor=M.+Wadleighauthor=S.+Sirhanauthor=J.+Kawashimaauthor=J.+A.+Maltzmanauthor=L.+Shaoauthor=V.+Guptaauthor=A.+Tefferi&title=Long-term+efficacy+and+safety+of+momelotinib%2C+a+JAK1+and+JAK2+inhibitor%2C+for+the+treatment+of+myelofibrosis&doi=10.1038%2Fleu.2017.330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis</span></div><div class="casAuthors">Pardanani, A.; Gotlib, J.; Roberts, A. W.; Wadleigh, M.; Sirhan, S.; Kawashima, J.; Maltzman, J. A.; Shao, L.; Gupta, V.; Tefferi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1035-1038</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) 2 mutation (JAK2V617F) is frequently present in patients with the BCR-ABL1-neg. myeloproliferative neoplasms,1 including primary myelofibrosis or secondary myelofibrosis (MF) following progression of polycythemia vera (PV) or essential thrombocythemia (ET).2, 3, 4, 5 Momelotinib, a JAK1 and JAK2 inhibitor, has demonstrated activity in preclin. studies.6, 7, 8 The efficacy and safety of momelotinib was evaluated in a two-part, phase 1/2 core study (NCT00935987) in patients with intermediate or high risk primary myelofibrosis or post-PV/ET MF.  In part 1 (dose-escalation study) five successive cohorts of three patients received increasing oral once-daily doses of momelotinib capsule (100, 150, 200, 300 and 400 mg).  In an initial preplanned anal. of 60 patients, momelotinib (max. tolerated dose 300 mg once daily) was well tolerated and led to significant anemia and spleen responses.9 In part 2 (dose-confirmation study), patients continued momelotinib treatment for up to nine 28-day cycles (in the absence of toxicity) with expansion of the 150 mg once-daily, 300 mg once-daily and 150 mg twice-daily cohorts.  Patients who completed nine cycles of momelotinib in the core study could enroll in the open-label extension study (NCT01236638).  More details on methods can be found in Supplementary Materials.  Of 166 patients enrolled in the core study between Nov. 2009 and August 2011, 165 received at least one dose of study drug and had at least one postbaseline efficacy evaluation.  In total, 124 (75%) patients completed the core study and 120 enrolled in the extension study (August 2010-Apr. 2012).  The study ended in June 2014 and the data cutoff for this anal. is Feb. 2015.  Thirty (25.0%) patients completed the extension study.  In both studies, the most common reasons for discontinuation were adverse events (AEs) and disease progression (Supplementary Table 1).  Most patients were male (58.4%) and white (91.0%); median age (range) was 67 (34-89) years.  Overall, 105 (63.3%) patients were diagnosed with primary myelofibrosis.  The JAK2V617F mutation was present in 116 (69.9%) patients and 145 (87.3%) had a spleen size ≥10 cm (median (range) 18 (6-34) cm; Supplementary Table 2).  At baseline, 73 (44.0%) patients were transfusion-dependent and 104 (62.7%) had Hb values <10 g/dL.  The median Hb level was 9.4 g/dL (range 5.9-15.1), and median platelets and abs. neutrophils counts were 182.0 × 109/l and 8.1 × 109/l, resp.  Overall, 23 (13.9%) and 15 (9.0%) patients received prior treatment with a JAK inhibitor or immunomodulatory drugs, resp.  Over the course of the core and extension studies (median (range) 15.3 (0.1-48.8) months), 95/165 (57.6%) patients achieved a response (partial response (n=1, in 150 mg twice-daily group), or clin. improvement (n=94)).  Sixty-nine patients had stable disease and one patient (300 mg once-daily group) experienced progressive disease.  Of 111 anemia-evaluable patients, defined as those who completed ≥8 wk on study and were, at baseline, either transfusion-dependent (n=72) or were not transfusion-dependent but had a Hb level <10 g/dL (n=39), 65 (58.6%) patients were 8-wk anemia responders; 54/72 (75.0%) transfusion-dependent patients achieved transfusion-independence response and 11/39 (28.2%) patients with a Hb level <10 g/dL achieved a Hb response (Table 1).  Median increase in Hb was 2.4 g/dL.  Median (95% confidence interval (CI)) duration of 8-wk anemia response was 7.7 (4.1, 16.1) months (Table 1, Supplementary Figure 1A).  Even when using the more stringent definition for anemia response (≥12 wk),10 the response among anemic patients was evident in over 50% of patients (Table 1).  Forty-nine patients achieved a 12-wk transfusion-independence response (8 in the extension study) and 11 patients experienced a 12-wk Hb response (7 in the extension study).  For the 11 Hb responders, the median (range) increase in Hb was 2.3 (2.1-3.6) g/dL.  Median (95% CI) duration of 12-wk anemia response was 12.8 (7.4, 26.7) months (Table 1, Supplementary Figure 1B).  Overall, the nos. of anemia responders were consistently higher, and the duration of responses was longer, in the dose cohort of momelotinib 300 mg once daily compared with momelotinib 150 mg once daily (Table 1).  Among 147 patients with palpable splenomegaly (>5 cm) at baseline, 59 (40.1%) patients achieved spleen response for clin. improvement (per 2006 IWG-MRT criteria)11 (Table 1)-48 during the core study and 11 during the extension study.  Median time (range) to onset of response was 0.8 (0.2, 33.4) months.  Median duration of spleen response was not reached (NR; Supplementary Figure 1C), and the median follow-up time during response was 14.2 (1.8, 49.3) months.  The estd. 2-yr probability of remaining in response was 68% (95 CI, 52, 80%).  Over the course of both studies, a redn. in palpable splenomegaly was obsd., with a mean decrease from baseline of 59.7% (Supplementary Figure 2).  MRI-assessment of spleen size was performed in 12 patients receiving momelotinib 150 mg twice daily, and confirmed a redn. in spleen vol. over time.  In eight patients evaluable at 197 days, the median decrease of spleen vol. was 35%, compared to baseline.  Although symptom response was not uniformly assessed in the core study, an overall improvement of constitutional symptoms was noted (Supplementary Table 3).  The JAK2V617F allele burden was not reduced by momelotinib treatment (Supplementary Figure 3).  Disease progression (per 2006 IWG-MRT criteria) or death occurred in 53/165 (32.1%) patients; 6 (3.6%) patients reported acute leukemia.  The estd. median (95% CI) time to disease progression or death was 43.7 (34.5, NR) months.  After a median follow-up of 19.5 (1.5, 49.8) months, the median OS was NR.  The min. follow-up time for patients who did not have an event at this data cutoff was 2.3 mo.  The progression free survival and overall survival Kaplan-Meier curves are depicted in Supplementary Figures 4a and b.  The median (range) duration of exposure to momelotinib was 15.3 (0.1, 48.8) months and median daily dose was 281 mg.  Dose redns. at any time during the study, based on total daily dose compared with initial dosing assignment, occurred in 96 (57.8%) patients (Supplementary Table 4).  All 166 patients experienced at least one treatment-emergent AE (TEAE) (Table 2).  Adverse events considered by the investigator to be related to momelotinib treatment were reported in 160 (96.4%) patients.  The most common grade 1/2 treatment-related AEs included diarrhea, peripheral neuropathy, peripheral sensory neuropathy, dizziness, nausea and thrombocytopenia (Supplementary Table 5).  A treatment-related first-dose effect was assocd. with AEs of dizziness, nausea, hypotension, headache and flushing.  Among AEs of neurol. origin considered related to study drug, the most frequent AEs were peripheral neuropathy (44 (26.5%)), peripheral sensory neuropathy (41 (24.7%)), dizziness (41 (24.7%)), and headache (26 (15.7); Supplementary Tables 5 and 6).  All peripheral neuropathy AEs were either grade 1 or 2.  Twenty (12.0%) patients who reported a TEAE of peripheral neuropathy had a past medical history of peripheral neuropathy.  Twenty-two of 166 (13.3%) patients and 23 of 120 (19.2%) patients discontinued the core and extension studies, resp., due to AEs, excluding disease progression.  The most common AEs leading to study discontinuation were thrombocytopenia, peripheral sensory neuropathy and peripheral neuropathy (Supplementary Table 7).  Overall, 32 patients (19.3%) died due to AEs during the core and extension studies (Supplementary Table 8); no deaths were considered related to momelotinib treatment.  Causes of death were consistent with known causes of death in patients with MF.  This study demonstrates that long-term treatment with momelotinib is effective and well tolerated in patients with MF at a daily oral dose of 300 mg capsule.  No new safety concerns emerged compared with the core study.9 Recently, a study by Gupta et al. reported evidence of efficacy and tolerability of momelotinib 200 mg twice daily in a similar patient population.12 The higher rates of anemia response with momelotinib, compared to those previously reported for ruxolitinib,13, 14 are consistent with data from the SIMPLIFY-1 study, where a significantly higher proportion of patients on the momelotinib arm achieved improvement in transfusion rate, transfusion independence and transfusion dependence, compared to the ruxolitinib arm.15.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDGpiOe7LpgbVg90H21EOLACvtfcHk0li5P3KdpeURSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejsbfO&md5=e70542f4b6ff1837e0f710f04fdc5dd7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.330%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DSirhan%26aufirst%3DS.%26aulast%3DKawashima%26aufirst%3DJ.%26aulast%3DMaltzman%26aufirst%3DJ.%2BA.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DLong-term%2520efficacy%2520and%2520safety%2520of%2520momelotinib%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1035%26epage%3D1038%26doi%3D10.1038%2Fleu.2017.330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pungolino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramazza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span> <span> </span><span class="NLM_article-title">Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-02-414631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2012-02-414631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=22718840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WjsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=1202-1209&author=S.+Verstovsekauthor=H.+M.+Kantarjianauthor=Z.+Estrovauthor=J.+E.+Cortesauthor=D.+A.+Thomasauthor=T.+Kadiaauthor=S.+Pierceauthor=E.+Jabbourauthor=G.+Borthakurauthor=E.+Rumiauthor=E.+Pungolinoauthor=E.+Morraauthor=D.+Caramazzaauthor=M.+Cazzolaauthor=F.+Passamonti&title=Long-term+outcomes+of+107+patients+with+myelofibrosis+receiving+JAK1%2FJAK2+inhibitor+ruxolitinib%3A+survival+advantage+in+comparison+to+matched+historical+controls&doi=10.1182%2Fblood-2012-02-414631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop M.; Estrov, Zeev; Cortes, Jorge E.; Thomas, Deborah A.; Kadia, Tapan; Pierce, Sherry; Jabbour, Elias; Borthakur, Gautham; Rumi, Elisa; Pungolino, Ester; Morra, Enrica; Caramazza, Domenica; Cazzola, Mario; Passamonti, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1202-1209</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ruxolitinib is JAK1/JAK2 inhibitor with established clin. benefit in myelofibrosis (MF).  We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial.  After a median of 32 mo of follow-up, 58 patients (54%) were still receiving ruxolitinib, with overall survival (OS) of 69%.  The splenomegaly and symptom redns. achieved with ruxolitinib were sustained with long-term therapy.  Therapy was well tolerated; discontinuation rates at 1, 2, and 3 years were 24%, 36%, and 46%, resp.  OS of 107 MDACC patients was significantly better (P = .005) than that of 310 matched (based on trial enrollment criteria) historical control patients, primarily because of highly significant difference in OS in the high-risk subgroup (P = .006).  Furthermore, among MDACC patients, those with high-risk MF experienced the same OS as those with intermediate-2 risk.  Patients with ≥ 50% redn. in splenomegaly had significantly prolonged survival vs. those with < 25% redn. (P < .0001).  Comparison of discontinuation rates and reasons for stopping the therapy to those reported for other 51 patients in the phase 1/2 trial, and 155 ruxolitinib-treated patients in phase 3 COMFORT-I study, suggest that continued therapy with ruxolitinib at optimal doses contributes to the benefits seen, including OS benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNPbH3KU9dQrVg90H21EOLACvtfcHk0li5P3KdpeURSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WjsrrJ&md5=d1d30c8d1ac158ff181e743dd56e3107</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-02-414631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-02-414631%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DRumi%26aufirst%3DE.%26aulast%3DPungolino%26aufirst%3DE.%26aulast%3DMorra%26aufirst%3DE.%26aulast%3DCaramazza%26aufirst%3DD.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DPassamonti%26aufirst%3DF.%26atitle%3DLong-term%2520outcomes%2520of%2520107%2520patients%2520with%2520myelofibrosis%2520receiving%2520JAK1%252FJAK2%2520inhibitor%2520ruxolitinib%253A%2520survival%2520advantage%2520in%2520comparison%2520to%2520matched%2520historical%2520controls%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D1202%26epage%3D1209%26doi%3D10.1182%2Fblood-2012-02-414631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1038/nrc2210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fnrc2210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=17721432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=673-683&author=R.+L.+Levineauthor=A.+Pardananiauthor=A.+Tefferiauthor=D.+G.+Gilliland&title=Role+of+JAK2+in+the+pathogenesis+and+therapy+of+myeloproliferative+disorders&doi=10.1038%2Fnrc2210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders</span></div><div class="casAuthors">Levine, Ross L.; Pardanani, Animesh; Tefferi, Ayalew; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The myeloproliferative disorders polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent hematopoietic progenitors.  The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F).  These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new mol. targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5nfhX3BsOrVg90H21EOLACvtfcHk0li5P3KdpeURSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsbg%253D&md5=89429b6786f421d06163a48540c03dcb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2210%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DRole%2520of%2520JAK2%2520in%2520the%2520pathogenesis%2520and%2520therapy%2520of%2520myeloproliferative%2520disorders%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D673%26epage%3D683%26doi%3D10.1038%2Fnrc2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffioli, M.</span></span> <span> </span><span class="NLM_article-title">The role of JAK2 inhibitors in MPNs 7 years after approval</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2426</span>– <span class="NLM_lpage">2435</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-01-791491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2018-01-791491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29650801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaqsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2426-2435&author=F.+Passamontiauthor=M.+Maffioli&title=The+role+of+JAK2+inhibitors+in+MPNs+7+years+after+approval&doi=10.1182%2Fblood-2018-01-791491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of JAK2 inhibitors in MPNs 7 years after approval</span></div><div class="casAuthors">Passamonti, Francesco; Maffioli, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2426-2435</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF).  Phenotype-driver mutations of JAK2, CALR, and MPL genes are present in MPNs and can be variably combined with addnl. mutations.  Driver mutations entail a constitutive activation of the JAK2/STAT pathway, the key signaling cascade inMPNs.  Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea.  Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF.  The primary end points in MF trials were spleen vol. response (SVR) and symptom response, whereas in PV trials they were hematocrit control with or without spleen response.  In advanced MF, RUX achieved a long lasting SVR of >35% in ∼60% of patients, establishing a new benchmark for MF treatment.  RUX efficacy in early MF is also remark-able and toxicity is mild.  In PV, RUX achieved hematocrit control in ∼60% of cases and SVR in 40%.  Symptom relief was evident in both conditions.  In the long-term, however, many MF patients lose their SVR.  Indeed, the definition of RUX failure and the design of new trials in this setting are unmet needs.  Decrease of Hb/ platelet levels and increased infection rates are the most common side effects of RUX, and nonmelanoma skin tumors need to be monitored while on treatment.  In conclusion, the introduction of JAKis raises the bar of treatment goals in MF and PV. (Blood. 2018; 131(22):2426-2435).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXyflp1d4F27Vg90H21EOLACvtfcHk0ljQ4F8hlUhs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaqsb7P&md5=067d39b49a22ac9b13f121c366afbd72</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-01-791491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-01-791491%26sid%3Dliteratum%253Aachs%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DMaffioli%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520JAK2%2520inhibitors%2520in%2520MPNs%25207%2520years%2520after%2520approval%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D2426%26epage%3D2435%26doi%3D10.1182%2Fblood-2018-01-791491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntly, B. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelsperger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2Fj.ccr.2005.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=15837627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=387-397&author=R.+L.+Levineauthor=M.+Wadleighauthor=J.+Coolsauthor=B.+L.+Ebertauthor=G.+Wernigauthor=B.+J.+P.+Huntlyauthor=T.+J.+Boggonauthor=I.+Wlodarskaauthor=J.+J.+Clarkauthor=S.+Mooreauthor=J.+Adelspergerauthor=S.+Kooauthor=J.+C.+Leeauthor=S.+Gabrielauthor=T.+Mercherauthor=A.+D%E2%80%99Andreaauthor=S.+Fr%C3%B6hlingauthor=K.+D%C3%B6hnerauthor=P.+Marynenauthor=P.+Vandenbergheauthor=R.+A.+Mesaauthor=A.+Tefferiauthor=J.+D.+Griffinauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=T.+R.+Golubauthor=S.+J.+Leeauthor=D.+G.+Gilliland&title=Activating+mutation+in+the+tyrosine+kinase+JAK2+in+polycythemia+vera%2C+essential+thrombocythemia%2C+and+myeloid+metaplasia+with+myelofibrosis&doi=10.1016%2Fj.ccr.2005.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span></div><div class="casAuthors">Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J. P.; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Froehling, Stefan; Doehner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-397</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.  An internet-based protocol was used to collect clin. information and biol. specimens from patients with these diseases.  High-throughput DNA re-sequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.  Mol. and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele.  JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not obsd. in 269 normal individuals.  In vitro anal. demonstrated that JAK2V617F is a constitutively active tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJNzUFm3Q3bVg90H21EOLACvtfcHk0ljQ4F8hlUhs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D&md5=2a3e893867b114e8749cd6f5e55990b7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%2BP.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DAdelsperger%26aufirst%3DJ.%26aulast%3DKoo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DMercher%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DActivating%2520mutation%2520in%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520polycythemia%2520vera%252C%2520essential%2520thrombocythemia%252C%2520and%2520myeloid%2520metaplasia%2520with%2520myelofibrosis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D387%26epage%3D397%26doi%3D10.1016%2Fj.ccr.2005.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span> <span> </span><span class="NLM_article-title">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">854</span>, <span class="refDoi"> DOI: 10.3390/cells8080854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.3390%2Fcells8080854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=854&author=F.+Pernerauthor=C.+Pernerauthor=T.+Ernstauthor=F.+H.+Heidel&title=Roles+of+JAK2+in+aging%2C+inflammation%2C+hematopoiesis+and+malignant+transformation&doi=10.3390%2Fcells8080854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span></div><div class="casAuthors">Perner, Florian; Perner, Caroline; Ernst, Thomas; Heidel, Florian H.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clonal alterations in hematopoietic cells occur during aging and are often assocd. with the establishment of a subclin. inflammatory environment.  Several age-related conditions and diseases may be initiated or promoted by these alterations.  JAK2 mutations are among the most frequently mutated genes in blood cells during aging.  The most common mutation within the JAK2 gene is JAK2-V617F that leads to constitutive activation of the kinase and thereby aberrant engagement of downstream signaling pathways.  JAK2 mutations can act as central drivers of myeloproliferative neoplasia, a pre-leukemic and age-related malignancy.  Likewise, hyperactive JAK-signaling is a hallmark of immune diseases and critically influences inflammation, coagulation and thrombosis.  In this review we aim to summarize the current knowledge on JAK2 in clonal hematopoiesis during aging, the role of JAK-signaling in inflammation and lymphocyte biol. and JAK2 function in age-related diseases and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbCzDy7BOo7Vg90H21EOLACvtfcHk0ljQ4F8hlUhs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D&md5=8433e74cbd00a65cd218101e5ca62d79</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fcells8080854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8080854%26sid%3Dliteratum%253Aachs%26aulast%3DPerner%26aufirst%3DF.%26aulast%3DPerner%26aufirst%3DC.%26aulast%3DErnst%26aufirst%3DT.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26atitle%3DRoles%2520of%2520JAK2%2520in%2520aging%252C%2520inflammation%252C%2520hematopoiesis%2520and%2520malignant%2520transformation%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D854%26doi%3D10.3390%2Fcells8080854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boissinot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleyrat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilaine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermouet, S.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1038/onc.2010.479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fonc.2010.479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=21042281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKit73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=990-1001&author=M.+Boissinotauthor=C.+Cleyratauthor=M.+Vilaineauthor=Y.+Jacquesauthor=I.+Correauthor=S.+Hermouet&title=Anti-inflammatory+cytokines+hepatocyte+growth+factor+and+interleukin-11+are+over-expressed+in+polycythemia+vera+and+contribute+to+the+growth+of+clonal+erythroblasts+independently+of+JAK2V617F&doi=10.1038%2Fonc.2010.479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F</span></div><div class="casAuthors">Boissinot, M.; Cleyrat, C.; Vilaine, M.; Jacques, Y.; Corre, I.; Hermouet, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">990-1001</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The V617F activating mutation of janus kinase 2 (JAK2), a kinase essential for cytokine signalling, characterizes Polycythemia vera (PV), one of the myeloproliferative neoplasms (MPN).  However, not all MPNs carry mutations of JAK2, and in JAK2-mutated patients, expression of JAK2V617F does not always result in clone expansion.  In the present study, we provide evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors.  In a first series of expts., we searched for cytokines over-expressed in PV using cytokine antibody (Ab) arrays, and enzyme-linked immunosorbent assays for analyses of serum and bone marrow (BM) plasma, and quant. reverse transcription-PCRs for analyses of cells purified from PV patients and controls.  We found that PV patients over-expressed anti-inflammatory hepatocyte growth factor (HGF) and interleukin-11 (IL-11), BM mesenchymal stromal cells (BMMSCs) and erythroblasts being the main producers.  In a second series of expts., autocrine/paracrine cytokine stimulation of erythroblasts was blocked using neutralizing Abs specific for IL-11 or c-MET, the HGF receptor.  The growth of JAK2V617F-mutated HEL cells and PV erythroblasts was inhibited, indicating that JAK2-mutated cells depend on HGF and IL-11 for their growth.  Addnl. expts. showed that transient expression of JAK2V617F in BaF-3/erythropoietin receptor cells, and invalidation of JAK2V617F in HEL cells using anti-JAK2 small interfering RNA, did not affect HGF and IL-11 expression.  Thus, anti-inflammatory HGF and IL-11 are upregulated in PV and their overprodn. is not a consequence of JAK2V617F.  As both cytokines contribute to the proliferation of PV erythroblasts, blocking the c-MET/HGF/IL-11 pathways could be of interest as an addnl. therapeutic option in PV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR59CpYTfgLbVg90H21EOLACvtfcHk0lgk1eZ_CewxQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKit73J&md5=0b3519e7a3fd7571a41fb9e694c43b1e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.479%26sid%3Dliteratum%253Aachs%26aulast%3DBoissinot%26aufirst%3DM.%26aulast%3DCleyrat%26aufirst%3DC.%26aulast%3DVilaine%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DY.%26aulast%3DCorre%26aufirst%3DI.%26aulast%3DHermouet%26aufirst%3DS.%26atitle%3DAnti-inflammatory%2520cytokines%2520hepatocyte%2520growth%2520factor%2520and%2520interleukin-11%2520are%2520over-expressed%2520in%2520polycythemia%2520vera%2520and%2520contribute%2520to%2520the%2520growth%2520of%2520clonal%2520erythroblasts%2520independently%2520of%2520JAK2V617F%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D990%26epage%3D1001%26doi%3D10.1038%2Fonc.2010.479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massé, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teyssandier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lécluse, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larbret, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koscielny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Couédic, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span> <span> </span><span class="NLM_article-title">The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-10-054940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2006-10-054940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=17389763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos1Cqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1013-1021&author=S.+Dupontauthor=A.+Mass%C3%A9author=C.+Jamesauthor=I.+Teyssandierauthor=Y.+L%C3%A9cluseauthor=F.+Larbretauthor=V.+Ugoauthor=P.+Saulnierauthor=S.+Koscielnyauthor=J.+P.+Le+Cou%C3%A9dicauthor=N.+Casadevallauthor=W.+Vainchenkerauthor=F.+Delhommeau&title=The+JAK2+617V%3EF+mutation+triggers+erythropoietin+hypersensitivity+and+terminal+erythroid+amplification+in+primary+cells+from+patients+with+polycythemia+vera&doi=10.1182%2Fblood-2006-10-054940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera</span></div><div class="casAuthors">Dupont, Sabrina; Masse, Aline; James, Chloe; Teyssandier, Irene; Lecluse, Yann; Larbret, Frederic; Ugo, Valerie; Saulnier, Patrick; Koscielny, Serge; Le Couedic, Jean Pierre; Casadevall, Nicole; Vainchenker, William; Delhommeau, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1013-1021</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The JAK2 617V>F mutation is frequent in polycythemia vera (PV) and essential thrombocythemia (ET).  Using quant. polymerase chain reaction (PCR), the authors found that high levels of JAK2 617V>F in PV correlate with increased granulocytes and high levels of Hb and endogenous erythroid colony formation.  The authors detected normal progenitors and those that were heterozygous or homozygous for the mutation by genotyping ET and PV clonal immature and committed progenitors.  In PV patients, the authors distinguished homozygous profiles with normal, heterozygous, and homozygous progenitors from heterozygous profiles with only heterozygous and normal progenitors.  PV patients with a heterozygous profile had more mutated, committed progenitors than did other PV and ET patients, suggesting a selective amplification of mutated cells in the early phases of hematopoiesis.  The authors demonstrated that mutated erythroid progenitors were more sensitive to erythropoietin than normal progenitors, and that most homozygous erythroid progenitors were erythropoietin independent.  Moreover, the authors obsd. a greater in vitro erythroid amplification and a selective advantage in vivo for mutated cells in late stages of hematopoiesis.  These results suggest that, for PV, erythrocytosis can occur through 2 mechanisms: terminal erythroid amplification triggered by JAK2 617V>F homozygosity, and a 2-step process including the upstream amplification of heterozygous cells that may involve addnl. mol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz7bdbCw13ArVg90H21EOLACvtfcHk0lgk1eZ_CewxQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos1Cqtrw%253D&md5=5f50d8dd790b2e266d7d1d616a8c3c18</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-10-054940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-10-054940%26sid%3Dliteratum%253Aachs%26aulast%3DDupont%26aufirst%3DS.%26aulast%3DMass%25C3%25A9%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DC.%26aulast%3DTeyssandier%26aufirst%3DI.%26aulast%3DL%25C3%25A9cluse%26aufirst%3DY.%26aulast%3DLarbret%26aufirst%3DF.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DSaulnier%26aufirst%3DP.%26aulast%3DKoscielny%26aufirst%3DS.%26aulast%3DLe%2BCou%25C3%25A9dic%26aufirst%3DJ.%2BP.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DDelhommeau%26aufirst%3DF.%26atitle%3DThe%2520JAK2%2520617V%253EF%2520mutation%2520triggers%2520erythropoietin%2520hypersensitivity%2520and%2520terminal%2520erythroid%2520amplification%2520in%2520primary%2520cells%2520from%2520patients%2520with%2520polycythemia%2520vera%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D1013%26epage%3D1021%26doi%3D10.1182%2Fblood-2006-10-054940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, E. J.</span></span> <span> </span><span class="NLM_article-title">JAK-STAT pathway and myogenic differentiation</span>. <i>JAK-STAT</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e23282</span>, <span class="refDoi"> DOI: 10.4161/jkst.23282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.4161%2Fjkst.23282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=24058805" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e23282&author=Y.-N.+Jangauthor=E.+J.+Baik&title=JAK-STAT+pathway+and+myogenic+differentiation&doi=10.4161%2Fjkst.23282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4161%2Fjkst.23282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.23282%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DY.-N.%26aulast%3DBaik%26aufirst%3DE.%2BJ.%26atitle%3DJAK-STAT%2520pathway%2520and%2520myogenic%2520differentiation%26jtitle%3DJAK-STAT%26date%3D2013%26volume%3D2%26spage%3De23282%26doi%3D10.4161%2Fjkst.23282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Couédic, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staerk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garçon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raslova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennaceur-Griscelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeval, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span> <span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span>,  <span class="NLM_fpage">1144</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.1038/nature03546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.-P.+Le+Cou%C3%A9dicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Gar%C3%A7onauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signalling+causes+polycythaemia+vera&doi=10.1038%2Fnature03546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0ljTub61CliXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCou%25C3%25A9dic%26aufirst%3DJ.-P.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGar%25C3%25A7on%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signalling%2520causes%2520polycythaemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148%26doi%3D10.1038%2Fnature03546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griesshammer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pane, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirron, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib versus standard therapy for the treatment of polycythemia vera</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1409002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1056%2FNEJMoa1409002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=25629741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=426-435&author=A.+M.+Vannucchiauthor=J.+J.+Kiladjianauthor=M.+Griesshammerauthor=T.+Massziauthor=S.+Durrantauthor=F.+Passamontiauthor=C.+N.+Harrisonauthor=F.+Paneauthor=P.+Zacheeauthor=R.+Mesaauthor=S.+Heauthor=M.+M.+Jonesauthor=W.+Garrettauthor=J.+Liauthor=U.+Pirronauthor=D.+Habrauthor=S.+Verstovsek&title=Ruxolitinib+versus+standard+therapy+for+the+treatment+of+polycythemia+vera&doi=10.1056%2Fnejmoa1409002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib versus standard therapy for the treatment of polycythemia vera</span></div><div class="casAuthors">Vannucchi, Alessandro M.; Kiladjian, Jean Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Mesa, Ruben; He, Shui; Jones, Mark M.; Garrett, William; Li, Jingjin; Pirron, Ulrich; Habr, Dany; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-435/1-426-435/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clin. benefit in patients with polycythemia vera in a phase 2 study.  We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib vs. std. therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea.  METHODS: We randomly assigned phlebotomy-dependent patients with splenomegaly, in a 1:1 ratio, to receive ruxolitinib (110 patients) or std. therapy (112 patients).  The primary end point was both hematocrit control through week 32 and at least a 35% redn. in spleen vol. at week 32, as assessed by means of imaging.  RESULTS: The primary end point was achieved in 21% of the patients in the ruxolitinib group vs. 1% of those in the std.-therapy group (P<0.001).  Hematocrit control was achieved in 60% of patients receiving ruxolitinib and 20% of those receiving std. therapy; 38% and 1% of patients in the two groups, resp., had at least a 35% redn. in spleen vol.  A complete hematol. remission was achieved in 24% of patients in the ruxolitinib group and 9% of those in the std.-therapy group (P = 0.003); 49% vs. 5% had at least a 50% redn. in the total symptom score at week 32.  In the ruxolitinib group, grade 3 or 4 anemia occurred in 2% of patients, and grade 3 or 4 thrombocytopenia occurred in 5%; the corresponding percentages in the std.-therapy group were 0% and 4%.  Herpes zoster infection was reported in 6% of patients in the ruxolitinib group and 0% of those in the std.- therapy group (grade 1 or 2 in all cases).  Thromboembolic events occurred in one patient receiving ruxolitinib and in six patients receiving std. therapy.  CONCLUSIONS: In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to std. therapy in controlling the hematocrit, reducing the spleen vol., and improving symptoms assocd. with polycythemia vera.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCL1K9GkL--rVg90H21EOLACvtfcHk0ljTub61CliXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGqsrw%253D&md5=de3cbe6f9bf1fc04b573c1dc4e74f085</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1409002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1409002%26sid%3Dliteratum%253Aachs%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DGriesshammer%26aufirst%3DM.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DDurrant%26aufirst%3DS.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DPane%26aufirst%3DF.%26aulast%3DZachee%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DM.%2BM.%26aulast%3DGarrett%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DPirron%26aufirst%3DU.%26aulast%3DHabr%26aufirst%3DD.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DRuxolitinib%2520versus%2520standard%2520therapy%2520for%2520the%2520treatment%2520of%2520polycythemia%2520vera%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D426%26epage%3D435%26doi%3D10.1056%2Fnejmoa1409002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Fedratinib: first approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01205-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1007%2Fs40265-019-01205-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=31571162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1719-1725&author=H.+A.+Blair&title=Fedratinib%3A+first+approval&doi=10.1007%2Fs40265-019-01205-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib: First approval for treating myelofibrosis</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1719-1725</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis.  In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.  Phase III clin. development for myelofibrosis is ongoing worldwide.  This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0phtMTwbye7Vg90H21EOLACvtfcHk0ljTub61CliXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP&md5=36fa843febf45050d5dd2d1044b715c8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01205-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01205-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DFedratinib%253A%2520first%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1719%26epage%3D1725%26doi%3D10.1007%2Fs40265-019-01205-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hexner, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serdikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swider, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span> <span> </span><span class="NLM_article-title">Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">5663</span>– <span class="NLM_lpage">5671</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-04-083402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2007-04-083402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=17984313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=5663-5671&author=E.+O.+Hexnerauthor=C.+Serdikoffauthor=M.+Janauthor=C.+R.+Swiderauthor=C.+Robinsonauthor=S.+Yangauthor=T.+Angelesauthor=S.+G.+Emersonauthor=M.+Carrollauthor=B.+Ruggeriauthor=P.+Dobrzanski&title=Lestaurtinib+%28CEP701%29+is+a+JAK2+inhibitor+that+suppresses+JAK2%2FSTAT5+signaling+and+the+proliferation+of+primary+erythroid+cells+from+patients+with+myeloproliferative+disorders&doi=10.1182%2Fblood-2007-04-083402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</span></div><div class="casAuthors">Hexner, Elizabeth O.; Serdikoff, Cynthia; Jan, Mahfuza; Swider, Cezary R.; Robinson, Candy; Yang, Shi; Angeles, Thelma; Emerson, Stephen G.; Carroll, Martin; Ruggeri, Bruce; Dobrzanski, Pawel</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5663-5671</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase.  A multikinase screen detd. that lestaurtinib (formerly known as CEP-701) inhibits wild type JAK2 kinase activity with a concn. that inhibits response by 50% (IC50) of 1 nM in vitro.  We hypothesized that lestaurtinib would inhibit mutant JAK2 kinase activity and suppress the growth of cells from patients with MPDs.  We found that lestaurtinib inhibits the growth of HEL92.1.7 cells, which are dependent on mutant JAK2 activity for growth in vitro and in xenograft models.  Erythroid cells expanded from primary CD34+ cells from patients with MPDs were inhibited by lestaurtinib at concns. of 100 nM or more in 15 of 18 subjects, with concomitant inhibition of phosphorylation of STAT5 and other downstream effectors of JAK2.  By contrast, growth of erythroid cells derived from 3 healthy controls was not significantly inhibited.  These results demonstrate that lestaurtinib, in clin. achievable concns., inhibits proliferation and JAK2/STAT5 signaling in cells from patients with MPDs, and therefore holds promise as a therapeutic agent for patients with these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWg4QF0tD5VbVg90H21EOLACvtfcHk0lgUUbr7Ocn2bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVOktbw%253D&md5=0fd7e1be98ccd01dde2220364a747877</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-04-083402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-04-083402%26sid%3Dliteratum%253Aachs%26aulast%3DHexner%26aufirst%3DE.%2BO.%26aulast%3DSerdikoff%26aufirst%3DC.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DSwider%26aufirst%3DC.%2BR.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DEmerson%26aufirst%3DS.%2BG.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDobrzanski%26aufirst%3DP.%26atitle%3DLestaurtinib%2520%2528CEP701%2529%2520is%2520a%2520JAK2%2520inhibitor%2520that%2520suppresses%2520JAK2%252FSTAT5%2520signaling%2520and%2520the%2520proliferation%2520of%2520primary%2520erythroid%2520cells%2520from%2520patients%2520with%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D5663%26epage%3D5671%26doi%3D10.1182%2Fblood-2007-04-083402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumm, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichberger, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">5232</span>– <span class="NLM_lpage">5240</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-223727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2009-05-223727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=20385788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=5232-5240&author=J.+W.+Tynerauthor=T.+G.+Bummauthor=J.+Deiningerauthor=L.+Woodauthor=K.+J.+Aichbergerauthor=M.+M.+Loriauxauthor=B.+J.+Drukerauthor=C.+J.+Burnsauthor=E.+Fantinoauthor=M.+W.+Deininger&title=CYT387%2C+a+novel+JAK2+inhibitor%2C+induces+hematologic+responses+and+normalizes+inflammatory+cytokines+in+murine+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-05-223727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</span></div><div class="casAuthors">Tyner, Jeffrey W.; Bumm, Thomas G.; Deininger, Jutta; Wood, Lisa; Aichberger, Karl J.; Loriaux, Marc M.; Druker, Brian J.; Burns, Christopher J.; Fantino, Emmanuelle; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">5232-5240</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating alleles of Janus kinase 2 (JAK2) such as JAK2V617F are central to the pathogenesis of myeloproliferative neoplasms (MPN), suggesting that small mol. inhibitors targeting JAK2 may be therapeutically useful.  We have identified an aminopyrimidine deriv. (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concns., with few addnl. targets.  Between 0.5 and 1.5μM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected.  In a murine MPN model, CYT387 normalized white cell counts, hematocrit, spleen size, and restored physiol. levels of inflammatory cytokines.  Despite the hematol. responses and redn. of the JAK2V617F allele burden, JAK2V617F cells persisted and MPN recurred upon cessation of treatment, suggesting that JAK2 inhibitors may be unable to eliminate JAK2V617F cells, consistent with preliminary results from clin. trials of JAK2 inhibitors in myelofibrosis.  While the clin. benefit of JAK2 inhibitors may be substantial, not the least due to redn. of inflammatory cytokines and symptomatic improvement, our data add to increasing evidence that kinase inhibitor monotherapy of malignant disease is not curative, suggesting a need for drug combinations to optimally target the malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOU9Loc4HZuLVg90H21EOLACvtfcHk0lgUUbr7Ocn2bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVWltLg%253D&md5=dc77faf0dbce8bf1cbbda4e1b5799e72</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-223727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-223727%26sid%3Dliteratum%253Aachs%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DBumm%26aufirst%3DT.%2BG.%26aulast%3DDeininger%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DAichberger%26aufirst%3DK.%2BJ.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DCYT387%252C%2520a%2520novel%2520JAK2%2520inhibitor%252C%2520induces%2520hematologic%2520responses%2520and%2520normalizes%2520inflammatory%2520cytokines%2520in%2520murine%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D5232%26epage%3D5240%26doi%3D10.1182%2Fblood-2009-05-223727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platzbecker, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winton, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltzman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e73</span>– <span class="NLM_lpage">e81</span>, <span class="refDoi"> DOI: 10.1016/s2352-3026(17)30237-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2FS2352-3026%2817%2930237-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29275119" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=e73-e81&author=C.+N.+Harrisonauthor=A.+M.+Vannucchiauthor=U.+Platzbeckerauthor=F.+Cervantesauthor=V.+Guptaauthor=D.+Lavieauthor=F.+Passamontiauthor=E.+F.+Wintonauthor=H.+Dongauthor=J.+Kawashimaauthor=J.+D.+Maltzmanauthor=J.-J.+Kiladjianauthor=S.+Verstovsek&title=Momelotinib+versus+best+available+therapy+in+patients+with+myelofibrosis+previously+treated+with+ruxolitinib+%28SIMPLIFY+2%29%3A+a+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2Fs2352-3026%2817%2930237-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2817%2930237-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252817%252930237-5%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DPlatzbecker%26aufirst%3DU.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLavie%26aufirst%3DD.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DWinton%26aufirst%3DE.%2BF.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DKawashima%26aufirst%3DJ.%26aulast%3DMaltzman%26aufirst%3DJ.%2BD.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DMomelotinib%2520versus%2520best%2520available%2520therapy%2520in%2520patients%2520with%2520myelofibrosis%2520previously%2520treated%2520with%2520ruxolitinib%2520%2528SIMPLIFY%25202%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Haematol.%26date%3D2018%26volume%3D5%26spage%3De73%26epage%3De81%26doi%3D10.1016%2Fs2352-3026%2817%2930237-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palandri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerds, A. T.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2018.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2Fj.leukres.2018.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=30025280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=82-88&author=J.+Berdejaauthor=F.+Palandriauthor=M.+R.+Baerauthor=D.+Quickauthor=J.+J.+Kiladjianauthor=G.+Martinelliauthor=A.+Vermaauthor=O.+Hamidauthor=R.+Walgrenauthor=C.+Pitouauthor=P.+L.+Liauthor=A.+T.+Gerds&title=Phase+2+study+of+gandotinib+%28LY2784544%29+in+patients+with+myeloproliferative+neoplasms&doi=10.1016%2Fj.leukres.2018.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms</span></div><div class="casAuthors">Berdeja, J.; Palandri, F.; Baer, M. R.; Quick, D.; Kiladjian, J. J.; Martinelli, G.; Verma, A.; Hamid, O.; Walgren, R.; Pitou, C.; Li, P. L.; Gerds, A. T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-88</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Philadelphia chromosome-neg. myeloproliferative neoplasms (MPNs) are assocd. with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation.  LY2784544 (gandotinib) is a potent, selective, small-mol. inhibitor of JAK2 that has potential dose-dependent selectivity for the JAK2 V617F mutation and may inhibit addnl. JAK2 mutant isoforms in nonclin. testing.  A multicenter, single-arm, outpatient phase 2 study evaluated the efficacy, safety, and pharmacokinetics (PK) of gandotinib administered to patients (120 mg once daily) with MPNs, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).  Between May 2012 and March 2015, 138 patients received at least one dose of study drug.  Most frequent Grade 3 or 4 treatment-emergent adverse events that were considered study-drug related were anemia (11.6%), hyperuricemia (3.2%), fatigue (2.9%), diarrhea (2.2%), and thrombocytopenia (2.2%).  Overall response rates (ORRs) in patients with JAK2 V617F-mutated PV, ET, and MF were 95%, 90.5%, and 9.1%, resp., while patients with ET and MF without the JAK2 V617F mutations had ORRs of 43.7% and 0%, resp.  LY2784544 demonstrated efficacy in JAK2 V617F-mutated MPNs, including in patients previously on ruxolitinib therapy, who had an ORR of 3.3%.  At the 1-yr visit, 44% of patients experienced a ≥50% improvement in the MPN-Symptom Assessment Form Total Symptom Score, and 26% of patients had a 50% redn. in Brief Fatigue Inventory score.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSGC6yNVigZ7Vg90H21EOLACvtfcHk0ljjBGdg5ppRIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrsrfJ&md5=897c90f8b02ad7dc1fbbe71bdf1667a9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2018.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2018.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DBerdeja%26aufirst%3DJ.%26aulast%3DPalandri%26aufirst%3DF.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DQuick%26aufirst%3DD.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DWalgren%26aufirst%3DR.%26aulast%3DPitou%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DP.%2BL.%26aulast%3DGerds%26aufirst%3DA.%2BT.%26atitle%3DPhase%25202%2520study%2520of%2520gandotinib%2520%2528LY2784544%2529%2520in%2520patients%2520with%2520myeloproliferative%2520neoplasms%26jtitle%3DLeuk.%2520Res.%26date%3D2018%26volume%3D71%26spage%3D82%26epage%3D88%26doi%3D10.1016%2Fj.leukres.2018.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerds, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pristupa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granston, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Fayoumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial</span>. <i>JAMA. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2017.5818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1001%2Fjamaoncol.2017.5818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29522138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsVaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=652-659&author=J.+Mascarenhasauthor=R.+Hoffmanauthor=M.+Talpazauthor=A.+T.+Gerdsauthor=B.+Steinauthor=V.+Guptaauthor=A.+Szokeauthor=M.+Drummondauthor=A.+Pristupaauthor=T.+Granstonauthor=R.+Dalyauthor=S.+Al-Fayoumiauthor=J.+A.+Callahanauthor=J.+W.+Singerauthor=J.+Gotlibauthor=C.+Jamiesonauthor=C.+Harrisonauthor=R.+Mesaauthor=S.+Verstovsek&title=Pacritinib+vs+best+available+therapy%2C+including+ruxolitinib%2C+in+patients+with+myelofibrosis%3A+a+randomized+clinical+trial&doi=10.1001%2Fjamaoncol.2017.5818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial</span></div><div class="casAuthors">Mascarenhas John; Hoffman Ronald; Talpaz Moshe; Gerds Aaron T; Stein Brady; Gupta Vikas; Szoke Anita; Drummond Mark; Pristupa Alexander; Granston Tanya; Daly Robert; Al-Fayoumi Suliman; Callahan Jennifer A; Singer Jack W; Gotlib Jason; Jamieson Catriona; Harrison Claire; Mesa Ruben; Verstovsek Srdan</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-659</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms.  Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib.  Objective:  To compare the efficacy and safety of JAK2 inhibitor pacritinib with that of best available therapy (BAT), including ruxolitinib, in patients with myelofibrosis and thrombocytopenia.  Design, Setting, and Participants:  For this phase 3 randomized international multicenter study-the PERSIST-2 study-of pacritinib vs BAT, 311 patients with myelofibrosis and platelet count 100 × 109/L or less were recruited for analysis.  Crossover from BAT was allowed after week 24 or for progression of splenomegaly.  Interventions:  Patients were randomized 1:1:1 to pacritinib 400 mg once daily, pacritinib 200 mg twice daily, or BAT.  Main Outcomes and Measures:  Coprimary end points were rates of patients achieving 35% or more spleen volume reduction (SVR) and 50% or more reduction in total symptom score (TSS) at week 24.  Efficacy analyses were performed on the intention-to-treat efficacy population, comprising all patients with a randomization date allowing for week 24 data.  Results:  Overall, 311 patients (mean [SD] age, 63.70 [9.08] years; 171 men [55%] and 140 women [45%]) were included in the study; 149 patients (48%) had prior ruxolitinib.  The most common BAT was ruxolitinib (44 patients [45%]); 19 patients (19%) received watchful-waiting only.  The intention-to-treat efficacy population included 75 patients randomized to pacritinib once daily; 74, pacritinib twice daily, and 72, BAT.  Pacritinib (arms combined) was more effective than BAT for 35% or more SVR (27 patients [18%] vs 2 patients [3%]; P = .001) and had a nonsignificantly greater rate of 50% or more reduction in TSS (37 patients [25%] vs 10 patients [14%]; P = .08).  Pacritinib twice daily led to significant improvements in both end points over BAT (≥35% SVR: 16 patients [22%] vs 2 patients [3%]; P = .001; ≥50% reduction in TSS: 24 patients [32%] vs 10 patients [14%]; P = .01).  Clinical improvement in hemoglobin and reduction in transfusion burden were greatest with pacritinib twice daily.  For pacritinib once daily, pacritinib twice daily, and BAT, the most common (>10%) grade 3 or 4 adverse events were thrombocytopenia (32 patients [31%], 34 patients [32%], 18 patients [18%]), and anemia (28 patients [27%], 23 patients [22%], 14 patients [14%]).  In the pacritinib once daily, twice daily, and BAT arms, discontinuation owing to adverse events occurred in 15 patients (14%), 10 patients (9%), and 4 patients (4%).  Conclusions and Relevance:  In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.  Trial Registration:  clinicaltrials.gov Identifier: NCT02055781.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7kXsuFf2C9pVVjGoY74BafW6udTcc2eaI6EA0QXrYALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsVaktA%253D%253D&md5=03e8bfd4e9b7566b07d1452a42346705</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2017.5818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2017.5818%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DGerds%26aufirst%3DA.%2BT.%26aulast%3DStein%26aufirst%3DB.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DSzoke%26aufirst%3DA.%26aulast%3DDrummond%26aufirst%3DM.%26aulast%3DPristupa%26aufirst%3DA.%26aulast%3DGranston%26aufirst%3DT.%26aulast%3DDaly%26aufirst%3DR.%26aulast%3DAl-Fayoumi%26aufirst%3DS.%26aulast%3DCallahan%26aufirst%3DJ.%2BA.%26aulast%3DSinger%26aufirst%3DJ.%2BW.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPacritinib%2520vs%2520best%2520available%2520therapy%252C%2520including%2520ruxolitinib%252C%2520in%2520patients%2520with%2520myelofibrosis%253A%2520a%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA.%2520Oncol.%26date%3D2018%26volume%3D4%26spage%3D652%26epage%3D659%26doi%3D10.1001%2Fjamaoncol.2017.5818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurgutis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuliczkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial</span>. <i>JAMA. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1001%2Fjamaoncol.2015.1590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=26181658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=643-651&author=A.+Pardananiauthor=C.+Harrisonauthor=J.+E.+Cortesauthor=F.+Cervantesauthor=R.+A.+Mesaauthor=D.+Milliganauthor=T.+Massziauthor=E.+Mishchenkoauthor=E.+Jourdanauthor=A.+M.+Vannucchiauthor=M.+W.+Drummondauthor=M.+Jurgutisauthor=K.+Kuliczkowskiauthor=E.+Gheorghitaauthor=F.+Passamontiauthor=F.+Neumannauthor=A.+Patkiauthor=G.+Gaoauthor=A.+Tefferi&title=Safety+and+efficacy+of+fedratinib+in+patients+with+primary+or+secondary+myelofibrosis%3A+a+randomized+clinical+trial&doi=10.1001%2Fjamaoncol.2015.1590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial</span></div><div class="casAuthors">Pardanani Animesh; Tefferi Ayalew; Harrison Claire; Cortes Jorge E; Cervantes Francisco; Mesa Ruben A; Milligan Donald; Masszi Tamas; Mishchenko Elena; Jourdan Eric; Vannucchi Alessandro M; Drummond Mark W; Jurgutis Mindaugas; Kuliczkowski Kazimierz; Gheorghita Emanuil; Passamonti Francesco; Neumann Frank; Patki Abhay; Gao Guozhi</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">643-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.  Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials.  OBJECTIVE:  To evaluate the efficacy and safety of fedratinib therapy in patients with primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF.  DESIGN, SETTING, AND PARTICIPANTS:  Double-blind, randomized, placebo-controlled phase 3 study in 94 sites in 24 countries in which 289 adult patients (≥18 years of age) with intermediate-2 or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF were randomly assigned between December 2011 and September 2012 to once-daily oral fedratinib, at a dose of 400 mg or 500 mg, or placebo, for at least 6 consecutive 4-week cycles.  MAIN OUTCOMES AND MEASURES:  The primary end point was spleen response (≥35% reduction in spleen volume from baseline as determined by magnetic resonance imaging or computed tomography) at week 24 and confirmed 4 weeks later.  The main secondary end point was symptom response (≥50% reduction in total symptom score, assessed using the modified Myelofibrosis Symptom Assessment Form).  RESULTS:  The primary end point was achieved by 35 of 96 (36% [95% CI, 27%-46%]) and 39 of 97 (40% [95% CI, 30%-50%]) patients in the fedratinib 400-mg and 500-mg groups, vs 1 of 96 (1% [95% CI, 0%-3%]) in the placebo group (P < .001).  Symptom response rates at week 24 were 33 of 91 (36% [95% CI, 26%-46%]), 31 of 91 (34% [95% CI, 24%-44%]), and 6 of 85 (7% [95% CI, 2%-13%]) in the fedratinib 400-mg, 500-mg, and placebo groups, respectively (P < .001).  Common adverse events with fedratinib treatment were anemia, gastrointestinal symptoms, and increased levels of liver transaminases, serum creatinine, and pancreatic enzymes.  Encephalopathy was reported in 4 women who received fedratinib 500 mg/d.  A diagnosis of Wernicke encephalopathy was supported by magnetic resonance imaging in 3 cases and suspected clinically in 1 case.  CONCLUSIONS AND RELEVANCE:  Fedratinib therapy significantly reduced splenomegaly and symptom burden in patients with MF.  These benefits were accompanied by toxic effects in some patients, the most important being encephalopathy of unknown mechanism.  Clinical development of fedratinib was subsequently discontinued.  TRIAL REGISTRATION:  clinicaltrials.gov identifier: NCT01437787.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMj69zv1FsJFMfW6udTcc2eY0y4SFM8bnu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVOmtw%253D%253D&md5=e7fe11f4b8edbd1a6ebc4edeca59b551</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1590%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DMilligan%26aufirst%3DD.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DMishchenko%26aufirst%3DE.%26aulast%3DJourdan%26aufirst%3DE.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DDrummond%26aufirst%3DM.%2BW.%26aulast%3DJurgutis%26aufirst%3DM.%26aulast%3DKuliczkowski%26aufirst%3DK.%26aulast%3DGheorghita%26aufirst%3DE.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DNeumann%26aufirst%3DF.%26aulast%3DPatki%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520fedratinib%2520in%2520patients%2520with%2520primary%2520or%2520secondary%2520myelofibrosis%253A%2520a%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA.%2520Oncol.%26date%3D2015%26volume%3D1%26spage%3D643%26epage%3D651%26doi%3D10.1001%2Fjamaoncol.2015.1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span> <span> </span><span class="NLM_article-title">Fedratinib in myelofibrosis</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1792</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fbloodadvances.2019000954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=32343799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A280%3ADC%252BB38vgsFehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=1792-1800&author=A.+Mullallyauthor=J.+Hoodauthor=C.+Harrisonauthor=R.+Mesa&title=Fedratinib+in+myelofibrosis&doi=10.1182%2Fbloodadvances.2019000954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib in myelofibrosis</span></div><div class="casAuthors">Mullally Ann; Mullally Ann; Mullally Ann; Hood John; Harrison Claire; Mesa Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Blood advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1792-1800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2.  It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM) and was identified to be selective for JAK2 relative to other JAK family members (eg, JAK1, JAK3, and TYK2).  It quickly moved into clinical development with a phase 1 clinical trial opening in 2008, where a favorable impact on spleen and myelofibrosis (MF) symptom responses was reported.  A phase 3 trial in JAK2 inhibitor treatment-naive MF patients followed in 2011 (JAKARTA); a phase 2 trial in MF patients resistant or intolerant to ruxolitinib followed in 2012 (JAKARTA-2).  Clinical development suffered a major setback between 2013 and 2017 when the US Food and Drug Administration (FDA) placed fedratinib on clinical hold due to the development of symptoms concerning for Wernicke encephalopathy (WE) in 8 of 608 subjects (1.3%) who had received the drug.  It was ultimately concluded that there was no evidence that fedratinib directly induces WE, but clear risk factors (eg, poor nutrition, uncontrolled gastrointestinal toxicity) were identified.  In August 2019, the FDA approved fedratinib for the treatment of adults with intermediate-2 or high-risk MF.  Notably, approval includes a "black box warning" on the risk of serious and fatal encephalopathy, including WE.  FDA approval was granted on the basis of the JAKARTA studies in which the primary end points (ie, spleen and MF symptom responses) were met in ∼35% to 40% of patients (JAKARTA) and 25% to 30% of patients (JAKARTA-2), respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr9kz2EmYIWxOk4JA3soTqfW6udTcc2eY0y4SFM8bnu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vgsFehuw%253D%253D&md5=1345b1b8335ab1c62a01cb546738a812</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000954%26sid%3Dliteratum%253Aachs%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DMesa%26aufirst%3DR.%26atitle%3DFedratinib%2520in%2520myelofibrosis%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26spage%3D1792%26epage%3D1800%26doi%3D10.1182%2Fbloodadvances.2019000954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghrim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penhallow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppugalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjundaswamy, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly selective JAK2 inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms</span>. <i>ACS. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=850-855&author=H.+Wanauthor=G.+M.+Schroederauthor=A.+C.+Hartauthor=J.+Inghrimauthor=J.+Grebinskiauthor=J.+S.+Tokarskiauthor=M.+V.+Lorenziauthor=D.+Youauthor=T.+McDevittauthor=B.+Penhallowauthor=R.+Vuppugallaauthor=Y.+Zhangauthor=X.+Guauthor=R.+Iyerauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=S.+Rueppauthor=J.+Lippyauthor=Y.+Blatauthor=J.+S.+Sackauthor=J.+A.+Khanauthor=K.+Stefanskiauthor=B.+Sleczkaauthor=A.+Mathurauthor=J.-H.+Sunauthor=M.+K.+Wongauthor=D.-R.+Wuauthor=P.+Liauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=B.+Pragalathanauthor=S.+Narayananauthor=K.+C.+Nanjundaswamyauthor=P.+Kuppusamyauthor=A.+V.+Purandare&title=Discovery+of+a+highly+selective+JAK2+inhibitor%2C+BMS-911543%2C+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1021%2Facsmedchemlett.5b00226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms</span></div><div class="casAuthors">Wan, Honghe; Schroeder, Gretchen M.; Hart, Amy C.; Inghrim, Jennifer; Grebinski, James; Tokarski, John S.; Lorenzi, Matthew V.; You, Dan; McDevitt, Theresa; Penhallow, Becky; Vuppugalla, Ragini; Zhang, Yueping; Gu, Xiaomei; Iyer, Ramaswamy; Lombardo, Louis J.; Trainor, George L.; Ruepp, Stefan; Lippy, Jonathan; Blat, Yuval; Sack, John S.; Khan, Javed A.; Stefanski, Kevin; Sleczka, Bogdan; Mathur, Arvind; Sun, Jung-Hui; Wong, Michael K.; Wu, Dauh-Rurng; Li, Peng; Gupta, Anuradha; Arunachalam, P. N.; Pragalathan, Bala; Narayanan, Sankara; Nanjundaswamy, K. C.; Kuppusamy, Prakasam; Purandare, Ashok V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-855</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway.  X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole (I) led to the discovery of a clin. candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LTsDfjeehLVg90H21EOLACvtfcHk0liwWaqo72si4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGitbvF&md5=d6bdb9b070a8f7492352600ea1222a8f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00226%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DHart%26aufirst%3DA.%2BC.%26aulast%3DInghrim%26aufirst%3DJ.%26aulast%3DGrebinski%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DMcDevitt%26aufirst%3DT.%26aulast%3DPenhallow%26aufirst%3DB.%26aulast%3DVuppugalla%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DNanjundaswamy%26aufirst%3DK.%2BC.%26aulast%3DKuppusamy%26aufirst%3DP.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520selective%2520JAK2%2520inhibitor%252C%2520BMS-911543%252C%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DACS.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D850%26epage%3D855%26doi%3D10.1021%2Facsmedchemlett.5b00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally effective dual janus kinase 2/FLT3 Inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10305</span>– <span class="NLM_lpage">10320</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10305-10320&author=T.+Yangauthor=M.+Huauthor=W.+Qiauthor=Z.+Yangauthor=M.+Tangauthor=J.+Heauthor=Y.+Chenauthor=P.+Baiauthor=X.+Yuanauthor=C.+Zhangauthor=K.+Liuauthor=Y.+Luauthor=M.+Xiangauthor=L.+Chen&title=Discovery+of+potent+and+orally+effective+dual+janus+kinase+2%2FFLT3+Inhibitors+for+the+treatment+of+acute+myelogenous+leukemia+and+myeloproliferative+neoplasms&doi=10.1021%2Facs.jmedchem.9b01348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></div><div class="casAuthors">Yang, Tao; Hu, Mengshi; Qi, Wenyan; Yang, Zhuang; Tang, Minghai; He, Jun; Chen, Yong; Bai, Peng; Yuan, Xue; Zhang, Chufeng; Liu, Kongjun; Lu, Yulin; Xiang, Mingli; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10305-10320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivs. that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases is described.  These screening cascades revealed that I was a preferred compd. with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, resp.  Moreover, I was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, resp., and possessed an excellent selectivity profile over the other 100 representative kinases.  In a series of cytokine-stimulated cell-based assays, I exhibited a higher JAK2 selectivity over other JAK isoforms.  The oral administration of 60 mg/kg of I could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, resp.  Addnl., I showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that I might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHnNcuajGNcLVg90H21EOLACvtfcHk0ljccorYbiLVfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE&md5=86c811cf77a95a7250996456cd29e6dc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520effective%2520dual%2520janus%2520kinase%25202%252FFLT3%2520Inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10305%26epage%3D10320%26doi%3D10.1021%2Facs.jmedchem.9b01348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+selective+and+rigidify%3A+the+discovery+path+toward+a+next+generation+of+EGFR+tyrosine+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0ljccorYbiLVfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520selective%2520and%2520rigidify%253A%2520the%2520discovery%2520path%2520toward%2520a%2520next%2520generation%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWolf, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas-Lindsay, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanusch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span> <span> </span><span class="NLM_article-title">A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-17-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1158%2F2159-8290.CD-17-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28578312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=963-972&author=A.+Drilonauthor=R.+Nagasubramanianauthor=J.+F.+Blakeauthor=N.+Kuauthor=B.+B.+Tuchauthor=K.+Ebataauthor=S.+Smithauthor=V.+Lauriaultauthor=G.+R.+Kolakowskiauthor=B.+J.+Brandhuberauthor=P.+D.+Larsenauthor=K.+S.+Bouhanaauthor=S.+L.+Winskiauthor=R.+Hamorauthor=W.-I.+Wuauthor=A.+Parkerauthor=T.+H.+Moralesauthor=F.+X.+Sullivanauthor=W.+E.+DeWolfauthor=L.+A.+Wollenbergauthor=P.+R.+Gordonauthor=D.+N.+Douglas-Lindsayauthor=M.+Scaltritiauthor=R.+Benayedauthor=S.+Rajauthor=B.+Hanuschauthor=A.+M.+Schramauthor=P.+Jonssonauthor=M.+F.+Bergerauthor=J.+F.+Hechtmanauthor=B.+S.+Taylorauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=D.+M.+Hyman&title=A+next-generation+TRK+kinase+inhibitor+overcomes+acquired+resistance+to+prior+TRK+kinase+inhibition+in+patients+with+TRK+fusion-positive+solid+tumors&doi=10.1158%2F2159-8290.cd-17-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors</span></div><div class="casAuthors">Drilon, Alexander; Nagasubramanian, Ramamoorthy; Blake, James F.; Ku, Nora; Tuch, Brian B.; Ebata, Kevin; Smith, Steve; Lauriault, Veronique; Kolakowski, Gabrielle R.; Brandhuber, Barbara J.; Larsen, Paul D.; Bouhana, Karyn S.; Winski, Shannon L.; Hamor, Robyn; Wu, Wen-I.; Parker, Andrew; Morales, Tony H.; Sullivan, Francis X.; DeWolf, Walter E.; Wollenberg, Lance A.; Gordon, Paul R.; Douglas-Lindsay, Dorothea N.; Scaltriti, Maurizio; Benayed, Ryma; Raj, Sandeep; Hanusch, Bethany; Schram, Alison M.; Jonsson, Philip; Berger, Michael F.; Hechtman, Jaclyn F.; Taylor, Barry S.; Andrews, Steve; Rothenberg, S. Michael; Hyman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">963-972</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histol.-agnostic efficacy in patients with TRK fusion-pos. cancers.  Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance.  LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs.  Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models.  As clin. proof of concept, the first 2 patients with TRK fusion-pos. cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titrn. guided by pharmacokinetic assessments.  This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients.  Significance: LOXO-195 abrogated resistance in TRK fusion-pos. cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs.  This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.  Cancer Discov; 7(9); 963-72. ©2017 AACR.  See related commentary by Parikh and Corcoran, p. 934.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG4KsnHeEsHLVg90H21EOLACvtfcHk0limP2OS1C3jXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyis7fE&md5=aac35c31a9645a16a61deaafba5f106e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0507%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DNagasubramanian%26aufirst%3DR.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKu%26aufirst%3DN.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DKolakowski%26aufirst%3DG.%2BR.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLarsen%26aufirst%3DP.%2BD.%26aulast%3DBouhana%26aufirst%3DK.%2BS.%26aulast%3DWinski%26aufirst%3DS.%2BL.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DSullivan%26aufirst%3DF.%2BX.%26aulast%3DDeWolf%26aufirst%3DW.%2BE.%26aulast%3DWollenberg%26aufirst%3DL.%2BA.%26aulast%3DGordon%26aufirst%3DP.%2BR.%26aulast%3DDouglas-Lindsay%26aufirst%3DD.%2BN.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DRaj%26aufirst%3DS.%26aulast%3DHanusch%26aufirst%3DB.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26atitle%3DA%2520next-generation%2520TRK%2520kinase%2520inhibitor%2520overcomes%2520acquired%2520resistance%2520to%2520prior%2520TRK%2520kinase%2520inhibition%2520in%2520patients%2520with%2520TRK%2520fusion-positive%2520solid%2520tumors%26jtitle%3DCanc.%2520Discov.%26date%3D2017%26volume%3D7%26spage%3D963%26epage%3D972%26doi%3D10.1158%2F2159-8290.cd-17-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&author=A.+Drilonauthor=S.-H.+I.+Ouauthor=B.+C.+Choauthor=D.-W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.-J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+is+a+next-generation+ROS1%2FTRK%2FALK+inhibitor+that+potently+inhibits+ROS1%2FTRK%2FALK+solvent-+front+mutations&doi=10.1158%2F2159-8290.cd-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0limP2OS1C3jXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520is%2520a%2520next-generation%2520ROS1%252FTRK%252FALK%2520inhibitor%2520that%2520potently%2520inhibits%2520ROS1%252FTRK%252FALK%2520solvent-%2520front%2520mutations%26jtitle%3DCanc.%2520Discov.%26date%3D2018%26volume%3D8%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.cd-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+novel+irreversible+FLT3+inhibitor%2C+FF-10101%2C+shows+excellent+efficacy+against+AML+cells+with+FLT3+mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lhOxaAN4-WF1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520novel%2520irreversible%2520FLT3%2520inhibitor%252C%2520FF-10101%252C%2520shows%2520excellent%2520efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barraco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willenbacher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymakers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liersch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wroclawska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumanchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisslinger, H.</span></span> <span> </span><span class="NLM_article-title">Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1111/bjh.16729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1111%2Fbjh.16729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=32583458" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Barracoauthor=R.+Greilauthor=R.+Herbrechtauthor=B.+Schmidtauthor=A.+Reiterauthor=W.+Willenbacherauthor=R.+Raymakersauthor=R.+Lierschauthor=M.+Wroclawskaauthor=R.+Packauthor=K.+Burockauthor=D.+Karumanchiauthor=H.+Gisslinger&title=Real-world+non-interventional+long-term+post-authorisation+safety+study+of+ruxolitinib+in+myelofibrosis&doi=10.1111%2Fbjh.16729"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fbjh.16729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.16729%26sid%3Dliteratum%253Aachs%26aulast%3DBarraco%26aufirst%3DF.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DHerbrecht%26aufirst%3DR.%26aulast%3DSchmidt%26aufirst%3DB.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DWillenbacher%26aufirst%3DW.%26aulast%3DRaymakers%26aufirst%3DR.%26aulast%3DLiersch%26aufirst%3DR.%26aulast%3DWroclawska%26aufirst%3DM.%26aulast%3DPack%26aufirst%3DR.%26aulast%3DBurock%26aufirst%3DK.%26aulast%3DKarumanchi%26aufirst%3DD.%26aulast%3DGisslinger%26aufirst%3DH.%26atitle%3DReal-world%2520non-interventional%2520long-term%2520post-authorisation%2520safety%2520study%2520of%2520ruxolitinib%2520in%2520myelofibrosis%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2020%26doi%3D10.1111%2Fbjh.16729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaap, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lager, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span> <span> </span><span class="NLM_article-title">Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e317</span>– <span class="NLM_lpage">e324</span>, <span class="refDoi"> DOI: 10.1016/s2352-3026(17)30088-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2FS2352-3026%2817%2930088-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28602585" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=e317-e324&author=C.+N.+Harrisonauthor=N.+Schaapauthor=A.+M.+Vannucchiauthor=J.-J.+Kiladjianauthor=R.+V.+Tiuauthor=P.+Zacheeauthor=E.+Jourdanauthor=E.+Wintonauthor=R.+T.+Silverauthor=H.+C.+Schoutenauthor=F.+Passamontiauthor=S.+Zweegmanauthor=M.+Talpazauthor=J.+Lagerauthor=Z.+Shunauthor=R.+A.+Mesa&title=Janus+kinase-2+inhibitor+fedratinib+in+patients+with+myelofibrosis+previously+treated+with+ruxolitinib+%28JAKARTA-2%29%3A+a+single-arm%2C+open-label%2C+non-randomised%2C+phase+2%2C+multicentre+study&doi=10.1016%2Fs2352-3026%2817%2930088-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2817%2930088-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252817%252930088-1%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DSchaap%26aufirst%3DN.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DTiu%26aufirst%3DR.%2BV.%26aulast%3DZachee%26aufirst%3DP.%26aulast%3DJourdan%26aufirst%3DE.%26aulast%3DWinton%26aufirst%3DE.%26aulast%3DSilver%26aufirst%3DR.%2BT.%26aulast%3DSchouten%26aufirst%3DH.%2BC.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DLager%26aufirst%3DJ.%26aulast%3DShun%26aufirst%3DZ.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DJanus%2520kinase-2%2520inhibitor%2520fedratinib%2520in%2520patients%2520with%2520myelofibrosis%2520previously%2520treated%2520with%2520ruxolitinib%2520%2528JAKARTA-2%2529%253A%2520a%2520single-arm%252C%2520open-label%252C%2520non-randomised%252C%2520phase%25202%252C%2520multicentre%2520study%26jtitle%3DLancet%2520Haematol.%26date%3D2017%26volume%3D4%26spage%3De317%26epage%3De324%26doi%3D10.1016%2Fs2352-3026%2817%2930088-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minturn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A. E.</span></span> <span> </span><span class="NLM_article-title">Trk receptor expression and inhibition in neuroblastomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-1815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1158%2F1078-0432.CCR-08-1815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=19417027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3244-3250&author=G.+M.+Brodeurauthor=J.+E.+Minturnauthor=R.+Hoauthor=A.+M.+Simpsonauthor=R.+Iyerauthor=C.+R.+Varelaauthor=J.+E.+Lightauthor=V.+Kollaauthor=A.+E.+Evans&title=Trk+receptor+expression+and+inhibition+in+neuroblastomas&doi=10.1158%2F1078-0432.ccr-08-1815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Trk Receptor Expression and Inhibition in Neuroblastomas</span></div><div class="casAuthors">Brodeur, Garrett M.; Minturn, Jane E.; Ho, Ruth; Simpson, Anisha M.; Iyer, Radhika; Varela, Carly R.; Light, Jennifer E.; Kolla, Venkatadri; Evans, Audrey E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3244-3250</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Neuroblastoma, the most common and deadly solid tumor in children, exhibits heterogeneous clin. behavior, from spontaneous regression to relentless progression.  Current evidence suggests that the TRK family of neurotrophin receptors plays a crit. role in these diverse behaviors.  Neuroblastomas expressing TrkA are biol. favorable and prone to spontaneous regression or differentiation, depending on the absence or presence of its ligand (NGF) in the microenvironment.  In contrast, TrkB-expressing tumors frequently have MYCN amplification and are very aggressive and often fatal tumors.  These tumors also express the TrkB ligand (BDNF), resulting in an autocrine or paracrine survival pathway.  Exposure to BDNF promotes survival, drug resistance, and angiogenesis of TrkB-expressing tumors.  Here we review the role of Trks in normal development, the different functions of Trk isoforms, and the major Trk signaling pathways.  We also review the roles these receptors play in the heterogeneous biol. and clin. behavior of neuroblastomas, and the activation of Trk receptors in other cancers.  Finally we address the progress that has been made in developing targeted therapy with Trk-selective inhibitors to treat neuroblastomas and other tumors with activated Trk expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XUqj0KJ-GLVg90H21EOLACvtfcHk0lhOxaAN4-WF1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmtbk%253D&md5=cb21a6625f5d8464325522fb5b87c710</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1815%26sid%3Dliteratum%253Aachs%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DMinturn%26aufirst%3DJ.%2BE.%26aulast%3DHo%26aufirst%3DR.%26aulast%3DSimpson%26aufirst%3DA.%2BM.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DVarela%26aufirst%3DC.%2BR.%26aulast%3DLight%26aufirst%3DJ.%2BE.%26aulast%3DKolla%26aufirst%3DV.%26aulast%3DEvans%26aufirst%3DA.%2BE.%26atitle%3DTrk%2520receptor%2520expression%2520and%2520inhibition%2520in%2520neuroblastomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3244%26epage%3D3250%26doi%3D10.1158%2F1078-0432.ccr-08-1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khotskaya, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills Shaw, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span> <span> </span><span class="NLM_article-title">Targeting TRK family proteins in cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2Fj.pharmthera.2017.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=28174090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=58-66&author=Y.+B.+Khotskayaauthor=V.+R.+Hollaauthor=A.+F.+Faragoauthor=K.+R.+Mills+Shawauthor=F.+Meric-Bernstamauthor=D.+S.+Hong&title=Targeting+TRK+family+proteins+in+cancer&doi=10.1016%2Fj.pharmthera.2017.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting TRK family proteins in cancer</span></div><div class="casAuthors">Khotskaya, Yekaterina B.; Holla, Vijaykumar R.; Farago, Anna F.; Mills Shaw, Kenna R.; Meric-Bernstam, Funda; Hong, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3 genes, resp.  Binding of neurotrophins to TRK proteins induces receptor dimerization, phosphorylation, and activation of the downstream signaling cascades via PI3K, RAS/MAPK/ERK, and PLC-gamma.  TRK pathway aberrations, including gene fusions, protein overexpression, and single nucleotide alterations, have been implicated in the pathogenesis of many cancer types, with NTRK gene fusions being the most well validated oncogenic events to date.  Although the NTRK gene fusions are infrequent in most cancer types, certain rare tumor types are predominately driven by these events.  Conversely, in more common histologies, such as lung and colorectal cancers, prevalence of the NTRK fusions is well below 5%.  Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations.  Currently, several TRK-targeting compds. are in clin. development.  The ongoing Phase 2 trials with entrectinib and LOXO-101, two of the leading TRK inhibitors, are designed as 'basket trials', inclusive of patients whose tumors harbor NTRK gene fusions, independent of histol.  Addnl. Phase 1 studies of other TRK inhibitors, including MGCD516, PLX7486, DS-6051b, and TSR-011, are underway.  Interim data examg. NTRK-rearranged tumors treated with entrectinib or LOXO-101 demonstrate encouraging activity, with patients achieving rapid and durable responses.  Consequently, both drugs have achieved orphan designation from regulatory agencies, and efforts are underway to further expedite their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozoy77YmUc_LVg90H21EOLACvtfcHk0lirHXf20_Gqjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisF2jtL8%253D&md5=f18f232e6d3c4c9a5d2e398fe60ae7e4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKhotskaya%26aufirst%3DY.%2BB.%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DMills%2BShaw%26aufirst%3DK.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DD.%2BS.%26atitle%3DTargeting%2520TRK%2520family%2520proteins%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.pharmthera.2017.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najfeld, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span> <span> </span><span class="NLM_article-title">A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1111/bjh.12220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1111%2Fbjh.12220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=23330839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2013&pages=68-75&author=J.+Mascarenhasauthor=M.+Luauthor=T.+Liauthor=B.+Petersenauthor=T.+Hochmanauthor=V.+Najfeldauthor=J.+D.+Goldbergauthor=R.+Hoffman&title=A+phase+I+study+of+panobinostat+%28LBH589%29+in+patients+with+primary+myelofibrosis+%28PMF%29+and+post-polycythaemia+vera%2Fessential+thrombocythaemia+myelofibrosis+%28post-PV%2FET+MF%29&doi=10.1111%2Fbjh.12220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)</span></div><div class="casAuthors">Mascarenhas, John; Lu, Min; Li, Timmy; Petersen, Bruce; Hochman, Tsivia; Najfeld, Vesna; Goldberg, Judith D.; Hoffman, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-75</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Panobinostat (LBH589), a novel histone deacetylase inhibitor (HDACi), was evaluated in a phase I study of patients with primary myelofibrosis (PMF) and post-essential thrombocythemia/polycythemia vera-related myelofibrosis (Post-ET/PV MF).  Eighteen patients (PMF 56%; Post-PV MF 28%; Post-ET MF 17%) were treated in three cohorts at oral doses of (i) 20, (ii) 30, and (iii) 25 mg three times weekly consecutively.  Reversible thrombocytopenia was the dose-limiting toxicity.  Five patients (two in Dose Cohort 1, one in Dose Cohort 2 and two in Dose Cohort 3) received six or more cycles and were evaluable for response assessment.  After the sixth cycle, three of these five patients achieved clin. improvement (CI) with 100% redn. in palpable splenomegaly from baseline, and two patients experienced stable disease.  Panobinostat therapy was also assocd. with improvement in the degree of anemia in two of the five patients.  Of the three patients who achieved CI after six cycles, one patient achieved a near complete remission after 15 cycles of treatment and another patient had resoln. of marrow fibrosis after 16 cycles.  We conclude that panobinostat is a well-tolerated, clin. active treatment for MF patients, regardless of JAK2V617F status, and most effective when given at low doses over long periods of time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEaXVB9hUs0LVg90H21EOLACvtfcHk0lirHXf20_Gqjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKnt7c%253D&md5=94aed025cf2409d836acb96994a8c849</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12220%26sid%3Dliteratum%253Aachs%26aulast%3DMascarenhas%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DB.%26aulast%3DHochman%26aufirst%3DT.%26aulast%3DNajfeld%26aufirst%3DV.%26aulast%3DGoldberg%26aufirst%3DJ.%2BD.%26aulast%3DHoffman%26aufirst%3DR.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520panobinostat%2520%2528LBH589%2529%2520in%2520patients%2520with%2520primary%2520myelofibrosis%2520%2528PMF%2529%2520and%2520post-polycythaemia%2520vera%252Fessential%2520thrombocythaemia%2520myelofibrosis%2520%2528post-PV%252FET%2520MF%2529%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D161%26spage%3D68%26epage%3D75%26doi%3D10.1111%2Fbjh.12220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistuz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluhm, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iype, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marvin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravichandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardecki, C.</span></span> <span> </span><span class="NLM_article-title">The protein data bank</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">907</span>, <span class="refDoi"> DOI: 10.1107/s0907444902003451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1107%2Fs0907444902003451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=12037327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2002&pages=899-907&author=H.+M.+Bermanauthor=T.+Battistuzauthor=T.+N.+Bhatauthor=W.+F.+Bluhmauthor=P.+E.+Bourneauthor=K.+Burkhardtauthor=Z.+Fengauthor=G.+L.+Gillilandauthor=L.+Iypeauthor=S.+Jainauthor=P.+Faganauthor=J.+Marvinauthor=D.+Padillaauthor=V.+Ravichandranauthor=B.+Schneiderauthor=N.+Thankiauthor=H.+Weissigauthor=J.+D.+Westbrookauthor=C.+Zardecki&title=The+protein+data+bank&doi=10.1107%2Fs0907444902003451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Battistuz, Tammy; Bhat, T. N.; Bluhm, Wolfgang F.; Bourne, Philip E.; Burkhardt, Kyle; Feng, Zukang; Gilliland, Gary L.; Iype, Lisa; Jain, Shri; Fagan, Phoebe; Marvin, Jessica; Padilla, David; Ravichandran, Veerasamy; Schneider, Bohdan; Thanki, Narmada; Weissig, Helge; Westbrook, John D.; Zardecki, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">D58</span>
        (<span class="NLM_cas:issue">6, No. 1</span>),
    <span class="NLM_cas:pages">899-907</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Munksgaard</span>)
        </div><div class="casAbstract">The Protein Data Bank [PDB; Berman, Westbrook et al. (2000), Nucleic Acids Res. 28, 235-242; http://www.pdb.org/] is the single worldwide archive of primary structural data of biol. macromols.  Many secondary sources of information are derived from PDB data.  It is the starting point for studies in structural bioinformatics.  This article describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information and plans for the future development of the resource.  The reader should come away with an understanding of the scope of the PDB and what is provided by the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsUFcMyys-PrVg90H21EOLACvtfcHk0lirHXf20_Gqjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKhtLg%253D&md5=d7594ad00ec8e5bacc413d38bceaa360</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2Fs0907444902003451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444902003451%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DBattistuz%26aufirst%3DT.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DBluhm%26aufirst%3DW.%2BF.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26aulast%3DBurkhardt%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%2BL.%26aulast%3DIype%26aufirst%3DL.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DFagan%26aufirst%3DP.%26aulast%3DMarvin%26aufirst%3DJ.%26aulast%3DPadilla%26aufirst%3DD.%26aulast%3DRavichandran%26aufirst%3DV.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DThanki%26aufirst%3DN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DWestbrook%26aufirst%3DJ.%2BD.%26aulast%3DZardecki%26aufirst%3DC.%26atitle%3DThe%2520protein%2520data%2520bank%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2002%26volume%3D58%26spage%3D899%26epage%3D907%26doi%3D10.1107%2Fs0907444902003451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/jm1011319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.-J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol-3-yl%29p+yrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+Jak%2FStat+pathway&doi=10.1021%2Fjm1011319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Wang, Tao; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Peng, Bo; Su, Mei; Zhang, Hai-Jun; Hoffmann, Ethan; Rivard, Caroline; Green, Isabelle; Howard, Tina; Pollard, Hannah; Read, Jon; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Min-Wei; Huszar, Dennis; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematol. malignancies characterized by clonal expansion of one or more myeloid lineages.  The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs.  Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.  9E inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent phys. properties and preclin. pharmacokinetics, and is currently being evaluated in Phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG6RQUv4HqbVg90H21EOLACvtfcHk0lhFuN099vb0oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN&md5=c8141c5b0e25a007e68b6e2567a576fe</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol-3-yl%2529p%2520yrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276%26doi%3D10.1021%2Fjm1011319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span> <span> </span><span class="NLM_article-title">Python: a programming language for software integration and development</span>. <i>J. Mol. Graphics Modell.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10660911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=57-61&author=M.+F.+Sanner&title=Python%3A+a+programming+language+for+software+integration+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Python: a programming language for software integration and development</span></div><div class="casAuthors">Sanner, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-61</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The use of interpreted languages in biocomputing has been investigated to create a programmable, dynamic environment in which components can be tied together at a high level.  This work has demonstrated the benefits of such an approach and the features of the interpreted language that are key to successful component integration.  This involved Python, an interpreted, interactive, object-oriented programming language.  It provides high-level data structures such as list and associative arrays, dynamic typing and dynamic binding, modules, classes, exceptions, automatic memory management and others.  Python has been found to be instrumental in the mol. modeling research environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaCFXA1JC8X7Vg90H21EOLACvtfcHk0lhFuN099vb0oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D&md5=3bf94934548080055dda54f68468c656</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanner%26aufirst%3DM.%2BF.%26atitle%3DPython%253A%2520a%2520programming%2520language%2520for%2520software%2520integration%2520and%2520development%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D1999%26volume%3D17%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open Babel: An open chemical toolbox</span>. <i>J. Cheminf</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=21982300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=33&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+Babel%3A+An+open+chemical+toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Open Babel: an open chemical toolbox</span></div><div class="casAuthors">O'Boyle, Noel M.; Banck, Michael; James, Craig A.; Morley, Chris; Vandermeersch, Tim; Hutchison, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Background: A frequent problem in computational modeling is the interconversion of chem. structures between different formats.  While std. interchange formats exist (for example, Chem. Markup Language) and de facto stds. have arisen (for example, SMILES format), the need to interconvert formats is a continuing problem due to the multitude of different application areas for chem. data, differences in the data stored by different formats (0D vs. 3D, for example), and competition between software along with a lack of vendor-neutral formats.  Results: We discuss, for the first time, Open Babel, an open-source chem. toolbox that speaks the many languages of chem. data.  Open Babel version 2.3 interconverts over 110 formats.  The need to represent such a wide variety of chem. and mol. data requires a library that implements a wide range of cheminformatics algorithms, from partial charge assignment and aromaticity detection, to bond order perception and canonicalization.  We detail the implementation of Open Babel, describe key advances in the 2.3 release, and outline a variety of uses both in terms of software products and scientific research, including applications far beyond simple format interconversion.  Conclusions: Open Babel presents a soln. to the proliferation of multiple chem. file formats.  In addn., it provides a variety of useful utilities from conformer searching and 2D depiction, to filtering, batch conversion, and substructure and similarity searching.  For developers, it can be used as a programming library to handle chem. data in areas such as org. chem., drug design, materials science, and computational chem.  It is freely available under an open-source license.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQ1lvaS5767Vg90H21EOLACvtfcHk0lhFuN099vb0oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF&md5=74e4f19b7f87417f916d57f7abcfb761</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520Babel%253A%2520An%2520open%2520chemical%2520toolbox%26jtitle%3DJ.%2520Cheminf%26date%3D2011%26volume%3D3%26spage%3D33%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+Automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lhFuN099vb0oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520Automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rurainski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhof, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, D.</span></span> <span> </span><span class="NLM_article-title">A new lamarckian genetic algorithm for flexible ligand-receptor docking</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1002/jcc.21478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1002%2Fjcc.21478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=20082382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=1911-1918&author=J.+Fuhrmannauthor=A.+Rurainskiauthor=H.+P.+Lenhofauthor=D.+Neumann&title=A+new+lamarckian+genetic+algorithm+for+flexible+ligand-receptor+docking&doi=10.1002%2Fjcc.21478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A new Lamarckian genetic algorithm for flexible ligand-receptor docking</span></div><div class="casAuthors">Fuhrmann, Jan; Rurainski, Alexander; Lenhof, Hans-Peter; Neumann, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1911-1918</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors present a Lamarckian genetic algorithm (LGA) variant for flexible ligand-receptor docking which allows to handle a large no. of degrees of freedom.  The authors' hybrid method combines a multi-deme LGA with a recently published gradient-based method for local optimization of mol. complexes.  The authors compared the performance of their new hybrid method to two non-gradient-based search heuristics on the Astex diverse set for flexible ligand-receptor docking.  The authors' results show that the novel approach is clearly superior to other LGAs employing a stochastic optimization method.  The new algorithm features a shorter run time and gives substantially better results, esp. with increasing complexity of the ligands.  Thus, it may be used to dock ligands with many rotatable bonds with high efficiency. © 2010 Wiley Periodicals, Inc.  J Comput Chem, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoFNlhZnxim7Vg90H21EOLACvtfcHk0ljim8xVhXBawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D&md5=34a78af702d8ee9bace9b5db8221e2db</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21478%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann%26aufirst%3DJ.%26aulast%3DRurainski%26aufirst%3DA.%26aulast%3DLenhof%26aufirst%3DH.%2BP.%26aulast%3DNeumann%26aufirst%3DD.%26atitle%3DA%2520new%2520lamarckian%2520genetic%2520algorithm%2520for%2520flexible%2520ligand-receptor%2520docking%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D1911%26epage%3D1918%26doi%3D10.1002%2Fjcc.21478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasteiger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsili, M.</span></span> <span> </span><span class="NLM_article-title">Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3219</span>– <span class="NLM_lpage">3228</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(80)80168-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1016%2F0040-4020%2880%2980168-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1980&pages=3219-3228&author=J.+Gasteigerauthor=M.+Marsili&title=Iterative+partial+equalization+of+orbital+electronegativity-a+rapid+access+to+atomic+charges&doi=10.1016%2F0040-4020%2880%2980168-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges</span></div><div class="casAuthors">Gasteiger, Johann; Marsili, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3219-22</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">A method is presented for the rapid calcn. of at. charges in σ-bonded and nonconjugated π-systems (alkyl halides and oxoalkanes, resp.), considering only the connectivities of the atoms.  Atoms are characterized by their orbital electronegativities.  Partial equalization of orbital electronegativity is obtained by an iterative procedure.  Excellent correlations of the at. charges with core-electron binding energies and with acidity consts. are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKA3wil1SiWrVg90H21EOLACvtfcHk0ljim8xVhXBawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D&md5=90c580857e6001482bee92450278fe9f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2880%2980168-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252880%252980168-2%26sid%3Dliteratum%253Aachs%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DMarsili%26aufirst%3DM.%26atitle%3DIterative%2520partial%2520equalization%2520of%2520orbital%2520electronegativity-a%2520rapid%2520access%2520to%2520atomic%2520charges%26jtitle%3DTetrahedron%26date%3D1980%26volume%3D36%26spage%3D3219%26epage%3D3228%26doi%3D10.1016%2F0040-4020%2880%2980168-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods I. method</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=10.1002%2Fjcc.540100208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=209-220&author=J.+J.+P.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+I.+method&doi=10.1002%2Fjcc.540100208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  I.  Method</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-20</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">A new method for obtaining optimized parameters for semiempirical methods is developed and applied to the MNDO method.  The method uses derivs. of calcd. values for properties with respect to adjustable parameters to obtain the optimized values of parameters.  The large increase in speed is a result of using a simple series expression for calcd. values of properties rather than employing full semiempirical calcns.  With this optimization procedure, the rate-detg. step for parameterizing elements changes from the mechanics of parameterization to the assembling of exptl. ref. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwG85ot7_Rq7Vg90H21EOLACvtfcHk0ljim8xVhXBawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu70%253D&md5=cbf1b7604277340a97e061539b65af71</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100208%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520I.%2520method%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D209%26epage%3D220%26doi%3D10.1002%2Fjcc.540100208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4','PDB','2XA4'); return false;">PDB: 2XA4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7','PDB','4RT7'); return false;">PDB: 4RT7</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i72"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_71467"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01488?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01488</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding affinities of <b>13ac</b> with 365 protein kinases;1H NMR, 13C NMR, MS/MS, and HPLC spectra of compound <b>13ac</b>; routine blood test in normal mice; and effect of <b>13ac</b> on mouse models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf">PDF</a>)</p></li><li><p class="inline">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> used for modeling docking in JAK2 of <b>13ac</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb">PDB</a>)</p></li><li><p class="inline">PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> used for modeling docking in FLT3 of <b>18e</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb">PDB</a>)</p></li><li><p class="inline">(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings of the prepared compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf">jm0c01488_si_001.pdf (527.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb">jm0c01488_si_002.pdb (184.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb">jm0c01488_si_003.pdb (742.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb">jm0c01488_si_004.pdb (504.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv">jm0c01488_si_005.csv (5.11 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01488&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01488%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01488" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797978cea7248d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
